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ABSTRACT 
15 million people suffer from stroke per year. Fundamentally, stroke is caused by a lack of 
oxygenated blood to brain tissue which results in tissue death. This entails a complex 
pathophysiology which encompasses 3 phases. Within minutes to hours, brain resident cells initiate 
excitotoxicity leading to irreversible neuronal death. From days to months, peripheral recruitment of 
immune cells to the brain drives neuroinflammation and exacerbates stroke outcome. Finally, within 
months to years, there is an increase in neuronal plasticity which enables reorganisation of cortical 
networks and restoration of broken circuits. Despite decades of research and intricate understanding 
of the physiological processes occurring after stroke, only one acute therapy is approved for use in 
clinics. An interesting therapeutic target for scientific researchers is modulation of the peripheral 
host immune system. Experimental research has shown that polarisation of the immune cell sub 
populations towards pro-/anti-inflammatory state can exacerbate or alleviate stroke outcome 
respectively. Polarised immune cell subsets migrate from peripheral secondary lymphoid organs to 
the brain lesion. While the intestinal immune compartment contains the majority of the immune 
cells in the body, it is the intestinal lumen that is the home to 1000 different readily adapting 
bacterial species. The gut microbiota has been shown to intimately interact with the immune system 
and alter the function of particular immune cell subsets. Recent experimental evidence has indicated 
a potential role for the interaction the gut microbiota and immune system in brain disease. We 
hypothesised that the gut microbiota could therefore play a role in the outcome of stroke. Within 
this thesis we explore the gut microbiota and its derived metabolites in experimental ischemic stroke 
models. This thesis incorporates four publications which have unravelled different aspects of how the 
gut microbiota affects stroke. The key experimental findings within this thesis can be summarised in 
five key concepts. 1) The gut microbiota and stroke have a bidirectional interaction, both having the 
ability to change the other. 2) The gut microbiota alters peripheral immune cells which after stroke, 
were shown to migrate to the brain and alter the inflammatory milieu. 3) The presence of the gut 
microbiota, or treatment with healthy gut microbiota transfer, improved stroke outcome. 4) Small 
changes in the gut microbiota can alter response to stroke immunotherapies. 5) Short-chain fatty 
acids, the dietary metabolites derived from the gut microbiota, improve functional post stroke 
recovery. Taken together, I hope this thesis reflects and demonstrates the interesting therapeutic 
potential of gut microbiota manipulation for treatment of stroke. The addition of microbiota-based 
treatments may not only be a stand-alone therapy to aid recovery after stroke, but additionally could 
be a practical add-on for existing procedural treatments. 
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LIST OF ABBREVIATIONS  
ACTH – Adrenocorticotropic hormone 
AD – Alzheimer’s Disease 
AhR – Aryl hydrocarbon receptor 
αβ – Alpha beta glycoprotein 
AMPA - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ASD – Autism spectrum disorder 
BDNF – Brain-derived neurotrophic factor 
Ca2+ - Calcium 
CARD9 - Caspase recruitment domain-containing protein 9 
CD28SA - CD28 superagonistic antibody 
CD - Cluster of differentiation  
CFSE - Carboxyfluorescein succinimidyl ester 
CIMT - Constraint-induced movement therapy 
CR – Charles River Laboratories 
CRF – Corticotropin-releasing factor 
CT – Computed tomography 
DAMPs - Danger associated molecular patterns 
dMCAo – Distal middle cerebral artery occlusion 
EAE – Experimental autoimmune encephalitis 
EGF – Epidermal growth factor 
Ex-GF – Germ-free recolonised  
FDA – Food and drug administration 
FFAR2 – Free fatty acid receptor 2 
FFAR3 – Free fatty acid receptor 3 
FGF – Fibroblast growth factor 
FITC - Fluorescein isothiocyanate 
fMCAo – Filamentous middle cerebral artery occlusion 
fMRI – Functional magnetic resonance imaging 
FMT – Fecal microbiota transplant 
GALT – Gut-associated lymphoid tissue 
γδ – Gamma delta glycoprotein 
GF – Germ-free 
GI – Gastrointestinal tract 
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Har – Harlan (now known as Envigo) 
HDAC - Histone deacetylases 
HIF-1 – Hypoxia-inducible factor 1-alpha 
HPA – Hypothalamic-pituitary-adrenal axis 
ICAM1 – Intercellular adhesion molecule 1 
IDO1 - Indoleamine 2, 3-dioxygenase 1 
IFNγ - Interferon gamma 
IL - Interleukin 
iTreg – “Induced” Treg 
K+ - Potassium  
LP – Lamina propria 
M cells – Microfold cell 
MALT – Mucosa-associated lymphoid tissues 
MCT1 – Monocarboxylate transporter 1 
MLN – Mesenteric lymph nodes 
MMPs – Matrix metalloproteinases 
MRI - Magnetic resonance imaging 
mRS - Modified rankin scale 
MS – Multiple sclerosis 
Na+ - Sodium  
NDMA - N-methyl-D-aspartate receptor 
NF-κB - Nuclear factor kappa-light-chain-enhancer of activated B cells 
nTreg – “Natural” Treg 
PD – Parkinson’s disease 
PET - Positron-emission tomography 
PP – Peyer’s patches 
PT – Photothrombosis 
RNA – Ribonucleic acid 
rRNA – Ribosomal RNA 
rtPA - Alteplase 
SAA - Serum amyloid A 
SCFA – Short-chain fatty acid 
SFB – Segmented filamentous bacteria 
SMCT1 – Sodium-coupled monocarboxylate transporter 1 
SPF – Specific pathogen free 
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SSRIs – Serotonin reuptake inhibitors  
STAT3 - Signal transducer and activator of transcription 3 
Tac – Taconic Biosciences 
Th1 – Type 1 T helper cells 
Th17 – Type 17 T helper cells 
Th2 – Type 2 T helper cells 
TNFα – Tumor necrosis factor alpha 
Tregs – Regulatory T cells 
TrkB – Tropomyosin receptor kinase B 
VCAM1 – Vascular cell adhesion molecule 1 
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INTRODUCTION  
AN INTRODUCTION TO STROKE 
Stroke is the leading cause of death and cause of disability worldwide (JohnsonNguyen et al., 2019). 
According to the world stroke organization, a remarkable 15 million people suffer from a stroke per 
year with 5.8 million of those patients who die. The majority of stroke patient survivors experience 
long term commodities such as dysphagia, paralysis and dementia. This leads to what is known as the 
socioeconomic burden of stroke; patients unable to return to work in addition to high prevalence of 
secondary diseases and costly hospitalization for rehabilitation. Together, this unequivocally 
demonstrates the absolute need for stroke research, to understand its pre-disposing factors, 
complex pathophysiology and post-stroke comorbidities. Essentially, stroke is caused by an occluded 
artery preventing oxygenated blood flow to brain tissue resulting in tissue death and loss of function. 
The aetiology of stroke itself is categorized into two main sub-types; haemorrhagic and ischemic. 
Haemorrhagic stroke accounts for 15% and amounts when a cerebral artery is ruptured causing 
bleeding into the brain tissue. Ischemic stroke is the most common form of stroke accounting for 
85% of all cases. This occurs when a terminal cerebral artery is occluded, and results in necrotic core 
tissue and surrounding at risk yet salvageable penumbra tissue. 
NEUROINFLAMMATION  
The brain consumes extensive amounts of energy for proper functioning; however, following an 
ischemic injury is unable to maintain energy stores. Under an ischemic event the continuous supply 
of oxygen is removed and thus cells undergo rapid K+ loss leading to membrane depolarisation 
(Katsura, Kristian et al., 1994). During this period, large amounts of Na+ and Ca2+ enter cells 
encouraging glutamate release, and consequently initiates a wave of repetitive peri-infarct 
depolarisations (Dirnagl, Iadecola et al., 1999). The large amounts of glutamate release leads to over 
stimulation of post synaptic excitatory receptors (NMDA, AMPA and kainite) further allowing influx of 
Ca2+. The elevated Ca2+ influx triggers a cascade of intracellular cytoplasmic events activating 
proteolytic enzymes and forcing free-radicals and cytochrome C from mitochondria. This cellular 
toxicity then induces cell death via apoptosis (delayed physiological and pathological conditions) or 
necrosis (acute, hypoxia conditions) depending on the stimulus (Chan, 2001) . Necrotic tissue can 
then secrete danger associated molecular patterns (DAMPs) such as ATP to further activate brain 
resident cells such as microglia. Simultaneously, these events occur within the acute phase after 
stroke lasting minutes to hours, and were coined excitotoxicity.  
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Within the sub-acute phase after stroke, neuroinflammation is the key driver of lesion progression. 
An elevated concentration of intracellular calcium stores is responsible for an increase in pro-
inflammatory transcription factors such as NF-κB (Oneill & Kaltschmidt, 1997), HIF-1 (Ruscher, Isaev 
et al., 1998) and STAT3 (Planas, Soriano et al., 1996). The up-regulation of these transcription factors 
induces a mass secretion of classic proinflammatory cytokines from brain resident cells such as IL-1β, 
TNFα, an IL-6 (Lambertsen, Biber et al., 2012, Rothwell & Hopkins, 1995) and chemokines (Asensio & 
Campbell, 1999, Mirabelli-Badenier, Braunersreuther et al., 2011). In turn, endothelial cells respond 
to the proinflammatory milieu with a higher expression of adhesion molecules displayed on the 
surface. The adhesions molecules such as ICAM-1, VCAM-1, selectins and integrins work to enhance 
the recruitment of peripheral immune cells to the brain parenchyma (Frijns & Kappelle, 2002). 
Furthermore, the release of nitrous oxide from various cell sources (Chen, Mou et al., 2017) and 
matrix metalloproteinases (MMPs) work to dilate and degrade basement membrane and tight-
junction proteins redesigning the extracellular matrix, and easing the migration of potential 
infiltrating immune cells into the brain parenchyma (Rosenberg, 2002).  
IMMUNE CELL INFILTRATION INTO THE BRAIN 
Immune cell recruitment from the periphery involves both chemokines and adhesion molecules. The 
innate and adaptive immune system are both engaged during this process (Iadecola & Anrather, 
2011, Planas, 2018). For a temporal illustration of the immune cell infiltration into the brain, please 
refer to Figure 1. In the periphery, the innate immune system, is the first to respond and particularly 
neutrophils have been detected within one hour of stroke onset, peaking at 1-3 days post lesion 
(Gelderblom, Leypoldt et al., 2009). Whilst a higher number of neutrophils have been associated with 
worst stroke outcome, the therapeutic blockage of neutrophil infiltration has delivered controversial 
results (Jickling, Liu et al., 2015). The next cell types are macrophage and monocyte populations 
along with microglia cells rapidly increasing in cell number, peaking at around 4 days post ischemia. 
Initially it was thought that the presence of monocytes at the lesion following ischemia exacerbated 
stroke outcome. However, experimental evidence has suggested that upon monocyte depletion, 
ischemic stroke injury is worsened (Gliem, Mausberg et al., 2012).   
 
Whilst the adaptive immune cells are present in the brain from as early as 24 hrs after ischemia, it is 
thought that they impose their effect within sub-acute phases. In support of this hypothesis, it was 
shown that T cells are increased in cell number within the brain up until 30 days post lesion in 
experimental mice models (Stubbe, Ebner et al., 2013). Furthermore, current research and discussion 
hints at the concept of T cells having a positive impact on neuroregeneration and not just having a 
detrimental role (Cramer, Benakis et al., 2019). T and B lymphocytes are derived from bone marrow 
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stem cells; however, T cells require further maturation in the thymus. In order for the lymphocytes to 
be fully functional, antigen must be presented in a secondary lymphoid organ. This enables cell 
division, differentiation and migration which in turn leads to clearance of specific proteins. The main 
secondary lymphoid organs are: lymph nodes, tonsils, spleen, Peyer's patches (PP) and mucosa 
associated lymphoid tissue (MALT). From here immune cells migrate to the brain after stroke and 
activate microglia and other brain resident cells. Importantly, the neuroinflammatory properties 
derived from lymphocytes has mainly been attributed to T cells and their cytokine release. This has 
been demonstrated in a number of elegant studies showing that T cells worsen stroke outcome, for 
example, lymphocyte deficient mice replenished with T cells had a worsened injury, whereas this 
affect was not seen with B cells (Hurn, Subramanian et al., 2007, Kleinschnitz, Schwab et al., 2010). 
Despite this, a recent growing body of evidence has suggested that B cells also contribute to the 
neuroinflammatory processes (Javidi & Magnus, 2019, Seifert, Vandenbark et al., 2018). T cells are 
the more widely investigated cell type in stroke, and can be classified into CD8+ cytotoxic cells and 
CD4+ helper cells. The latter, CD4+ T cells come in a variety of different subsets for example pro-
inflammatory Th1, Th17, Th2 and anti-inflammatory regulatory T cells (Tregs). Classically it is was 
shown that upon treatment with anti-CD25, a key receptor found important for the suppressor 
function of Tregs, mice had significantly worse outcome at 7 days post lesion (Liesz, Suri-Payer et al., 
2009), clarifying the neuroprotective properties of Tregs in stroke. Th1 cells mainly secrete 
proinflammatory cytokines including: IL-2, IL-12 IFNγ and TNFα. Th1 cells protect against bacterial 
infection, and in stroke have also been found in ischemic lesions where they contribute to secondary 
neuronal damage (Arumugam, Granger et al., 2005). Th2 cells secrete mainly anti-inflammatory 
cytokines such as IL-4, IL-5, IL-10 and IL-13, they aid in resolution of parasitic infection and also 
support antibody-mediated responses (Mosmann & Sad, 1996). Th17 cells secrete proinflammatory 
IL-21, IL-22 and IL-17. Th17 cells were shown to activate neutrophils and are also highly implicated in 
autoimmune disease. A subset of unconventional T cells (T cell receptor composed of γδ glycoprotein 
instead of αβ) called γδ cells, were found to be the main source of proinflammatory cytokine IL-17 in 
the brain, which exacerbated stroke outcome (Shichita, Sugiyama et al., 2009). Interestingly, it is now 
known that microglia are the main antigen presenting cells within the brain suggesting that 
potentially lymphocytes are re-stimulated in the brain parenchyma (Schetters, Gomez-Nicola et al., 
2018). 
 
After stroke, T cells migrate to the brain from secondary lymphoid organs. The spleen has been by far 
the most investigated secondary lymphoid organ after stroke. It was shown that following ischemia 
the spleen reduces in size and the number of circulating lymphocytes increase suggesting that they 
are derived from the spleen (Offner, Subramanian et al., 2006). However, the only experiment 
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performed which tracked cells from the spleen to the brain after stroke failed to show an increase in 
CFSE positive cells in the brain after injection of the dye in the spleen (Seifert, Hall et al., 2012). 
Another major secondary lymphoid tissue is the Gut-associated-lymphoid-tissue (GALT). A 
remarkable 70% of all immune cells from the body reside in the gut, insinuating that the GALT is a 
highly influential area for priming of the immune cells prior to brain infiltration post stroke. 
Interestingly, after stroke, T cells appear to have a higher migratory rate compared to B cells 
(Benakis, Brea et al., 2016b, Morton, Sefik et al., 2014). Furthermore, we found that 25% of all T cells 
found within the brain after stroke were originating from the GALT (Singh, Roth et al., 2016). More 
information about the importance of the immune cells residing in the gut will be listed in the next 
section. 
 
 
Figure 1. Time-dependant immune cell infiltration after stroke. Temporal dynamics of immune cell in filtration into the post 
stroke ischemic hemisphere following 60 mins transient occlusion of the middle cerebral artery. A is an overview of number 
of cells per hemisphere. B represents a higher magnification of the number of cells and different types found in the brain. 
Extracted from (Gelderblom et al., 2009).  
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REGENERATION AFTER STROKE 
Many mechanisms occurring during the recovery phase after stroke are akin to those employed 
during brain development. The physiological processes involved in motor and sensory recovery of the 
debilitated limb is often termed neuroregeneration. The extent of neurodegenerative processes is 
generally assessed in human patients and animal models using behavioural tests. The nurturing or 
boosting of these regenerative processes therefore leads to improved functional recovery after 
stroke. The brain is topographically organised and provides information about the anatomical 
structure, and function in the brain, i.e. there is an area of the brain associated with hand sensory 
and motor function. This concept has been clearly depicted in homunculus models of the motor and 
sensory cortex (Penfield & Boldrey, 1937). Furthermore, the control centers for i.e. limb movement 
are distributed over many neuronal networks some even existing in the other hemisphere (Brus-
Ramer, Carmel et al., 2009, Gonzalez, Gharbawie et al., 2004). This is an important factor to consider 
after stroke, and shines light on the importance of the contralesional hemisphere during recovery. 
Resting state fMRI in stroke patients has indicated that the homotypical contralateral region receives 
less neuronal inhibition from the stroked ipsilateral hemisphere. This indicated that the contralateral 
region is therefore more active after stroke. During the recovery period, the ipsilateral hemisphere 
gradually gains more functional activity, restoring inhibition to the contralateral hemisphere, and 
therefore decreasing the contralateral activity. It has been shown that after stroke, eventually the 
contralateral hemisphere activity reduces back to “normal state” and is accompanied with motor 
improvements (Rehme & Grefkes, 2013). This was found to be comparable in experimental stroke 
performed in rodent models. With fMRI in combination with behavioural tests researchers saw an 
extensive activation of the contralesional hemisphere after stroke which over time decreased, and at 
this time the peri-infarct territory slowly re-gained activity (Dijkhuizen, Ren et al., 2001).  
 
Within the peri-infarct region there is a rapid loss of neuronal dendritic spines in acute phases after 
stroke (Brown, Wong et al., 2008). The peri-infarct area undergoes a decidedly specific rewiring and 
remapping, and processes involving synaptic plasticity are highly upregulated (Jablonka, Witte et al., 
2007). The gene regulation in stroke specific plasticity compared to experience dependant plasticity 
has been well defined (Carmichael, Archibeque et al., 2005). Furthermore, the growth promoting 
neurotrophic factors has been extensively studied and it is well considered that factors such as brain 
derived neurotrophic factor (BDNF) improves functional recovery after stroke (Ploughman, Windle et 
al., 2009). The functional reorganisation after stroke is mainly governed by two classes of plasticity: 
homeostatic and Hebbian (Murphy & Corbett, 2009). Homeostatic plasticity is defined as a negative 
feedback loop which aims to restore the attenuated synaptic activity back to baseline (Turrigiano & 
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Nelson, 2004). After a stroke the infarct region displays a decrease in synaptic activity which is 
compensated by the surrounding penumbra hyperexcitability. Interestingly, it is thought that the 
hyperexcitability phase within the peri-infarct region after stroke is a result from homeostatic 
plasticity overcompensating for the loss of synaptic activity. On the other hand, Hebbian plasticity 
favours already existing strong functioning synapses. It uses existing robust synapses to redistribute 
connections and enable the functioning of circuits (Buma, Kwakkel et al., 2013). Taken together it 
suggests that the main plasticity mechanisms occurring after stroke, first begins with homeostatic 
plasticity and then develops into Hebbian plasticity.  
 
The survival of synapses and spines after stroke is partly orchestrated via microglia pruning (Zhang, 
Malik et al., 2014). The cross talk of microglia and neurons is key for successful reorganisation and 
functional integration of new connections. Microglia perform activation-or complement-dependent 
pruning of synapses in the post ischemic brain (Sandvig, Augestad et al., 2018). During 
neuroinflammation, the preference for microglia to phagocytose synapses is mainly driven by the 
neuronal activity itself, i.e. less active pre-synaptic inputs are more likely to be phagocytosed 
(Schafer, Lehrman et al., 2012, Wu, Dissing-Olesen et al., 2015). Additionally, the activation state of 
microglia largely influences synaptic pruning and reorganisation after stroke. Upon pro-inflammatory 
stimuli, microglia take on an activated phenotype, which, in stroke has been associated with lower 
rates of phagocytosis (Faustino, Wang et al., 2011). Evidence for this is provided in studies where 
microglia are pharmacologically entirely depleted and spine turnover rate was reduced (Reshef, 
Kudryavitskaya et al., 2017) or specifically in stroke where overall neuronal coverage was altered 
(Szalay, Martinecz et al., 2016).   
 
The activation state of microglia can be assessed by their phenotypic markers and morphology. 
Classically within acute phases it is known that that activated or more amoeboid shaped microglia 
are pro-inflammatory, whilst the ramified microglia are resting-state and anti-inflammatory. 
Unfortunately, no study to date has done a time course to investigate the longer-term changes of 
microglia following stroke, however it is likely that the amoeboid shape in the stroke hemisphere is 
maintained much longer than 5d after stroke (Heindl, Gesierich et al., 2018). There are many stimuli 
which can influence microglia activation after stroke. Within the acute phase, the initial sterile 
inflammation forces damaged cells to release DAMPs such as  lipids, nucleic acid and proteins which 
activate microglia (Gulke, Gelderblom et al., 2018). Later sub-acute or chronic phases, pre-primed 
infiltrating immune cells from the periphery have the potential to influence microglia activation state 
via cytokine release. For example release of IFN-γ from Th1 cells has been shown to cause microglia 
activation and worsen stroke outcome (Chabot, Charlet et al., 2001). Recently the role of T cells 
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affecting neurons in post stroke regeneration has come into discussion. The effects of T cells 
expressing glucocorticoid-induced TNF receptor was shown to deteriorate neural stem cell 
progenitors in the brain, whereas Tregs were shown to promote survival of the neural stem cell 
populations after stroke (Wang, Xie et al., 2015). Further investigation needs to be complete to 
elucidate the exciting role of brain invading immune cells and the direct effect on neurons in 
regeneration after stroke.   
STROKE THERAPIES AND TREATMENTS 
ACUTE PHASE 
Typically, a stroke is recognised by weakness in face or arm, sudden confusion or speech difficulties, 
problems seeing in eyes, sudden trouble walking and dizziness. At the hospital a stroke diagnosis is 
given using a combination of physical examination, blood diagnostics, and a brain scan within 1 hour. 
Computed tomography (CT) scan helps diagnose an ischemic or haemorrhagic stroke. Magnetic 
resonance imaging (MRI) provides detailed information about brain structure identifying also smaller, 
not yet demarcated lesions and approximate information about the time of stroke onset. An 
echocardiography or carotid ultrasound is given later to confirm the aetiology of the stroke. 
 
The only pharmacological intervention for ischemic stroke still lies with utilisation of one drug. 
Intravenous alteplase (rtPA) a thrombolytic agent, is administered to 7-12% of all stroke patients 
globally (Craig, Middleton et al., 2019). The rtPA actively converts plasminogen (precursor found in 
the liver) into plasmin. This then allows for the conversion of the fibrin clot into fibrin degradation 
products. The drug rtPA reduces post-stroke disability as seen with the Modified Rankin Score (mRS) 
score at 3-6 months (Hankey, 2017). Despite this, rtPA has the limitation of time, as the drug must be 
administered within 4.5 hours of ischemic stroke, and still poses threat for potential bleeding from 
the brain. 
 
The second approved therapy typically for larger clots, where the rtPA is not feasible, involves 
surgical removal of the clot itself. Endovascular thrombectomy considerably reduces disability and 
has recently shown multiple positive results in randomised controlled trials (Campbell, Donnan et al., 
2016). Despite these two promising therapies tackling the acute phase following stroke, large efforts 
in research have been focusing on discovering treatment for the neuroinflammatory phase after 
stroke (Lo, 2008). However, treatments shown to be beneficial in experimental models, often 
ineffective or even worsen stoke outcome, and therefore fail to be translated into clinics. In order to 
15 | P a g e  
 
prevent the chances of a second clot forming, patients are also given anti-platelets, anti-coagulants, 
anti-hypertensives and statins. To summarise, the target of the acute phase therapy is primarily the 
clot, the main goal is to salvage the threatened brain tissue and limit tissue damage (Lin, Finklestein 
et al., 2018).  
CHRONIC PHASE 
The chronic phase treatments tend to promote neural growth and regeneration in the existing tissue. 
This phase poses as an attractive therapeutic window, as a longer treatment time-frame is available. 
Additionally, the effectiveness of the treatment can be measured by a range of parameters. In 
humans depending on the location of the lesion the list of deficits to assess include:  motor, sensory, 
cognitive, attention, language, visual, coordination, and gait disturbances, among others. Most 
interesting for translational research are the motor deficits, which are practical to measure and 
assess in rodent models. Rodent studies have shown long-lasting if not permanent behavioural motor 
deficits after stroke (Girard, Murray et al., 2014, Murphy & Corbett, 2009).  
 
While spontaneous recovery does occur after stroke, it is highly variable and potentially could be 
enhanced, in order to encourage regeneration after stroke. To date there is no small molecule or 
biologic approved by the Food and Drug Administration (FDA). Conventional therapies such as 
physical, occupational and speech therapies are offered to recovering stroke patients. Other 
therapies include constraint-induced movement therapy (CIMT), this is the physical restraint of the 
less-active arm. CIMT was shown to significantly improve motor defects which persisted up until 1 
year after stroke (Wolf, Winstein et al., 2006). Other experimental research therapies which have not 
yet been approved can be broken down into two categories; biological interventions and computer-
based therapies. For the scope of this thesis I will focus on the biological interventions. 
 
Currently the most promising drugs to enhance motor recovery post stroke are serotonergic and 
dopaminergic (Cramer, 2015, Lin et al., 2018, Viale, Catoira et al., 2018). A systematic review showed 
that trials using serotonin reuptake inhibitors (SSRIs) primarily to treat symptoms of post-stroke 
depression, also showed improvement in disability (Mead, Hsieh et al., 2013). However, phase III 
trials failed to show an improved functional outcome after stroke (Dennis, Forbes et al., 2019). 
Similarly, dopaminergic inhibitors displayed improved motor recovery in initial studies, however 
multi-centre trials revealed no difference in the primary end-point (the ability to walk independently) 
(Ford, Bhakta et al., 2015, Lin et al., 2018, Scheidtmann, Fries et al., 2001). Taken together, the 
unsuccessful trials in stroke patients highlight the complex modulation of excitatory/inhibitory 
synaptic and cortical network balance.  
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Growth factors work to promote angiogenesis and neural sprouting to facilitate stroke recovery. 
Whilst many have been shown to be neuroprotective in rodent stroke models such as fibroblast 
growth factor (FGF) (Kawamata, Dietrich et al., 1997) epidermal growth factor (EGF) (Jin, Sun et al., 
2004) and Brain derived growth factor (BDNF) (Schabitz, Schwab et al., 1997), clinical trials fail to 
show improvement as shown with trafermin (basic FGF) (Bogousslavsky, Victor et al., 2002). Finally, 
new investigations focus on the physical administration of cells, in hope of replacing lost cells after 
stroke, or engineering them to secrete neuroprotective agents into the brain parenchyma. Transfer 
of cells has been performed with different cell lines and administration routes. At 24-48hrs post 
stroke, patients were administered allogeneic marrow-derived cells intravenously (Hess, Wechsler et 
al., 2017). At 6-60 months post stroke, improvements were also seen with stereotaxic implanted cells 
in the ipsilateral hemisphere from allogeneic immortalized human fetal neurons (Kalladka, Sinden et 
al., 2016) and allogeneic modified marrow-derived mesenchymal cells (Steinberg, Kondziolka et al., 
2016). However, these treatments still remain to be further investigated and are not yet approved 
for the clinic. 
RELIABILITY AND REPRODUCIBILITY 
Striving and achieving reproducibility among experimental research is a high priority within many 
fields. As mentioned previously, there is a clear struggle and roadblock between basic experimental 
research and successful translation into clinics. To tackle this, it is essential that reproducibility begins 
at the basic pre-clinical stage prior to use in the clinic. Despite this knowledge, still, only a small 
fraction of experimental basic stroke research is able to be replicated (Llovera & Liesz, 2016, McNutt, 
2014).  The main obstacles within replication of pre-clinical research include; insufficient power, 
missing cross-validation of data, study design, exclusion criteria, models used, experimental animals, 
researchers, statistics and analysis strategy, sharing of original data. To overcome these obstacles 
and “bridge the gap” between basic and clinical research, pre-clinical randomised control trials are 
being utilised (Llovera, Hofmann et al., 2015). While strict homogenisation of protocols enables 
reproducibility, there are some hidden confounding variables which are difficult to control but still 
may alter experimental results. Animal husbandry is thought to be a standardised procedure, 
however there are many confounding factors which cause the environments in which the animals 
live to be completely different. Chow, water, bedding, type of caging, frequency of bedding change, 
circadian rhythms, animal keeper, co-housing, drugs, commercial breeder purchased are some 
examples of the subtle differences which can alter the gut microbiota content (Figure 2). 
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Figure 2. Animal husbandry alters the gut microbiota. Illustration highlighting the different variables in animal husbandry 
practice. These variables may affect the content of the gut microbiota and in turn alter experimental reproducibility or result 
in different results from the same genetic mouse model. Extracted from (Franklin & Ericsson, 2017). 
 
It is important to acknowledge the potential existing difference between the gut microbiota of 
animals and can even reveal new mechanistic information about diseases. A study investigating bone 
marrow density serendipitously recognised that bone density was associated with presence of 
certain gut bacteria (McCabe, Irwin et al., 2013). Furthermore, other studies have shown than mice 
originating from The Jackson Laboratory or Charles River Laboratories (CR) are absent of segmented 
filamentous bacteria (SFB), a bacterium intimately interacting with the gut mucosa and priming Th17 
cells (Ivanov, Frutos et al., 2008). Recently the difference between commercial breeder microbiome 
composition and the effects on immune system balance has been investigated in context of disease. 
The study showed by using mice from different commercial breeders that the Enterobacteriaceae 
bacterial family determine the susceptibility to Salmonella infection (Velazquez, Nguyen et al., 2019). 
Therefore, the gut microbiota could potentially affect disease models and act as a link to help 
understand the differences found in irreproducible experimental research. On the other hand, 
representation of the diverse gut microbiota as found in humans could potentially be modelled in a 
single study with use of mice from different research centres and mouse breeders.  
AN INTRODUCTION TO THE GUT MICROBIOTA 
Over the last 15 years, the field of gut microbiota research has blossomed. It is now considered as an 
important confounding factor in many diseases and is even recognised as a therapeutic target. While 
it is important that viruses, fungi, phages and yeast also reside in the gut, the majority of microbiome 
research is focused on bacteria. The gastrointestinal tract is colonised by 1014 bacterial cells, and 
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weighs on average 1 kg (Gill, Pop et al., 2006). A recently revised quantification of the gut microbiota 
has shown us that we are equal part human cells to bacterial cells (Sender, Fuchs et al., 2016), but 
perhaps the most remarkable information lies within the genetic material. There is 200 times more 
bacterial genetic material in our bodies compared to human genetic material. Despite this, the gut 
microbiota has an essential physiological function within our body such as: maintaining integrity of 
the gut epithelium (Natividad & Verdu, 2013), metabolism of indigestible food sources (den Besten, 
van Eunen et al., 2013) pathogenic control (Baumler & Sperandio, 2016) and host immunity 
regulation (Gensollen, Iyer et al., 2016).  
 
The human genome project revealed that the human genome was in fact much smaller than our 
bacterial genome (LanderInt Human Genome Sequencing et al., 2001). This encouraged the initiation 
of the human microbiota project in 2007. Now in 2014 a second integrative human microbiome 
project has been launched, which aims to investigate diseases specific and longitudinal microbiome 
changes (HuttenhowerGevers et al., 2012, Turnbaugh, Ley et al., 2007). 16S ribosomal sequencing 
has become a powerful tool in order to assess the bacterial communities found within the gut 
microbiota. Essentially, 16S ribosomal RNA (rRNA) is highly conserved between bacterial species and 
contains 9 highly variable regions. This allows species to be easily identified. In terms of taxonomy, 
the phyla present in the adult gut are Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, 
Fusobacteria, and Verrucomicrobia. Firmicutes and Bacteroidetes compile 90% of the gut 
microbiome (Arumugam, Raes et al., 2011). For a further break down of species and their taxonomic 
classification refer to Figure 3.  
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Figure 3. Taxonomic tree of bacteria from the gut microbiome. Taxonomic classification of different bacteria found in the 
gut microbiome. The box contains Firmicutes and Bacteroides phyla which represent 90% of the gut microbiota composition. 
Extracted from  (Rinninella, Raoul et al., 2019). 
 
There are many contributing factors which may potentially alter the gut microbiome composition of 
an individual, and in fact within an individual the gut microbiota alters over life, seasons and even 
within same day. The adult gut microbiota composition is challenged by diet, drugs, exercise, body 
mass and disease on a regular basis and adapts accordingly (Rinninella et al., 2019). Richness and a 
high diversity of bacterial species within the gut microbiota is considered “healthy” (Rinninella et al., 
2019). Regular antibiotic use has been shown to completely decrease diversity of the gut microbiota. 
Some patients treated with antibiotics experienced complete eradication of bacterial species 
showing no complete restoration (Dethlefsen & Relman, 2011). The overuse of antibiotics and the 
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induced microbiome changes has now been linked to the differences in polarisation of the immune 
system and the development of an allergic disease (Droste, Wieringa et al., 2000).   
 
One method to study the impact of the gut microbiota composition and its effects within the body is 
by faecal microbial transfer (FMT). FMT works to transfer the composition of a donor microbiota to 
another recipient. Resent research has shown the alterations observed in the gut microbiota of 
obese mice can be transferred into recipient mice and in turn induce obesity, thus highlighting the 
causality of the gut microbiota in disease pathophysiology (Wang, Huang et al., 2018). In 
experimental research germ-free (GF) mice or antibiotic-treated mice that have complete absence or 
depletion of their microbiota are used to investigate the influence of the gut microbiota on the host. 
GF mice are reared in complete sterile environments. Due to this fact they have immunological, 
developmental defects and alterations to their anatomical gut structures (Round & Mazmanian, 
2009). On the other hand, mice treated with antibiotics have depleted gut bacterial population 
similar to GF mice, however have no developmental defects due to lack of bacterial exposure. One 
draw-back of using antibiotics as a tool to deplete gut microbiota is that antibiotics have off-target 
affects. This off-target affects include reduced protein aggregation, and countering 
neuroinflammation found in neurodegenerative diseases (Santa-Cecilia, Leite et al., 2019). This 
makes it challenging to investigate the gut microbiota importance in brain disease, and using 
antibiotics as a method to deplete the bacterial species. Furthermore, there is a risk that only specific 
bacterial populations are susceptible to treatment, therefore leaving bacterial populations which are 
antibiotic resistant. While both these approaches have pros and cons a combination of the two of 
these methods to validate one another is ideal to investigate the gut microbiota (Kennedy, King et al., 
2018). 
GUT MICROBIOTA AND THE IMMUNE SYSTEM 
While the gut is the home of many readily adapting bacterial species, we know that the majority of 
immune cells are also located here. This allows the immune cell priming in the GALT to be highly 
influenced by the content of the gut microbiota. The GALT landscape consists of many highly 
specialised regions which allows interaction of the gut microbiota with the immune system (Figure 
4). The lamina propria (LP) spans the entire gut, supports epithelium and contains the highest 
number of innate immune cells. The mesenteric lymph nodes (MLN) found in the gut (ileocolic), 
contain germinal centres, are found in the ileum and contain antigen presenting cells, which present 
antigen to local T and B cells. The intraepithelial cells are found throughout the epithelium of the gut 
and contain highly specialised lymphocytes which do not require priming. Finally, the PP are grape 
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like looking structures containing germinal centers, are located along the ileum and contain 
microfold cells (M cells). M cells have unique pocket-like structures which are found directly on the 
follicle-associated epithelium by the lumen of the gut. They allow dendritic cells located here to gain 
direct contact and sample the content of the gut lumen. This then allows antigen presentation within 
the germinal centers to local T and B cells. Within the MLN activated B cells undergo what is termed 
class switching. Class switching changes the type of immunoglobulin produced by the B cell from one 
isotype to another. In the MLN antigen presentation for example from dendritic cells switches the 
immunoglobin isotype to IgA (Lycke & Bemark, 2017). B cells secrete IgA which trancytosed into the 
gut lumen, and prevents bacterial translocation across the tight gut barrier (Macpherson, Gatto et 
al., 2000, Macpherson & Uhr, 2004) 
 
 
Figure 4 The Gut-associated-lymphoid (GALT) tissue landscape. A schematic highlighting the highly specialised areas in the 
GALT where immune cells reside and interact with the gut microbiota content. DC, dendritic cell; IEL, intraepithelial 
lymphocyte; LP, lamina propria; M-cell, microfold cell. Extracted from (Wu, Zhang et al., 2014). 
 
To date there is a reasonable amount of research articles indicating the effect of specific bacterial 
species on the adaptive immune system. Most prominently, the effects of the commensal microbial 
species are shown to alter the homeostatic balance of Treg and Th17 cells whilst additionally there 
are few studies reporting effects on Th1 or Th2 cells (Zhao & Elson, 2018). Specifically, the gut 
microbiota appears to target cells located outside of the thymus i.e iTregs (Tregs induced outside the 
thymus from mature CD4+ cells) are altered but not nTregs (Tregs which are developed in the 
thymus) (Josefowicz, Niec et al., 2012). Mono-colonisation of GF mice with Bacteroides fragilis from 
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the Bacteroidetes phylum promoted differentiation of CD4+ cells toward a Treg phenotype, thereby 
increasing Foxp3 expression and the immunosuppressive cytokine IL-10. Authors reported that it was 
polysaccharide A,  a molecule released Bacteroides fragilis which was responsible for the induction of 
Tregs (Round & Mazmanian, 2010). Additionally, the unique glycosphingolipids produced by 
Bacteroides fragilis has also been shown to lower host invariant natural killer T cells in a colitis model 
(An, Oh et al., 2014). Other studies showed that not just single bacterial species but groups of gram-
positive bacteria were involved in the accumulation of Tregs within the gut. Specifically, oral gavage 
with 46 strains of bacteria from the Clostridium genus identified an environment rich in transforming 
growth factor beta and altered Treg function (Atarashi, Tanoue et al., 2011, Furusawa, Obata et al., 
2013). On the contrary from the Firmicutes phylum SFB are gram-positive bacteria which intimately 
interact with the PP. GF mice colonised with SFB showed an increased abundance of host cell 
secreted serum amyloid A proteins in the terminal ileum. Furthermore, it was shown the SFB 
presence affected type 3 innate lymphoid cells prompting the releasing of IL-22, the release of SAA 
from epithelial cells. This was found to prime dendritic cells and was able to induce Th17 cells and IL-
17 secretion (Atarashi, Tanoue et al., 2015, Farkas, Panea et al., 2015, Goto, Panea et al., 2014, 
Ivanov, Atarashi et al., 2009, Sano, Huang et al., 2015). 
Dietary microbial metabolites and the immune system  
Following the recent increase in focused research of gut microbiota and the immune system, it has 
become more evident that is not only the bacterial species themselves but also the microbial 
metabolites produced from our diet which can affect the immune system. The dietary metabolites 
derived from the gut microbiota are estimated at a total of 10% of metabolites found in human blood 
(Wikoff, Anfora et al., 2009). As mentioned previously, one of the main functions of the gut 
microbiota is to digest dietary complex carbohydras for their own energy source. Short-chain fatty 
acids (SCFA) are bioactive bacterial metabolites derived from bacterial fermentation of dietary fibre 
which otherwise is not digested by host enzymes. SCFA are 1-6 carbons in length, with acetate (C2), 
propionate (C3) and butyrate (C4) being the most abundant in the intestine (Cummings, Pomare et 
al., 1987). Bacteroidetes and Firmicutes mainly produce SCFA and it is considered that acetate and 
propionate are mainly produced by Bacteroidetes whereas butyrate is mainly produced by Firmicutes 
phyla (Hoverstad & Midtvedt, 1986, Macfarlane & Macfarlane, 2003). The majority of butyrate is 
rapidly absorbed by the colonocytes, whereas propionate and acetate enter the systemic circulation. 
Propionate is mainly absorbed by the liver whereas acetate has been shown to reach very distant 
organs such as the brain (Frost, Sleeth et al., 2014, Morrison & Preston, 2016). In general, data 
suggests that SCFA impose their effect via activation of the FFAR2 and FFAR3 receptors, or by entry 
into cells via monocarboxylate transporters MCT1 and SMCT1. Furthermore, SCFA can passively 
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diffuse into the cell where they act as histone deacetylase inhibitors (Brown, Goldsworthy et al., 
2003, Hinnebusch, Meng et al., 2002, Kamp & Hamilton, 2006, Miyauchi, Gopal et al., 2004, 
Waldecker, Kautenburger et al., 2008). SCFA are considered to be anti-inflammatory, and in-vitro it 
was shown that SCFA inhibit the release of proinflammatory cytokines (Chang, Hao et al., 2014). SCFA 
were also shown to act as chemoattractants for neutrophils (Le Poul, Loison et al., 2003). Other 
innate phagocytic cell types such as dendritic cells, microglia and monocytes have also been shown 
to have anti-inflammatory properties following SCFA treatment. Additionally, the adaptive immune 
system responds to SCFA. SCFA influences B cells and increases antibody production (Kim, Qie et al., 
2016) and most importantly it is now well considered that SCFA expand the Treg population (Arpaia, 
Campbell et al., 2013, Smith, Howitt et al., 2013). 
 
Another dietary metabolite tryptophan, like fibre, is also metabolised by bacterial species resulting in 
indole derivative production. Indole derivatives such as: indole, tryptamine, indoleethanol, 
indolepropionic acid, indolelactic acid, indoleacetic acid, skatole, indolealdehyde and indoleacrylic 
acid, have been shown to act as ligands for the aryl hydrocarbon receptor (AhR). The AhR is widely 
expressed on immune cells and therefore the indole derivatives act as immunomodulators 
(Stockinger, Di Meglio et al., 2014). Indoleamine 2, 3-dioxygenase 1 (IDO1) is an endogenous enzyme 
required for the metabolism of tryptophan to the AhR ligand, kynurenine. It was found that under 
high levels of tryptophan IDO1–/– mice had an impact on the microbiome with an expansion of 
bacteria from the Lactobacillus genus. The Lactobacillus expansion led to an increase in bacterial 
derived indoles. The high levels of indoles in turn induced immune cells to secrete IL-22 (Zelante, 
Iannitti et al., 2013). Furthermore, in the irritable bowel syndrome mouse CARD9–/–model, mice had 
an altered microbiota composition with a decrease in the Lactobacillus genus. The reduction of 
Lactobacillus once again led to an impaired metabolism of tryptophan to indole derivatives, this was 
linked to the inflammatory milieu in this disease model. However upon inoculation of these mice 
with Lactobacilli strain, intestinal inflammation was reduced (Lamas, Richard et al., 2016). Taken 
together this highlights the impact of microbial metabolites over endogenous metabolites which also 
play a role in activation of the immune system.   
BRAIN DISEASE AND THE GUT MICROBIOTA 
The earliest piece of evidence to suggest the gut microbiota plays a role in brain disease 
pathophysiology was found in 1993 within multiple sclerosis (MS); a demyelinating disorder of the 
central nervous system. The study reported that dirtier animal facilities, i.e. facilities with higher 
amounts of bacteria, had greater prevalence of the experimental mouse of MS, spontaneous 
experimental autoimmune encephalitis (EAE) (Goverman, Woods et al., 1993). In contrast, a study 
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performed using EAE mice reared under GF conditions found that the absence of the gut microbiota 
led to protection from disease onset (Berer, Mues et al., 2011). Furthermore, it was also shown that 
antibiotics and probiotics modulated EAE via proinflammatory cytokine reduction (Mangalam, Shahi 
et al., 2017, Ochoa-Reparaz, Mielcarz et al., 2009).  
 
Parkinson disease (PD) is linked to decreased dopamine production from neurons within the 
substantia nigra pars compacta. This is accompanied with alpha-synuclein accumulation, deposited in 
surviving neurons, also known as Lewy bodies. Patients often have gastrointestinal complaints and 
gut motility problems for example constipation (Noyce, Bestwick et al., 2012) and recently the 
progression of PD has been associated with gut dysbiosis (Minato, Maeda et al., 2017). In 
experimental GF models of PD, mice experience less inflammation within the gut and additionally 
less alpha synuclein compared to SPF mice. Furthermore, in the same GF PD mouse models, FMT 
with human PD microbiota revealed the exacerbation of motor deficits (Sampson, Debelius et al., 
2016).  
 
The pathological hallmarks of Alzheimer disease (AD) include amyloid plaques and neurofibrillary 
tangles, this is accompanied with cognitive decline and dementia (Braak & Braak, 1991). There was a 
clear indication that the gut microbiota played a role in AD pathology when antibiotic treatment was 
administered, resulting in fewer plaques and less microglia activity (Cattaneo, Cattane et al., 2017). 
Additionally, it was shown that probiotic treatment of AD patients for 12 weeks improved cognitive 
function (Leblhuber, Egger et al., 2018). This indicated that the AD gut dysbiotic microbiome was 
beneficially altered with antibiotic treatment, but additionally, physically adding a cocktail of 
“healthy” bacteria, was beneficial. Some studies suggest the reduction of bacterial populations found 
in dysbiotic AD microbiota or in aged and dementia patients were specifically butyrate producers 
(Biagi, Nylund et al., 2010). Therefore, suggesting that FMT of SCFA-producing bacteria could be 
beneficial in alleviating AD symptoms. 
 
Finally, stroke has only recently been linked to gut microbial dysbiosis in 2015. Interestingly it was 
reported that patients with Crohn’s disease, an aliment also associated with a disturbed gut 
microbiota, had an increased stroke prevalence (Keller, Wang et al., 2015). More specifically in stroke 
patients it was found that the gut microbiota was indeed disturbed (Yin, Liao et al., 2015). Based on 
the changes in the gut microbiome composition after stroke, a study has combined the common 
bacterial populations which alter after stroke in comparison to controls, and formulated a 
computerised gut microbiome dysbiosis index. They causally showed that patients with a high gut 
dysbiosis were linked to a worse outcome (Xia, You et al., 2019).  Experimental mouse research on 
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microbiota in stroke has resulted in an array of conflicting studies. First, it was shown that antibiotic 
pre-treatment did not alter stroke outcome or immune cell populations (Winek, Engel et al., 2016). 
Shortly after, another study reared a mouse strain to contain antibiotic resistant gut microbiota. This 
enabled comparison of mice with antibiotic sensitive gut microbiota and allowed the investigation of 
the direct effects of antibiotics on the gut microbiota, ruling out any off-target systemic affects. In 
contrary to the first study it was reported that antibiotics decreased infarct volume, and was 
associated with higher number of Tregs plus lower number of γδ T cells within the gut. Furthermore 
the study showed a lower migration of γδ T cells to the meninges and lower levels of IL-17 after 
stroke (Benakis et al., 2016b). Whilst investigating the effects of gut microbiota with antibiotic 
treatment results in eradication certain populations of bacteria, on the other hand adding bacteria to 
the existing gut microbiota can also be used. FMT treatment from young mouse donors improved 
stroke outcome assessed by infarct volume (Spychala, Venna et al., 2018). Over the last decade, the 
key role of the gut microbiota in many brain diseases has been highlighted. New research is 
beginning to unravel and identify the key mechanism in how exactly gut microbiota potential can 
modulate the outcome of these diseases via bi-directional gut-brain interactions.  
MECHANISM OF GUT MICROBIOTA BRAIN INTERACTION 
Understanding the bi-directional interaction of the gut microbiota and brain is key to unravelling how 
the gut microbiota can potentially impose therapeutic effects within brain disease. These pathways 
are indirect and direct actions of the gut microbiota on the brain and have been classified into three 
main pathways; biochemically, immune and via neural pathways. Within this section, I will highlight 
the evidence which has been proposed to support these various pathways, as shown in Figure 5. 
 
Biochemically. As mentioned previously, the gut microbiota produces a variety of bioactive and even 
neuroactive substances (Kim, Yun et al., 2018). Whilst bacteria produce these primarily for their own 
energy sources and survival, due to their resemblance in structure, they can additionally affect host 
cells. Interestingly, 90% of serotonin, and 50% of dopamine within our body is produced within our 
guts. This is largely dependent on our dietary input, however, is strongly regulated by the gut 
microbiota metabolism. Furthermore, it has been shown that bacteria within the gut microbiota are 
capable of producing serotonin and dopamine (Lyte, 2011). A study performed in GF mice identified a 
60% reduction of serotonin (Yano, Yu et al., 2015). These neuroactive compounds released by the gut 
microbiota may have an indirect (acting on host cells) or direct (travelling via the blood stream) effect 
on the brain. A recent investigation in schizophrenic mice models showed modulation of glutamine 
and GABA pathways within the brain after FMT of schizophrenic patient microbiota (Zheng, Zeng et 
al., 2019). Despite this interesting finding, a substantial amount of work needs to be performed to 
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determine whether or not the gut microbial metabolites directly alter host neurotransmission 
(Strandwitz, 2018). Other metabolites produced by the gut microbiota such as SCFA and tryptophan, 
also have the ability to enter the blood stream via the distal ileum portal vein and have systemic 
effects elsewhere within the body. Small molecules such as SCFA cross the blood brain barrier and 
passively enter the brain (Frost et al., 2014). Not only does biochemical communication occur from 
the gut to the brain but also from the brain to the gut via the hypothalamus-pituitary-adrenal axis 
(HPA). Under stressful conditions, the HPA axis releases cortisol into the systemic circulation. 
Specifically, research has shown that the chronic stress and increased cortisol release altered 
immune cells to an inflammatory state, increased intestinal permeability and altered the composition 
of the gut microbiota (Bailey, Dowd et al., 2011). 
 
Immune. As previously described, the gut microbiota holds an intimate interaction with the immune 
system. Depending on the bacterial content of our gut microbiota, the antigens, or bioactive 
mediators available to local immune cells differ, and thus the polarisation and priming of the immune 
cells changes accordingly. The cells within our immune system are able to travel via the systemic 
blood circulation from the gut and are recruited into the brain. As discussed in the earlier sections, 
dysbiotic gut microbiota obtained from animals with brain disease does alter the immune cells. While 
currently research has been focused on the priming of the immune cells from specific bacterial 
species namely SFB inducing proinflammatory Th17 cells, and B. fraglis inducing anti-inflammatory 
Treg cells (Ivanov et al., 2009, Round & Mazmanian, 2010). More effort needs to be focused on the 
effect of the entire disease microbiome signature and immune populations within the gut.  
 
Neural. The vagus nerve (cranial nerve X) acts as a direct link from the gut to the brain. Interestingly 
20% of its efferent fibres send signals from the brain to the gut, and 80% of the fibres send signals 
from the gut to the brain (Agostoni, Chinnock et al., 1957, Thayer & Sternberg, 2009). There are two 
types of nerves which perform as chemosensory (detecting metabolites and substances released 
from the gut microbiota) and also mechanosensory (which detect physical stimulation of nerve 
endings) both acting to communicate with the brain. There are several studies indicating this 
powerful connection. First within the gut, microbiota absence has been shown to alter the 
excitability within the ENS which was reversible upon FMT or colonisation with bacteria (Keita & 
Soderholm, 2010, Neufeld, Mao et al., 2013). Additionally, a study investigating anxiety and 
depression saw a beneficial effect of administration of L. rhamnosus. The improvement in symptoms 
from the bacteria were however not seen when the vagus nerve was surgically severed (Bercik, Park 
et al., 2011, Bravo, Forsythe et al., 2011, Siopi, Saha et al., 2019). Additionally, bacterial-derived SCFA 
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were able to stimulate vagal afferents (Lal, Kirkup et al., 2001). The physical interaction between 
bacteria and the vagus mechanosensory afferents still needs to be further elucidated.  
 
Taken together gut microbiota communicates with the brain along multiple different pathways, 
which enable potential alteration of brain disease. While on the one-hand very fascinating, this 
provides challenge to researchers to pin-point the exact pathway in which the gut microbiota may 
alter brain disease.   
 
  
Figure 5. The bidirectional communication between the gut microbiota and the brain. This illustration highlights the 
complex interactions between gut microbiota and the brain. It shows the three pathways which are considered the main 
routes of communication. Biochemical, shown in black arrows, immune shown in grey arrows and neural shown in purple 
arrows. SCFA; Short-chain fatty acids, ACTH, adrenocorticotropic hormone; CRF, corticotropin-releasing factor. Extracted 
from (Cryan & Dinan, 2012) 
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AIMS 
The major goals of this thesis were to 1) investigate the extent of gut microbiota alterations after 
stroke and the bi-directional interaction between the gut and the brain. 2) Reflect how differences in 
the gut microbiota composition may contribute to discrepancies in stroke research. 3) Elucidate the 
role of the gut microbiota in the recovery phase after stroke. 
 
To address the first aim, we used 16S RNA sequencing and revealed differences in the gut microbiota 
composition between sham and different experimental stroke surgeries. We then utilised GF mice 
treated with FMT in order to investigate the altered stroke microbiome vs. sham microbiome on the 
intestinal immune system. Immune cell labelling was used to track cells from the gut to the brain and 
to show the significance of gut microbiome immune cell polarisation on stroke outcome. Finally using 
GF mice, we characterised whether gut microbiota presence affected stroke outcome.  
 
For the second aim, we obtained mice from 3 commercial breeders and characterised the content of 
their gut microbiome and intestinal immune compartment. The hypothesis was that the potentially 
different microbiome composition from different commercial breeders would partly explain stroke 
studies which were unable to be reproduced in different laboratories. From our previous study, we 
learnt that dMCAo stroke model did not alter the microbiome composition. We used the dMCAo in 
order to investigate the prevailing gut microbiome composition from the respective breeders, rather 
than stroke induced changes. Additionally, we used CD28 superagonist, as a therapeutic to reduce 
stroke infarct volume. In experimental research, this drug had previously inconclusive results, and 
within this study we addressed the role of the gut microbiota in this phenomenon.  
 
For the third aim we set out to investigate the microbiota in the recovery phase after stroke and 
assessed the multimodal features which characterise regeneration. As a result, from the first study 
we saw that the composition of the gut microbiome was different; therefore we hypothesised that 
the key bioactive metabolites produced by the gut microbiota would also differ.  Here we 
administered SCFA within the drinking water as a 4-week pre-supplementation paradigm. We utilised 
a photothrombotic (PT) stroke model to target motor areas of the cortex and performed specific 
motor deficit assessment. The automated assessment of affected limb motor deficits allowed us to 
observe the effects of SCFA on functional recovery after stroke. Furthermore, we employed in vivo 
widefield calcium imaging to investigate network connectivity and Golgi-Cox staining to investigate 
synaptic alterations. Finally, we investigated brain resident (microglia) and peripheral (lymphocytes) 
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immune cells and their potential involvement in altered synaptic changes following SCFA 
supplementation.  
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RESEARCH ARTICLES 
MICROBIOTA DYSBIOSIS CONTROLS THE NEUROINFLAMMATORY RESPONSE AFTER 
STROKE 
SUMMARY 
In this first study we characterised to what extent the gut microbiota composition changes after 
stroke and how this affects acute stroke outcome. Using faecal 16S RNA sequencing, we initially 
identified a decrease in species diversity. We mainly observed an expansion of the Bacteroides 
phylum in mice after fMCAo compared to sham surgery. We then hypothesised that the stroke itself 
induces gastrointestinal (GI) paralysis. Using a FITC dextran oral gavage bolus, we were able to track 
the fluorescence in various segments of the gut and identify a reduction of motility after stroke. The 
reduced gut motility seen after fMCAo was also associated with an increased protein leakage of the 
gut and furthermore, an increase in stress hormones such as catecholamine. Surgical ileus was 
performed to disrupt gastrointestinal motility and confirmed that gut motility alterations induced gut 
microbial dysbiosis. Interestingly there was no change in gut motility within the dMCAo model, and 
no significant alterations in gut microbiota composition. For a next step, we utilised the faecal gut 
microbial dysbiosis induced by fMCAo and not dMCAo stroke models to investigate the role of the 
gut microbiota in stroke. This question was addressed using FMT donors from mice which underwent 
fMCAo surgery. The fMCAo microbiome samples were then transferred into GF mice, which then 
underwent dMCAo surgery. From our previous experiment, we knew that dMCAo would not alter the 
microbiome content, and thus allow us to investigate the direct effects of the fMCAo stroke-dysbiotic 
microbiome on dMCAo stroke outcome. The fMCAo faecal receiver experienced larger strokes, with 
greater behavioural deficits and a more proinflammatory immune system. Using CFSE dye we 
labelled all cells in the PP, and then identified these cells within the brain after stroke. Here we 
discovered that 25% of all T cells in the brain after stroke were originating from the gut. This showed 
that the dysbiotic microbiota composition polarised a proinflammatory immune response, which 
later contributed to the inflammatory milieu and worsened stroke outcome. Furthermore, we 
showed that FMT treatment with a healthy microbiome was beneficial and reduced the severity of 
stroke, which was associated with a higher number of Tregs. This beneficial effect of healthy 
microbiome FMT was not evident in Rag–/– mice, a transgenic model absent in T and B lymphocytes. 
This confirmed that the immune modulation via the gut microbiome was affecting stroke outcome.  
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for Infection Research (DZIF), partner site Munich, 80336 Munich, Germany
Acute brain ischemia induces a local neuroinflammatory reaction and alters peripheral immune homeostasis at the same time. Recent
evidence has suggested a key role of the gut microbiota in autoimmune diseases by modulating immune homeostasis. Therefore, we
investigated the mechanistic link among acute brain ischemia, microbiota alterations, and the immune response after brain injury. Using
two distinct models of acute middle cerebral artery occlusion, we show by next-generation sequencing that large stroke lesions cause gut
microbiota dysbiosis, which in turn affects stroke outcome via immune-mediated mechanisms. Reduced species diversity and bacterial
overgrowth of bacteroidetes were identified as hallmarks of poststroke dysbiosis, which was associated with intestinal barrier dysfunc-
tion and reduced intestinal motility as determined by in vivo intestinal bolus tracking. Recolonizing germ-free mice with dysbiotic
poststroke microbiota exacerbates lesion volume and functional deficits after experimental stroke compared with the recolonization with
a normal control microbiota. In addition, recolonization of mice with a dysbiotic microbiome induces a proinflammatory T-cell polar-
ization in the intestinal immune compartment and in the ischemic brain. Using in vivo cell-tracking studies, we demonstrate the
migration of intestinal lymphocytes to the ischemic brain. Therapeutic transplantation of fecal microbiota normalizes brain lesion-
induced dysbiosis and improves stroke outcome. These results support a novel mechanism in which the gut microbiome is a target of
stroke-induced systemic alterations and an effector with substantial impact on stroke outcome.
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Introduction
The inflammatory reaction to sterile tissue injury is a critical
pathophysiological component in organ-specific injuries, includ-
ing ischemic stroke (Iadecola and Anrather, 2011; Chamorro et
al., 2012), myocardial infarction (Hofmann and Frantz, 2015),
and other conditions (Huang et al., 2007). Previous reports have
shown that T cells play a defining role in secondary neuroinflam-
mation after brain ischemia (Shichita et al., 2009; Liesz et al.,
2013c; Schwartz and Raposo, 2014). Experimental approaches
using pharmacological or genetic lymphocyte depletion para-
digms (Yilmaz et al., 2006; Kleinschnitz et al., 2010) or pharma-
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Significance Statement
We have identified a bidirectional communication along the brain– gut microbiota–immune axis and show that the gut microbi-
ota is a central regulator of immune homeostasis. Acute brain lesions induced dysbiosis of the microbiome and, in turn, changes
in the gut microbiota affected neuroinflammatory and functional outcome after brain injury. The microbiota impact on immunity
and stroke outcome was transmissible by microbiota transplantation. Our findings support an emerging concept in which the gut
microbiota is a key regulator in priming the neuroinflammatory response to brain injury. These findings highlight the key role of
microbiota as a potential therapeutic target to protect brain function after injury.
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cological approaches to block cerebral lymphocyte invasion
(Liesz et al., 2011; Neumann et al., 2015) have established a pri-
mary role for lymphocytes, particularly T cells, as crucial media-
tors of an inflammatory collateral damage to the injured brain
after stroke. Previous work from our group and others has pro-
posed that Thelper cell subpopulations might have differential ef-
fects on stroke outcome: proinflammatory Th1, Th17, and  T
cells have been associated with increased inflammatory damage
and worse outcome, whereas regulatory T cells (Tregs) have been
shown to suppress an overshooting neuroinflammatory reaction
to brain injury (Liesz et al., 2009a; Shichita et al., 2009; Gelder-
blom et al., 2012; Liesz et al., 2013c). In contrast to primary
autoimmune diseases of the CNS, acute brain ischemia induces a
rapid local and peripheral immune activation (Iadecola and An-
rather, 2011; Shichita et al., 2012; Liesz et al., 2015). T cells are
recruited to the injured brain already within the first days after stroke
(Gelderblom et al., 2009; Zhou et al., 2013) and peripheral T-cell
activation can also be observed (Offner et al., 2006; Yilmaz et al.,
2006; Liesz et al., 2009b; Vogelgesang et al., 2010). Nevertheless, the
mechanisms of peripheral T-cell activation, specifically Thelper cell
polarization, after acute brain injury are still elusive.
Several lines of evidence suggest that the gut microbiota is a key
regulator of T-cell homeostasis and is intricately involved in the mat-
uration of the immune system and maintaining the mutual coexis-
tence of host and microbe (Ivanov et al., 2009; Hooper et al., 2012;
Arpaia et al., 2013). Recently, the functional relation between the gut
microbiota and brain function, termed the “gut–brain axis,” has
become an emerging field in neuroscience and neuroimmunology
(Collins et al., 2012; Cryan and Dinan, 2012). The gut microbiota has
been attributed a decisive role in autoimmune diseases of the CNS
(Berer et al., 2011; Lee et al., 2011). A recent report by l (Benakis et al.
(2016) has demonstrated that antibiotic-treatment-induced dysbio-
sis of intestinal microbiota influences poststroke neuroinflamma-
tion and outcome in an experimental stroke model. However, the
impact of stroke on the microbiota composition and the contribu-
tion of stroke-specific microbiota alterations on neuroinflammation
were previously unknown. Therefore, the aim of this work was to
investigate microbiota alterations after brain ischemia and their role
in the poststroke neuroinflammatory reaction.
In this study, we observe dysbiosis of the gut microbiota via
stress-mediated intestinal paralysis after stroke. In turn, microbi-
ota dysbiosis is causally linked to changes in T-cell homeostasis,
induction of a proinflammatory response, and deterioration of
stroke outcome. Fecal microbiota transplantation to normalize
poststroke dysbiosis is associated with an improved stroke out-
come. Altogether, our data point to a novel and highly complex
interplay between the brain and the gut microbiota after acute
brain injury in which the microbiota is a target of stress-mediated
pathways resulting dysbiosis, as well as an effector of immune
homeostasis with profound impact on stroke outcome.
Materials and Methods
Animal experiments. All animal experiments were performed consistent
with the guidelines for the use of experimental animals and were ap-
proved by the governmental committee of Upper Bavaria (Regier-
ungspraesidium Oberbayern #2532-65-2014). Wild-type C57BL/6J mice
and Rag1  /  male mice were obtained from Charles River Laboratories.
Germ-free (GF) C57BL/6J and GF Rag1  /  female mice were obtained
from the Clean Mouse Facility, University of Bern, Switzerland. A priori
sample size calculation was based on either variance and effect size from
previous studies or on preliminary pilot experiments performed during
this study. Data were excluded from all mice that died after surgery.
Animals were randomized to treatment groups and all analyses were
performed by investigators blinded to group allocation. Unblinding was
performed after completion of statistical analyses. All animal experi-
ments were performed and reported consistent with the ARRIVE guide-
lines (Kilkenny et al., 2010).
GF mouse handling and intestinal recolonization. GF mice were housed
in sterile HAN-gnotocages and received the same sterile water and pel-
leted food as conventional or recolonized mice. All surgical procedures,
cage changes, and behavioral tests of GF mice were performed in a dis-
infected laminar flow microbiological safety cabinet. GF mice were re-
colonized with gut microbiota obtained from sham or post-filament
middle cerebral artery (MCA) occlusion model (fMCAo) donor mice by
gastric gavage of freshly prepared cecum microbiota. In brief, the donor
mice were killed, cleaned with 70% ethanol, and the peritoneal cavity was
opened to expose the cecum. The contents of the cecum were collected in
sterile tubes, diluted in sterile water to 200 mg/ml, and centrifuged at
2000 rpm for 10 min to remove the large particles. The supernatants were
collected into fresh sterile tubes and each recipient mouse received a
single 200 l bolus of the freshly prepared microbiota suspension.
Permanent distal MCA occlusion model (cMCAo). Focal cerebral isch-
emia was induced as described previously by permanent occlusion of the
MCA distal of the lenticulostriate arteries (Llovera et al., 2014). In brief,
the mice were anesthetized with an intraperitoneal injection of fentanyl
(0.05 mg/kg), midazolam (5 mg/kg), and medetomidine (0.5 mg/kg).
The skull was exposed by skin incision, a burr hole was drilled in the
temporal bone, and the MCA was permanently occluded using high-
frequency electrocoagulation forceps. Immediately after surgery, anes-
thesia was antagonized by intraperitoneal injection of a combination of
naloxon (1.2 mg/kg), flumazenil (0.5 mg/kg), and atipamezol (2.5 mg/
kg). After recovery, mice were returned to their cages with ad libitum
access to water and food. Sham surgery was performed by the same
surgical procedures without coagulation of the exposed MCA. Through-
out the surgical procedure, body temperature was maintained at 37°C
using a feedback-controlled heating pad. The overall mortality rate in
this experimental group was 5%. Exclusion criteria were subarachnoid
hemorrhage or death during surgery.
Transient fMCAo. Mice were anesthetized with isoflurane delivered in
a mixture of 30% O2 and 70% N2O. An incision was made between the
ear and the eye to expose the temporal bone. A laser Doppler probe was
affixed to the skull above the MCA territory and the mice were placed in
the supine position. An incision was made in the midline neck region and
the common carotid artery and left external carotid artery were isolated
and ligated; a 2 mm silicon-coated filament (catalog #701912PKRe; Doc-
col) was inserted into the internal carotid artery and MCA occlusion was
confirmed by a corresponding decrease in blood flow (i.e., a decrease in
the laser Doppler flow signal). After 60 min of occlusion, the animals
were reanesthetized and the filament was removed. For the survival pe-
riod, the mice were kept in their home cage with facilitated access to
water and food. Sham-operated mice received the same surgical proce-
dure except the filament was inserted and immediately removed. Body tem-
perature was maintained throughout surgery using a feedback-controlled
heating pad. The overall mortality rate in this group (excluding the sham-
operated animals) was 10%. Exclusion criteria were as follows: insufficient
MCA occlusion (a reduction in blood flow to 20% of the baseline value),
mice that died during the surgery, and mice without induction of brain
ischemia as quantified postmortem by histological analysis.
Cylinder test. GF mice that were inoculated with a fecal suspension
obtained from control and fMCAo-induced mice were tested for forepaw
use and asymmetry by measuring behavioral asymmetry and general
activity on the first and third days after cMCAo surgery. The test was
performed in a sterile laminar flow safety cabinet. Mice were placed in a
transparent acrylic glass cylinder (diameter: 8 cm; height: 25 cm) in front
of two mirrors and videotaped (Llovera et al., 2014). To assess independent
forelimb use, contact with one forelimb during full rear and landing with
only one forelimb after full rear were scored by performing a frame-by-frame
analysis of the recorded videos. All rearing movements during the trial were
counted and used as a measure of the animal’s overall activity.
Fecal microbiota transfer (FMT). Freshly defecated feces were collected
from restrained mice and placed in sterile tubes. Donor mice (Charles
River) were housed under SPF conditions and the same ones were used
for all recipient mice in a given group. After collection, the fecal pellets
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were immediately mixed in sterile water (to 200 mg/ml) and the suspen-
sion was centrifuged at 2000 rpm for 10 min. The supernatant was col-
lected and 200 l was administered to each mouse by gastric gavage. FMT
treatment was administered daily for the survival period starting on
the same day of stroke induction. For FMT experiments, the recipient
mice were housed in cages with sterile bedding and ad libitum access to
sterile water. For the fMCAo model, the mice did not have access to food
to eliminate any confounding effects of differing food consumption be-
tween the fMCAo, sham-operated, and treatment groups. Therefore,
fMCAo and FMT recipient mice received three daily oral doses of water-
suspended ultra-fine ground chow containing the same composition and
caloric intake as the pelleted food (equivalent to 2.5 mg of chow).
Infarct volumetry. Perfused brains were removed at the indicated time
points after stroke induction and frozen on powdered dry ice. Coronal
cryosections (20 m thick) were cut at 400 m intervals. The sections
were stained with cresyl violet consistent with standard protocols and
scanned at 600 dpi. Infarct area was measured in each section using
ImageJ software. For the fMCAo model, an edema correction for infarct
volume was performed using the following formula: (ischemic area) 
(direct lesion volume)  [(ipsilateral hemisphere)  (contralateral
hemisphere)]. The total infarct volume was calculated by integrating the
measured areas and intervals between the sections.
Preparation of cells from lymphoid organs. Mice were deeply anesthe-
tized with ketamine (120 mg/kg) and xylazine (16 mg/kg). Blood was
obtained by intracardiac puncture and collected into EDTA test tubes;
the plasma was isolated by centrifugation at 3000 rpm for 10 min and
stored at 80°C until further use. The mice were then transcardially
perfused with normal saline and the spleen and Peyer’s patches (PPs)
were removed into cold Hank’s balanced salt solution. The organs were
homogenized and filtered through 30 – 40 m cell strainers; in the spleen
samples, the erythrocytes were lysed using isotonic ammonium chloride
buffer. The total cell counts per organ were measured using an auto-
mated cell counter (Bio-Rad). For the isolation of mucosal leukocytes,
the distal ileum was dissected carefully to remove the muscle layer. The
mucosal tissue was then minced into small pieces and incubated in RPMI
medium containing 10 g/ml DNase I and 0.5 mg/ml collagenase D
(Roche) for 10 min at 37°C. The cell suspensions were then mechanically
homogenized, filtered, and washed before flow cytometric analysis.
Isolation of brain-invading leukocytes. Mice were deeply anesthetized
with ketamine (120 mg/kg) and xylazine (16 mg/kg) and transcardially
perfused with normal saline. Brains were carefully removed and ipsilat-
eral hemispheres were used for preparation of cells as described previ-
ously (Liesz et al., 2011). Briefly, brains were cut into small pieces and
digested in RPMI medium containing 10 g of DNase I and 0.5 mg/ml
collagenase D (Roche) for 10 min at 37°C. The cell suspension was me-
chanically homogenized and passed through a 40 m cell strainer
(Falcon). The cell suspension was resuspended with 40% Percoll solution
(GE Healthcare) and overlayed on a 70% Percoll solution. After centrif-
ugation at 2100 rpm for 25 min at room temperature, cells at the inter-
phase were collected and washed in isotonic buffer.
Flow cytometry analysis. The following mouse antigen-specific anti-
bodies were purchased from eBioscience/BioLegend: CD3 FITC (17A2),
CD4 PerCP Cy5 (clone RM4 –5), CD45 eF450 (30-F11), CD11b PerCP
Cy5.5 (M1/70), IFN- FITC (XMG1.2), and IL-17 APC (17B7). To
quantify the various cell populations, cells were stained with specific
antibodies in accordance with the manufacturer’s protocols. For intra-
cellular cytokine staining, cell suspensions from the spleen and PPs were
resuspended in RPMI medium containing 10% heat-inactivated fetal calf
serum, 1% penicillin/streptomycin, and 10 M 2-mercaptoethanol. The
cells were plated at a density of 3  10 5 cells/well on anti-CD3 antibody
(clone 145-2C11; eBioscience)-coated 96-well plates, costimulated with
soluble CD28 antibody (clone 37.51; eBioscience), and incubated for
40 h at 37°C and 5% CO2. After incubation, GolgiPlug (BD Biosciences)
was added to the cells for 4 h, after which the cells were harvested for
intracellular staining using the Foxp3/Transcription Factor Staining Kit
(eBioscience). Stained cells were measured in a FACSverse flow cytome-
ter (BD Biosciences) and analyzed using FlowJo version 10 (TreeStar).
FISH and histochemical staining. The distal ileum was ligated on both
sides with surgical sutures, removed, fixed in 4% paraformaldehyde, and
6-m-thick transverse sections were prepared. The sections were
mounted on glass slides and FISH was performed in an equilibrated
humidity chamber at 46°C in hybridization buffer containing 0.9 M NaCl,
20 mM Tris-HCl, pH 7.2, 30% formamide, and 0.01% SDS for 3 h. Probes
(EUB 338: Cy5-GCT GCC TCC CGT AGG AGT-Cy5; EUB 338-III: Cy5-
GCT GCC ACC CGT AGG TGT-Cy5) were used at a final concentration
of 5 ng/l. Sections were hybridized in 20 l of hybridization buffer
containing the EUB 338 or EUB 338-III probe. The sections were then
placed in prewarmed (48°C) wash buffer containing 100 mM NaCl, 20
mM Tris-HCl, pH 7.2, and 5 mM EDTA in autoclaved Milli-Q water
(Millipore) for 10 min. SYTOX green (1:5000) was used to counterstain
the nuclei. Images (1024  1024 pixels, 400 Hz scan rate) were acquired
as z-stacks using a 63 glycerol objective on a confocal microscope (TCS
SP5 X; Leica).
Immunohistology. For analysis of labeled T cells from PPs, 12 m
coronal brain sections at bregma height were stained with anti-mouse
CD3 polyclonal antibody (1:50; Abcam) and goat anti-rabbit Alexa
Fluor 488 (1:200; Jackson Laboratories) antibodies. After nuclear
staining with DAPI, sections were analyzed for the presence of CM-
DiI CD3 DAPI  cells using confocal microscopy (TCS SP5 X; Leica).
Tracing migration of leukocytes from PPs to the brain. Forty-eight hours
after cMCAo or sham surgery, cells within PPs were labeled by microin-
jection of fluorescent-cell-staining dyes CFSE (25 M in 2 l of PBS per
PP) or CM-DiI (5 M in 2 l of PBS per PP) (Life Technologies). Mice
were killed 24 h after cell labeling and brains prepared either for flow
cytometric analysis (CFSE labeling) or immunohistological analysis
(CM-DiI labeling) as described above.
Postoperative ileus model. Mice were anesthetized with isoflurane de-
livered in a mixture of 30% CO2 and 70% N2O. Before surgery, an injec-
tion of carprofen (5 mg/kg) was administered to the mice. After this, mice
were fixed with surgical tape in the supine position on a feedback-regulated
heating pad. The abdominal cavity was then opened 2 cm in length along the
linea alba. With two moist sterile cotton applicators, the small intestine con-
tent was carefully touched from the pylorus to the cecum as described pre-
viously (Vilz et al., 2012). After surgery, the mice were sutured, monitored in
a recovery chamber, and then returned to their home cages. Fecal samples
were collected before and 3 d after the surgery for microbial DNA isolation
and metagenomic analysis. Directly afterward, an oral bolus of FITC-
dextran was administered for the gut motility test.
Gastrointestinal motility analysis. Mice received a 100 l oral bolus of
50 mg/ml FITC-dextran (70,000 kDa; Sigma-Aldrich) in 0.9% PBS. One
hour after administration, the mice were killed and the entire intestinal
tract from the stomach to the colon was removed and imaged using a
chemiluminescence detection system (Fusion FX7). To quantify gastro-
intestinal transit (i.e., motility), the complete gastrointestinal tract was
divided into segments, each segment was flushed with distilled water, and
the fluorescence of the purified recovered flushing solution was mea-
sured using a fluorescence plate reader (Promega). The values obtained
were normalized to blank controls and expressed as the percentage of
fluorescence per intestinal segment.
ELISA for albumin quantification. Mice were killed 3 d after fsham or
fMCAo surgery and feces and plasma samples were collected for mea-
surement of albumin concentrations. Sampled feces (50 mg/ml) and
plasma (1:50000) were diluted in assay buffer (50 mM Tris, 0.1 M NaCl,
0.05% Tween 20, pH 7.4) and ELISA was performed with corresponding
albumin standard dilutions. Albumin was quantified by ELISA and the
ratio of feces to plasma albumin are presented (Bethyl Labratories).
Bacterial cultures. Mice were deeply anesthetized and perfused tran-
scardially with normal saline. The cecum’s contents were then trans-
ferred to sterile tubes under strict aseptic conditions. A fixed amount of
cecum content from each mouse was mixed in PBS to 50 mg/ml and
dilutions were prepared. Two dilutions (1:40,000 and 1:400,000) from
each sample were plated on blood agar plates (Oxoid) and incubated at
37°C for 48 –72 h. To generate an anaerobic environment, the plates were
placed in anaerobic jars containing AnaeroGen paper sachets (Oxoid).
After the incubation period, the plates were examined for bacterial
growth and the number of colonies was determined.
Microbial community analysis. DNA from mouse feces was isolated
using the QIAamp Fast DNA Stool Mini Kit (Qiagen). The total amount
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of DNA in each sample was measured using a Qubit fluorometer (Life
Technologies). 16S rRNA amplicons were generated using primers cor-
responding to the hypervariable regions V1-V3 (primer 27F: AGA
GTTTGATCCTGGCTCAG; primer 534R: ATTACCGCGGCTGCT
GG), and the PCR products were purified. Libraries were prepared using
the standard tagmentation procedure (Nextera XT; Illumina). All sam-
ples were sequenced on an Illumina MiSeq platform using a 300 bp
paired-end approach. Amplicon sequencing datasets were analyzed us-
ing the Metagenomics (MG)-RAST pipeline (version 3.3.6) (Meyer et al.,
2008). Low-quality reads (comprising 0.01% of all reads) were
trimmed using the SolexaQA program; only high-quality reads were in-
cluded in the subsequent analysis. 16S rRNA genes were identified by
performing a BLAT (Kent, 2002) search, and amplicons were clustered at
97% identity with an e-value cutoff of 1e-5. A BLAT similarity search for
the longest cluster representative was performed against the Ribosomal
Database Project (RDP) database. Rarefaction curves,  diversity, and
phylogenetic analysis were performed and phylogenetic trees were drawn
using the MG-RAST platform. Read counts were normalized logarithmi-
cally for subsequent analysis. Principal component analysis plots were
drawn using normalized values and Bray–Curtis distance. Differences
between group means for genera were analyzed using ANOVA or Stu-
dent’s t test. p-values were adjusted for comparison of multiple compar-
isons using Bonferroni correction. The DNA sequences have been
deposited in MG-RAST (http://metagenomics.anl.gov/) under accession
number 9778. The linear discriminant analysis (LDA) effect size (LEfSe)
method was used to identify microbial taxa showing a statistically different
relative abundance between the microbiota after sham and fMCAo surgery
(Segata et al., 2011). Experiments were performed with an  error set to 0.05
and the LDA threshold set to 2.0.
Quantitative RT-PCR. Brain tissue from the ipsilateral and contralat-
eral hemispheres was lysed in Qiazol Lysis Reagent (Qiagen) and total
RNA was extracted using the MaXtract High Density kit (Qiagen). RNA
was purified using the RNeasy Mini Kit in accordance with the manufac-
turer’s instructions (Qiagen). Equal amounts of RNA from each sample
were used to synthesize cDNA with the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). The quantitative expression of
various cytokines was measured using predesigned RT 2 qPCR Primer
Assays and SYBR Green ROX qPCR Mastermix (Qiagen) in a LightCycler
480 II (Roche). A linear dilution-amplification curve was obtained from
diluted pooled samples. Using this curve, the expression of each gene was
measured relative to the expression of the housekeeping gene encoding
peptidylprolyl isomerase A (i.e., cyclophilin). All assays were performed
in duplicate.
Statistical analysis. Data were analyzed using GraphPad Prism version
6.0. All summary data are expressed as the mean 	 SD. All datasets were
tested for normality using the Shapiro–Wilk normality test. The groups
containing normally distributed data were tested using a two-way Stu-
dent’s t test (for two groups) or ANOVA (for more than two groups). The
remaining data were analyzed using the Mann–Whitney U test. Similar
variance was assured for all groups, which were compared statistically.
Differences with a p-value 0.05 were considered to be statistically sig-
nificant. p-values were adjusted for comparison of multiple comparisons
using Bonferroni correction. More detailed methods for analyzing the
amplicon sequencing results and the metabolomics data are provided in
the respective Materials and Methods sections.
Results
Stroke induces intestinal microbiota dysbiosis
To investigate the impact of acute stroke on the gut microbiota,
we used fMCAo, an experimental stroke model resulting in large
hemispheric lesions (mean 	 SD of all control experiments in
this study: 72 	 18 mm 3; Fig. 1a). Next-generation sequencing of
gut microbiota composition in mice after fMCAo and controls
(naive and sham treatment) revealed substantial changes 3 d after
severe stroke (Fig. 1b). We observed significant reduction in spe-
cies diversity as a key feature of after stroke microbiota dysbiosis
(Fig. 1c). Hallmarks of poststroke dysbiosis included changes in
specific bacterial genera within the most abundant phyla: Firmi-
cutes, Bacteroidetes, and Actinobacteria (Fig. 1d). We next per-
formed an indicator taxa analysis using LEfSe algorithm analysis
for the detection of specific features that were statistically differ-
ent between sham- and fMCAo-operated mice. Using this anal-
ysis strategy, we identified several significantly changed species
after stroke induction consistent with the above-shown phyloge-
netic tree analysis; however, we also identified corresponding
changes in higher-order taxa of the respectively altered species
(Fig. 1e). These results suggested a consistent and specific impact
of brain injury on microbiota populations within the most abun-
dant bacterial phyla.
Extensive brain injury impairs gastrointestinal function
Next, we investigated which mechanisms link acute brain injury
and microbiota dysbiosis. It was reported previously that patients
with severe brain injuries experience reduced gastrointestinal
motility (Olsen et al., 2013; Engler et al., 2014). Consistent with
these clinical observations, we detected severe gastrointestinal
paralysis after large infarcts induced by the fMCAo stroke model
using a gastric fluorescent bolus tracking technique (Fig. 2a,b).
Reduced gastrointestinal motility was associated with over-
growth of intestinal bacteria after severe experimental stroke
compared with sham surgery (Fig. 2c). Due to this functional
gastrointestinal impairment, we further investigated the impact
of stroke on intestinal barrier function. We did not observe bac-
terial translocation or transmucosal bacterial invasion after
stroke by in situ hybridization with a general bacteria (EUB 388)
probe (Fig. 2d). However, we measured a significantly increased
protein leakage by feces/plasma albumin ratio after fMCAo
compared with sham-treated controls (Fig. 2e). These results
suggested a functionally, but not morphologically, impaired in-
testinal barrier after fMCAo in association with poststroke intes-
tinal paralysis. Previous reports from our group and others have
identified dysregulation of the autonomous nervous system and a
pronounced stress response after stroke as one of the key path-
ways involved in mediating systemic effects on remote organ
function after acute brain injury (Meisel et al., 2005; Chamorro et
al., 2007; Chamorro et al., 2012; Liesz et al., 2013b; Mracsko et al.,
2014). We detected increased blood catecholamine levels after
extensive stroke in the fMCAo model to be associated with post-
stroke intestinal paralysis (Fig. 2f). Consistent with our results, a
recent report by Houlden et al. (2016) demonstrated poststroke
intestinal changes as a consequence of the catecholaminergic
stress response. It was shown previously that the severity of the
brain injury is correlated with the extent of secondary systemic
immunomodulation (Meisel et al., 2005; Liesz et al., 2009b).
Consistent with these previous immunological findings, induc-
tion of only small cortical lesions in a second stroke model
(cMCAo, mean infarct volume in this model: 8 	 2 mm 3) caused
no significant change in the microbiota composition and species
diversity (Fig. 2g,h). Small brain lesions in the cMCAo model also
did not induce gastrointestinal paralysis (Fig. 2i). These results
indicate that infarct severity might be the key factor determining
intestinal dysfunction, although we cannot ultimately exclude the
possibility that other factors differing between the investigated
stroke model also contributed to this effect.
To investigate the causality of gut motility changes after stroke
and observed microbiota dysbiosis, we further determined effects
of inducing gastrointestinal paralysis by physical intestinal ma-
nipulation, a model for postsurgical ileus (Vilz et al., 2012). Post-
surgical ileus mimicked the disturbed gastrointestinal motility
pattern of stroke animals (Fig. 3a) and recapitulated general fea-
tures of microbiota dysbiosis such as reduced  diversity (Fig.
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Figure 1. Severe stroke induces microbiota dysbiosis. a, Representative images of cresyl-violet-stained coronal brain sections 3 d after fMCAo. In each section, the infarct area is
outlined in red 5 mm). b, Principal component (PC) analysis of the intestinal microbiota by taxonomic abundance patterns in naive mice (before sham or fMCAo surgery) and after sham
and fMCAo surgery. c, Quantitative analysis of  diversity confirms significantly reduced species diversity of the gut microbiota after brain injury in the fMCAo model (Mann–Whitney U
test). d, Phylogenetic tree illustrating the distribution of the identified bacterial genera within the most abundant phyla (Actinobacteria, Bacteroidetes, and Firmicutes) comparing
post-fMCAo mice with sham-operated and before-fMCAo mice. Genera that were significantly altered in the fMCAo group compared with the sham and before-fMCAo groups are
indicated in red (ANOVA, n  5 mice per group). e, LEfSe algorithm analysis was performed for indicator taxa analysis identifying features that are statistically different between sham-
and fMCAo-operated mice. Labels in boxes define significantly regulated operational taxonomic units (OTU, numbers) and higher order taxa, respectively.
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3b,c). Despite this, in-depth phylogenetic analysis also revealed
substantial differences in specifically regulated taxa between
stroke and mechanically induced dysbiosis (Fig. 3d). Collectively,
these results suggest stress-mediated paralytic ileus as a potential
cause of poststroke microbiota dysbiosis, although alternative
CNS-specific pathways could be involved in poststroke dysbiosis.
Dysbiosis is causally linked to deteriorated stroke outcome
We next investigated whether poststroke dysbiosis has a func-
tional impact on stroke outcome. To investigate this mechanism,
we used a microbiota-transfer model into GF mice. We trans-
planted microbiota obtained from sham- and fMCAo-operated
mice into GF recipient mice; 3 d later, we induced cortical lesions
by the cMCAo model, which does not alter microbiota composi-
tion per se, as shown above (Fig. 4a). Metagenomic analysis of
recipients’ feces samples at the time point of cMCAo induction
(i.e., 3 d after transplantation) confirmed establishment of dis-
tinct microbiota in the recipient mice, which resembled the spe-
cific pattern of the microbiota donors (Fig. 4b). Remarkably,
mice that had received microbiota from brain-injured animals
developed significantly larger infarct volumes after cortical le-
sions in the cMCAo stroke model compared with littermates that
were recolonized with sham-surgery microbiota (Fig. 4c). In
addition, functional impairment in recipients of the dysbiotic
Figure 2. Lesion severity determines gastrointestinal dysfunction. a, Intestinal motility was measured 24 h after fMCAo or sham surgery. Representative fluorescence images of the complete
gastrointestinal tract 60 min after gastric instillation of FITC-dextran showing retention of the fluorescent bolus in the upper gastrointestinal tract as a marker of severely impaired motility after
fMCAo compared with sham mice. Arrowheads indicate cecum. b, Quantification of fluorescence intensity in intestinal segments. Note the retention of fluorescence signal in the upper gastroin-
testinal tract after fMCAo (n  8 per group, 3 individual experiments). c, Number of colony forming units (CFUs) per milligram of murine cecal content cultured under anaerobic conditions after sham
or fMCAo surgery (n  8 –9 mice per group, 2 independent experiments). d, No bacterial invasion into lamina propria was found in transverse sections of mouse ileum, which were hybridized using
a general bacteria-specific EUB 338 probe with Sytox green counterstaining. Left panels: Magnification, 20; scale bars, 100 m; right panels: magnification, 63, scale bars, 10 m. e, Albumin
concentrations were determined by ELISA and are represented as the ratio of the concentrations in feces and plasma from sham- and fMCAo-operated mice (n  5 mice per group, 2 individual
experiments). f, Plasma catecholamine levels, represented as catecholamine metabolite concentrations of metanephrine and normetanephrine, were significantly increased 24 h after fMCAo
compared with sham surgery (n  10 per group, 3 individual experiments). g, Representative cresyl-violet-stained coronal brain sections 3 d after stroke induction in the cMCAo model. The small
cortical lesions are outlined in red. h, Principal component (PC) analysis (left) for fecal taxonomic abundance after csham and cMCAo compared with fMCAo, and  diversity for the indicated groups
(right) illustrate that small cortical lesions do not affect microbiota compositon. i, Representative fluorescence images (left) and quantitative analysis (right, n  6) of gastrointestinal motility after
csham and cMCAo surgery corresponding to data shown in a and b. Bar graph: *p  0.05, mean 	 SD.
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Figure 3. Postsurgical ileus induces intestinal motility dysfunction and dysbiosis of the gut microbiota. a, Intestinal motility was measured 3 d after surgical ileus induction or sham surgery.
Shown are representative images of the gastrointestinal tract 60 min after an oral dose of FITC-dextran showing retention of fluorescence signal in the upper gastrointestinal tract (left).
Corresponding quantification of fluorescence intensity per intestinal segment (n  3 per group, right panel). b, Principal component (PC) analysis of the microbiota composition in mice before and
3 d after mechanical manipulation of the ileus reveals microbiota alteration. c, Analysis of Shannon diversity index show a significantly reduced species diversity induced by the postsurgical ileus
model. d, Shown is a phylogenetic tree illustrating the distribution of the identified bacterial orders comparing microbiota before and 3 d after surgery. Orders that significantly differed are
highlighted in red (n  3 mice per group, t test [unpaired]). All bar graphs: *p  0.05, mean 	 SD.
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microbiota was exacerbated, as determined by forelimb use
asymmetry and overall activity (rearing efforts) in the established
cylinder test for this stroke model (Fig. 4d). We next analyzed the
expression of the cytokines IL-17 and IFN- and of the transcrip-
tion factor Foxp3 as markers of Thelper cell polarization in brains
5 d after cMCAo. Recipients of post-fMCAo microbiota exhib-
ited massively increased expression of the proinflammatory
IFN- and IL-17 cytokines, which are markers of Th1 and Th17 T
cell polarization, respectively, and have previously been associ-
ated with worse outcome in experimental stroke models (Yilmaz
et al., 2006; Liesz et al., 2009a; Shichita et al., 2009; Gelderblom et
al., 2012). In contrast, Foxp3 expression, as a marker for neuro-
protective Treg cells, did not differ significantly between sham
and fMCAo microbiota recipients (Fig. 4e). In addition, we per-
formed flow cytometry analysis for intracellular cytokine
expression of T cells in PPs to investigate the effect of the distinct
microbiota on intestinal T-cell polarization. Here, we detected a
4-fold increased expression of proinflammatory Th17 (IL-
17) and Th1 (IFN-) cells in PPs of fMCAo microbiota com-
pared with sham microbiota recipients, consistent with results
obtained from brain tissue (Fig. 4f). These results indicate that
the dysbiotic microbiota after large (fMCAo) brain infarcts in-
duces a predominantly proinflammatory Th1 and Th17 re-
sponse, which is associated with increased infarct volume. This
finding is consistent with previous studies showing that T-cell
polarization can be induced by selected members of Bacte-
roidetes and Firmicutes (Round and Mazmanian, 2010; Magrone
and Jirillo, 2013). In addition to lymphocyte polarization/activa-
tion, microbial products can regulate innate immunity and con-
tribute to intestinal monocyte/macrophage maturation and
activation (Bain and Mowat, 2014). Here, we found increased
number of mucosal CD11b monocytes in mice that were recip-
ients of post-fMCAo microbiota (Fig. 4g). Together, these results
indicate an activation of intestinal innate and adaptive immune
cells in response to poststroke dysbiotic microbiota.
T cells migrate from the intestine to the poststroke brain
Interestingly, the peripheral immune responses coincided pre-
cisely with the massively increased cerebral gene expression for
proinflammatory cytokines, suggesting that peripherally acti-
vated and/or polarized T cells may migrate to the injured brain
after cMCAo in GF recipient mice. To investigate potential T-cell
Figure 4. Brain ischemia-induced dysbiosis alters the poststroke immune reaction and exacerbates stroke outcome. a, Experimental design for recolonizing GF mice with gut microbiota from
sham- or fMCAo- operated SPF donor mice. Three days after recolonization, mice underwent cMCAo induction and were killed another 5 d later for subsequent analysis. b, Principal component
analysis of the microbiota composition in donor mice after sham and fMCAo surgery and microbiota composition in GF recipient mice 3 d after transplantation with donor microbiota. Analysis
revealed a distinct pattern of the two donor populations before and after transplantation to recipient GF mice. c, Comparison of brain infarct volumes (cMCAo) in the recolonized recipient mice 5 d
after cMCAo induction. d, Recolonizing mice with the gut microbiota obtained from post-fMCAo donors significantly increased brain lesion volumes and significantly reduced behavioral performance
assessed by measuring forelimb use asymmetry (left) and total rearing activity (right) in the cylinder test (n  5– 8 per group, 2 individual experiments). e, Relative gene expression levels of IL-17,
IFN-, and Foxp3 in the ipsilateral (ipsi) and contralateral (contra) hemispheres of GF recipient mice (n  5– 8 per group, 2 individual experiments). Recolonization with microbiota from fMCAo
donor mice massively increased Th17 (IL-17) and Th1 (IFN-) expression compared with recipients of sham-microbiota. f, Representative dot plots with gating strategy for the flow cytometry
analysis of Th17 (IL-17) and Th1 (IFN-) T cells in PPs (left). Percentages of IL-17  and IFN-  T cells were significantly increased in PPs of mice recolonized with the fMCAo-microbiota (right
panel). g, Percentage of CD11b  monocytes/macrophages in the mucosal layer of the small intestine (terminal ileum) was significantly increased in mice receiving the microbiota from fMCAo
donors compared with sham microbiota. All bar graphs: *p  0.05, mean 	 SD.
Singh, Roth et al. • The Gut Microbiota in Acute Stroke J. Neurosci., July 13, 2016 • 36(28):7428 –7440 • 7435
migration from PPs to the brain, we used a fluorescent labeling
technique by microinjection of either CFSE or CM-DiI in all
detectable PPs of the mice intestines after cMCAo or sham sur-
gery (Fig. 5a). We confirmed that this microinjection technique
labeled cells only locally in PPs, but no systemic cell labeling by
potentially diffusing dye occurred in blood or spleen (Fig. 5b).
Consistent with a previous report (Benakis et al., 2016), T cells
and monocytes fluorescently labeled after microinjection in PPs
were detected in the ischemic hemisphere 3 d after cMCAo
consistent with the previously demonstrated kinetics of post-
stroke leukocyte invasion (Gelderblom et al., 2009; Liesz et al.,
2011) (Fig. 5c,d). CFSE-positive cells derived from labeled PPs
accounted for 25% of total T cells and the Thelper cell subpop-
ulation 3 d after cMCAo (Fig. 5e). We confirmed these findings in
an independent experiment using Cm-DiI as a lipophilic labeling
dye and subsequent histological analysis (Fig. 5f). Here, superim-
posing localization of T cells from five mice on one coronal sec-
tion map, we detected brain-invading T cells surrounding the
ischemic core consistent with previous reports using the same
stroke model (Liesz et al., 2011; Zhou et al., 2013); moreover, the
percentage of PP-derived T cells was consistent with results ob-
tained from the above-shown flow cytometric analysis (Fig. 5f,g).
These results unequivocally demonstrate the invasion of consid-
erable numbers of T cells from the intestine to the periinfarct
tissue at risk in the postischemic brain with a remarkably fast
kinetics.
Fecal microbiota transplantation is neuroprotective
after stroke
Based on our results, we hypothesized that poststroke dysbiosis is
a key novel target for modulating the systemic immune response
after stroke. Therefore, we tested the use of FMT as a therapeutic
approach to restore a healthy microbiome in animals after stroke.
Indeed, FMT treatment starting at the day of stroke induction
and performed once daily during the survival period significa-
ntly reduced the lesion after large stroke using the fMCAo stroke
model for severe brain infarctions (Fig. 6a). This improvement in
stroke outcome was associated with increased numbers of
Foxp3 Treg cells in peripheral immune organs and in the isch-
emic brain after stroke (Fig. 6b). To further elucidate the contri-
bution of lymphocytes to this effect, we examined FMT in a
model of lymphocyte-deficient Rag1 /  mice. FMT had no ef-
fect on lesion size in Rag1 /  mice, supporting the notion that
microbiome-mediated effects on brain injury are mediated by
lymphocytes (Fig. 6c). Metagenomic analysis of microbial com-
munities showed a normalization of stroke-induced dysbiosis
and partially restored microbiota diversity by the FMT treatment
in mice with extensive infarcts (Fig. 6d,e). More in-depth analysis
revealed that FMT treatment increased abundance of several of
the very same taxa, which were reduced by stroke-induction
compared with sham treatment (Fig. 6f). These findings suggest
that FMT therapy normalizes stroke-induced changes to micro-
Figure 5. Lymphocytes migrate from PPs to the brain after stroke. a, Experimental design for tracing the migration of PP-derived lymphocytes in mice after cMCAo or sham surgery. CSFE or CM-DiI
was injected in PP 2 d after the respective surgery and, 24 h later, brain and lymphoid organs were dissected and analyzed for dye-positive T cells. b, Validation of site-specific T-cell labeling with CFSE
in PP 3 h after microinjection; T-cell labeling was not detectable in blood and spleen. c, Representative histogram for CFSE  T cells (gated for CD45 CD3  expression) from flow cytometry analysis
of brain homogenates of the ipsilateral hemisphere 24 h after CFSE microinjection in all detectable PPs. d, Quantification of flow cytometry analysis shows increased numbers of CFSE  total T cells
(CD3 ) and Thelper cells (CD4
) and monocytes (CD11b ) in ischemic hemispheres 3 d after cMCAo compared with sham control. e, Percentage of CFSE-labeled CD3  and CD4  T cells identified
in ischemic hemispheres 3 d after cMCAo and 24 h after PP labeling. f, Brain-invading CM-DiI  T cells derived from PPs were identified in the peri-infarct region and are illustrated as a cumulative
map from five mice on one topographical coronal brain section at the bregma level g, Quantification of CM-DiI- and CM-DiI  T cells (CD3 ) per one histological brain section used to generate the
cumulative map shown in f.
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Figure 6. Fecal microbiota transplantation improves stroke outcome. a, Brain infarct volume 3 d after fMCAo was compared between mice receiving vehicle or FMT; FMT treatment
significantly reduced brain lesion volume (three independent experiments). b, Flow cytometric analysis shows increased Foxp3  Treg cell counts in spleens and ischemic hemispheres
after FMT treatment compared with controls 3 d after fMCAo (n  5 per group). c, Brain infarct volume 3 d after fMCAo in lymphocyte-deficient Rag1  /  mice did not differ between
vehicle and FMT treatment, suggesting a lymphocyte-mediated effect (two independent experiments). d, FMT treatment normalized microbiota composition after fMCAo-induced
dysbiosis as demonstrated by the taxonomic abundance of eubacterial phyla. Note the normalization in the abundance ratio between Firmicutes, Bacteroidetes, and the less abundant
phyla (others) in the FMT-treated group. e, Analysis of the corresponding  diversity by the Shannon diversity index showing that FMT treatment partially reversed the reduced species
diversity induced by fMCAo (n  5 mice per group). f, Phylogenetic tree illustrating the distribution of the identified bacterial orders comparing vehicle- and FMT-treated mice 3 d after
fMCAo. Orders that significantly differed between groups are highlighted in red (n  5 mice per group, t test [unpaired]). All bar graphs: *p  0.05, mean 	 SD.
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bial communities efficiently and might thereby exert a neuropro-
tective function after stroke.
Discussion
Our results support the concept of a bidirectional communica-
tion along the brain– gut–microbiome–immune axis. Recent re-
ports have suggested that the microbiota plays an evident role in
developmental and autoimmune brain disorders (Berer et al.,
2011; Cryan and Dinan, 2012) and that antibiotic treatment-
induced dysbiosis affects stroke outcome (Benakis et al., 2016).
Here, we report that stroke itself markedly affects the intestinal
microbial composition and that these changes in turn can deter-
mine stroke outcome.
In our study, we have demonstrated the substantial effects of
brain injury on microbiota composition; these effects included
reduction in microbiota species diversity and intestinal bacterial
overgrowth with a preferential expansion of the Bacteroidetes
phylum. In addition, we identified more specific stroke-induced
changes on the bacterial genus and even the species level. These
findings on poststroke dysbiosis are consistent with recent re-
ports describing changes in intestinal microbiota composition in
stroke patients (Karlsson et al., 2012; Swidsinski et al., 2012; Yin
et al., 2015). Several of these features of microbiota alterations are
of direct pathophysiological relevance; specifically, high microbi-
ota diversity has been suggested as a key feature of a healthy
microbiome (Claesson et al., 2012; Human Microbiome Project,
2012). Our analyses also revealed that the surgical procedure it-
self (i.e., sham surgery) also induced apparent changes in micro-
biota composition, thus highlighting the sensitivity of microbiota
composition to stress responses (Carabotti et al., 2015). How-
ever, brain injury compared with sham surgery imposed an ad-
ditional and substantial impact on microbiota composition and
we were able to detect specific species and their corresponding
higher-order taxa most significantly associated with acute brain
injury compared with sham surgery using indicator taxa analysis.
Our results suggested that microbiota dysbiosis after stroke is
associated with reduced gastrointestinal motility and intestinal
paralysis in a postsurgical ileus model recapitulated several key
features of poststroke dysbiosis. These findings have broad clin-
ical implications; specifically, the intestinal dysfunction revealed
by our animal model was recently reported in patients after acute
brain injury (Bansal et al., 2009; Olsen et al., 2013). However, a
decisive causality among poststroke stress response, impaired
motility, and dysbiosis could not be clarified in this study. In
addition, we cannot exclude other direct mediators released from
the necrotic brain tissue affecting microbiota composition via
currently unknown mechanisms. One potential alternative
mechanism not investigated in this study is the release of proin-
flammatory alarmins such as ATP, HMGB1, and S100 proteins
from the injured brain with potential direct effects on intestinal
immunity and microbiota composition (Liesz et al., 2015; Singh
et al., 2016).
Our results demonstrate that microbiota dysbiosis is an im-
portant factor in determining poststroke inflammation and
thereby stroke outcome in an experimental stroke model. Nu-
merous reports over the last decade have highlighted the impor-
tance of the secondary inflammatory response to brain injury as a
key pathophysiological mechanism (Iadecola and Anrather,
2011; Chamorro et al., 2012). Moreover, immunotherapeutic
strategies emerge to be tested progressively in human stroke pa-
tients and first studies report a beneficial effect of inhibiting ce-
rebral lymphocyte invasion in stroke patients (Fu et al., 2014; Zhu
et al., 2015). However, the role of the gut microbiota in stroke
patients was elusive until the very recent publication of an elegant
report by Benakis et al. (2016), who observed alteration of lym-
phocyte populations in the intestinal immune compartment after
induction of dysbiosis by antibiotic treatment. Dysbiosis-
induced changes in the peripheral immune system had a striking
impact on stroke outcome with changes in infarct volume by 60%
between treatment groups. In contrast to our study, antibiosis-
induced intestinal dysbiosis had a neuroprotective effect with
reduced infarct volumes and improved functional outcome after
amoxicillin treatment. Nevertheless, the underlying mechanisms
of microbiota-brain communication identified in the study by
Benakis et al. (2016) and our report are largely identical, such as
alteration in T-cell homeostasis, changes in the Treg/Th17 ratio,
and migration of intestinal lymphocytes to the ischemic brain.
The at-first-sight contradictory impact of dysbiosis on final
stroke outcome might depend on the differential immune polar-
ization by specific bacterial species. In fact, whereas antibiotic
treatment induced Treg expansion and reduction of Th17 cells
(Benakis et al., 2016), poststroke dysbiosis investigated in our
study itself favors an opposing pattern with predominant expan-
sion of proinflammatory T-cell subpopulations. Future studies
will be required to analyze the contribution of specific microbial
species in this highly complex interplay to identify neuroprotec-
tive or harmful bacteria in stroke.
Results from our microbiota transplantation experiments to
GF animals using microbiota from donors undergoing stroke
induction or sham surgery have clearly demonstrated a causal
link between poststroke microbiota dysbiosis and changes in pe-
ripheral immunity and finally a worse outcome after stroke. A
potential limitation of this experiment was the only short recol-
onization time of 3 d from transplantation to stroke induction or
8 d from transplantation to analysis, because previous reports
have suggested that recolonization of GF mice with a complete
fecal microbial induces pronounced immune activation with a
peak at 4 d after the start of colonization (El Aidy et al., 2012).
This short time period for recolonization was nevertheless chosen
deliberately to avoid shifts in microbiota composition during
longer recolonization periods. Therefore, whereas the results
from this specific recolonization experiment might overestimate
immunological differences, they nevertheless provide a first
proof-of-concept for the causality between dysbiosis and post-
stroke immune alterations.
In our study, we have observed a substantial induction of
proinflammatory Th1 and Th17 Thelper cell polarization by trans-
fer of a dysbiotic microbiome. A consistent cytokine expression
pattern with markedly increased IFN- and IL-17 levels were
observed in brains of mice receiving the dysbiotic microbiota.
Moreover, we could determine in a cell-tracking experiment
from intestinal PPs to the ischemic brain that at least one-fourth
of all brain-invading T cells within the acute phase after stroke are
derived from the intestinal immune compartment, which is con-
sistent with a previous report (Benakis et al., 2016). This obser-
vation of T-cell invasion and activation is consistent with
numerous reports on the surprisingly fast kinetics of poststroke
adaptive immunity (Schroeter et al., 1994; Jander et al., 1995;
Gelderblom et al., 2009; Liesz et al., 2011; Chamorro et al., 2012).
The central neuroinflammatory reaction starts as early as hours
after stroke, with T cells invading the brain in substantial num-
bers between 3 and 5 d after brain injury (Gelderblom et al., 2009;
Chamorro et al., 2012). Furthermore, we have detected previ-
ously substantial clonal expansion of T cells using spectratype
analysis within the first week after acute brain injury (Liesz et al.,
2013a). Therefore, initiation of an adaptive immune response
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and particularly activation of T cells occurs within few days after
stroke, consistent with results presented in this study. Specifi-
cally, it was shown previously that Thelper cell polarization occurs
very early after brain injury and the Treg/Th17 balance contrib-
utes to outcome within the first 3 d after stroke (Liesz et al., 2009a;
Shichita et al., 2009; Kleinschnitz et al., 2010).
The assumption of intestinal priming of Thelper cells by the
microbiota and rapid translocation to the ischemic brain after
stroke was further corroborated by the results obtained in exper-
iments in which we treated mice after extensive brain ischemia
(fMCAo model) by FMT from healthy donors. FMT treatment
reduced lesion size and was associated with expansion of regula-
tory (neuroprotective) T cells in the peripheral immune system
and in the ischemic brain. These findings are consistent with
numerous previous reports demonstrating a key role for differ-
ential Thelper cell priming in stroke pathophysiology, in which
proinflammatory Th1, Th17, and  T cells deteriorate post-
stroke inflammation, whereas Treg cells limit the inflammatory
collateral damage (Shichita et al., 2009; Iadecola and Anrather,
2011; Chamorro et al., 2012).
Interestingly, the protective effect of FMT treatment was absent
in lymphocyte-deficient Rag1 / mice, supporting a key role of
lympyhocytes in mediating the microbiota’s effect on brain func-
tion. However, the specific mechanisms underlying this complex
phenomenon are still unclear and will need further investigations.
Specifically, the interaction of microbiota-dependently activated T
cells with other immunocompetent cells of the poststroke brain (mi-
croglia, astrocytes, endothelium, invading leukocyte subpopula-
tions) requires further analyses. A previous report by Erny et al.
demonstrated a key role of the gut microbiota in microglial function
and proposed microbiota-derived short chain fatty acids as the un-
derlying mediator of microbiota–microglia communication (Erny
et al., 2015). Therefore, it remains to be elucidated whether the im-
portant role of microbiota-dependent T-cell polarization after
stroke shown by us and others (Benakis et al., 2016) affects neuronal
protection/toxicity directly or if it affects stroke outcome indirectly
via microglial function, as was shown previously to occur by brain-
invading lymphocytes (Appel, 2009; Lucin and Wyss-Coray, 2009;
Liesz et al., 2011). In addition, we have also observed activation of
intestinal monocytes/macrophages by a dysbiotic poststroke micro-
biome. Moreover, intestinal monocytes were detected to invade the
brain in the acute phase after stroke. Therefore, in addition to T-cell
polarization, brain-invading monocytes could also potentially play a
role in microbiota-mediated effects on stroke outcome.
Our results suggest a novel concept in which dysbiosis of the
gut microbiota is a consequence of acute brain injury and a key
effector in poststroke immune alterations with considerable im-
pact on stroke outcome. Our findings suggest that restoring the
health and balance of the intestinal microbiome could add to the
treatment of stroke patients.
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Reichardt P, Schraven B, Hermann DM, Reymann KG, Gunzer M (2015)
Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils
leads to interactions with microglia, increased ischemic injury and im-
paired behavior in experimental stroke. Acta Neuropath 129:259 –277.
CrossRef Medline
Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A,
Vandenbark AA, Hurn PD (2006) Splenic atrophy in experimental
stroke is accompanied by increased regulatory T cells and circulating
macrophages. J Immunol 176:6523– 6531. CrossRef Medline
Olsen AB, Hetz RA, Xue H, Aroom KR, Bhattarai D, Johnson E, Bedi S, Cox
CS Jr, Uray K (2013) Effects of traumatic brain injury on intestinal con-
tractility. Neurogastroenterol Motil 25:593-e463. CrossRef Medline
Round JL, Mazmanian SK (2010) Inducible Foxp3 regulatory T-cell de-
velopment by a commensal bacterium of the intestinal microbiota. Proc
Natl Acad Sci U S A 107:12204 –12209. CrossRef Medline
Schroeter M, Jander S, Witte OW, Stoll G (1994) Local immune responses
in the rat cerebral cortex after middle cerebral artery occlusion. J Neuro-
immunol 55:195–203. CrossRef Medline
Schwartz M, Raposo C (2014) Protective Autoimmunity: A Unifying Model
for the Immune Network Involved in CNS Repair. Neuroscientist 20:
343–358. CrossRef Medline
Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Hutten-
hower C (2011) Metagenomic biomarker discovery and explanation.
Genome Biol 12:R60. CrossRef Medline
Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I,
Iwaki T, Okada Y, Iida M, Cua DJ, Iwakura Y, Yoshimura A (2009)
Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in
the delayed phase of ischemic brain injury. Nat Med 15:946 –950.
CrossRef Medline
Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T,
Ooboshi H, Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishi-
bori M, Kuroda K, Akira S, Miyake K, Yoshimura A (2012) Peroxire-
doxin family proteins are key initiators of post-ischemic inflammation in
the brain. Nat Med 18:911–917. CrossRef Medline
Singh V, Roth S, Veltkamp R, Liesz A (2016) HMGB1 as a key mediator of
immune mechanisms in ischemic stroke. Antioxid Redox Signal 24:
635– 651. CrossRef Medline
Swidsinski A, Loening-Baucke V, Krüger M, Kirsch S (2012) Central ner-
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GUT MICROBIOME PRIMES A CEREBROPROTECTIVE IMMUNE RESPONSE AFTER 
STROKE 
SUMMARY  
Within the next publication we continued with the notion that the gut microbiota-induced immune 
cell alterations would alter stroke outcome. However, within this study we wanted to characterise 
the importance of the presence of the microbiome as a mediator of immunity. We compared three 
groups GF, Ex-GF (GF recolonised) and conventional specific pathogen free (SPF) mice allowing us to 
rule out potential confounding developmental immune deficits of GF mice as previously reported 
(Falk, Hooper et al., 1998). Due to the coprophagic behaviour of mice, GF mice were naturally 
colonised three weeks prior to experimentation by housing with SPF mice. We performed dMCAo 
surgery and saw that GF mice had larger stroke lesions compared to Ex-GF and SPF mice. This was 
associated with a higher microglial cell count and increased levels of proinflammatory cytokines; 
however, we did not observe an alteration in microglia morphology. This suggested that the absence 
of the microbiota was not neuroprotective and also worsened stroke outcome. In the peripheral 
immune compartment’s, within spleen and the gut (PP) we saw a general expansion in the number of 
immune cells of Ex-GF, compared to GF mice. Additionally, this was not found to be in certain subsets 
of T cells as both proinflammatory Th17, and anti-inflammatory Tregs were both increased. The 
microbiota presence did not affect stroke outcome in GF Rag–/–mice compared SPF Rag–/– mice as 
infarct size did not change. This study once again highlighted the influential ability of the gut 
microbiome on T and B cells in the context of stroke outcome. 
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Brief Communication
The gut microbiome primes a
cerebroprotective immune response
after stroke
Vikramjeet Singh1, Rebecca Sadler1, Steffanie Heindl1,
Gemma Llovera1, Stefan Roth1, Corinne Benakis1 and
Arthur Liesz1,2
Abstract
Microbiome alterations have been shown to affect stroke outcome. However, to what extent the presence of a gut
microbiome per se is affecting post-stroke neuroinflammation has not been tested. By comparing germfree mice with
recolonized (Ex-GF) and conventional SPF mice, we were able to demonstrate that bacterial colonization reduces stroke
volumes. Bacterial colonization increased cerebral expression of cytokines as well as microglia/macrophage cell counts in
contrast to improved stroke outcome. Interestingly, the microbiome-mediated brain protection was absent in lympho-
cyte-deficient mice. These findings support the concept of lymphocyte-driven protective neuroinflammation after stroke
under control of the microbiome.
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Introduction
Stroke triggers a neuroinflammatory reaction which
encompasses activation of brain resident microglia
and invasion of leukocytes.1 T cells are potent contribu-
tors to post-stroke neuroinflammation. While pro-
inflammatory Thelper cell subpopulations (e.g. Th1,
Th17) promote neuroinflammation, other populations
with anti-inflammatory properties (e.g. Treg cells) can
be cerebroprotective. Current findings have highlighted
the role of commensal gut microbiota in the regulation
of T cell responses to brain ischemia.2,3 Recently, we
have shown that stroke changes the bacterial compos-
ition in the gut, which was causally linked to a pro-
inflammatory T cell polarization and worse stroke
outcome.2 Similarly, a study by Benakis et al.3 demon-
strated the impact of antibiotic treatment-induced dys-
biosis on stroke outcome. Although these first studies
demonstrated a previously unrecognized key role of
changes in microbiota composition to affect stroke out-
come, we are still lacking the proof-of-concept that bac-
terial colonization per se affects stroke outcome and
post-stroke neuroinflammation. In order to fill this
gap, we investigated stroke outcome and neuroinflam-
mation in GF animals and colonized littermates (Ex-
GF) and specifically analyzed the role of T cells as
potential mediators along the gut-brain axis in stroke.
Material and methods
Detailed material and methods can be found in the
online Supplementary material. All original raw data
of this study as well as detailed protocols are available
from the corresponding author upon reasonable
request.
All animal experiments were performed under the
institutional guidelines for the use of animals for
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research and were approved by the governmental ethics
committee of Upper Bavaria (Regierungspraesidium
Oberbayern). GF mice were housed in sterile HAN-
gnotocages and received sterile food pellets and water.
All surgical procedures including stroke induction,
mouse handling and cage changes were performed
under sterile conditions in a sterile microbiological lam-
inar flow (Supplementary Figure 1(a)). Germfree status
of GF mice was confirmed after surgery and survival
period by 16 s PCR of fecal samples. Littermates of GF
mice were colonized through co-housing with conven-
tional specific pathogen-free (SPF) C57BL/6 J mice for
three weeks and co-housing was maintained also after
stroke surgery. Animals were randomized to the treat-
ment groups and all analyses were performed by inves-
tigators blinded to group allocation. Unblinding was
done after the completion of statistical analysis. All
animal experiments were performed and reported
according to the ARRIVE guidelines.1
Results
Bacterial colonization is cerebroprotective
after stroke
Stroke was induced in GF, Ex-GF and SPF mice in
order to test the impact of bacterial colonization on
stroke outcome (Figure 1(a)). All surgical procedures
were performed in a sterile microbiological safety cab-
inet (Supplementary Figure 1(a)). Reduced caecum-
body weight index increased total fecal DNA and
eubacteria amount verified bacterial colonization in
Ex-GF mice as well as maintaining the germfree
status after surgery in GF mice (Supplementary
Figure 1(b) to (d)). Sequencing of bacterial 16s rRNA
showed comparable alpha diversity and abundance of
bacterial phyla between Ex-GF and SPF mice as a key
markers of successful colonization in the Ex-GF group
(Supplementary Figure1(e) and (f)). Quantification of
infarct volume five days after stroke induction revealed
an improved stroke outcome in Ex-GF and SPF mice
compared to GF littermates (Figure 1(b)). This sub-
stantial effect of colonization on lesion volume has
been consistently observed in three independent experi-
ments performed by three different surgeons. After con-
firmation of comparable outcome and colonization in
SPF and Ex-GF animals, we used Ex-GF generated by
randomized colonization of GF littermates as the
favourable ‘‘colonized’’ control group.
Gut microbiota increase the neuroinflammatory
response after stroke
In order to test the impact of bacterial colonization on
the local neuroinflammatory milieu, we investigated cell
counts and morphology of microglia/macrophages as
well as key transcriptional markers of innate immune
responses after stroke. In contrast to reduced lesion
volumes, we found an increased number of microglia/
macrophages in the ischemic hemisphere of Ex-GF
mice compared to the GF group (Figure 1(c) and
(d)). Automated analysis of microglial morphology4
revealed massive activation of microglia in the peri-
infarct area characterized by enhanced sphericity
index and reduced ramifications compared to the
contralateral side (Figure 1(e)). While bacterial recol-
onization did not further affect already activated
peri-lesional microglia/macrophages, a significant
effect was observed on cell sphericity and ramifications
in the contralateral hemispheres in Ex-GF mice
(Figure 1(e)). Accordingly, we also observed a signifi-
cant increase in the transcriptional regulation of
pro-inflammatory cytokine expression associated
with microglial activation such as Il-1 and Tnf-
(Figure 1(f)).
Cerebroprotection is mediated by
microbiome-induced T cell priming
Previous studies using models of altered microbiota
composition have proposed modification in lymphocyte
priming and particularly in T cell polarization as key
mediators of the microbiome effect on stroke out-
come.2,3,5 Therefore, we first sought to determine the
impact of the gut microbiome on T cell priming in sec-
ondary lymphatic organs by flow cytometry. While the
overall leukocyte count was unaltered between GF and
Ex-GF animals, we detected increased T and B cells
counts in spleens of Ex-GF compared to GF animals
(Figure 2(a)). More specifically, we observed an
increase in overall Thelper cell (CD4
þ) counts as well
as polarized regulatory T cells (Foxp3þ) and Th17
cells (RoRgtþ) in the intestinal immune compartments
of the Peyer’s patches (Figure 2(b) and (c)) and even
more pronounced in the spleens of Ex-GF compared to
GF mice at five days after stroke (Figure 2(d)).
Interestingly, we observed a similar pattern in the ische-
mic brain with increased mRNA levels for specific
Thelper cell subpopulations including Foxp3 and Il-10
(Treg) and Il-17 (Th17) in Ex-GF animals compared
to GF littermates (Figure 2(e)). Additionally, we
observed by flow cytometry also an increase in total
T cell counts in the ischemic hemispheres of Ex-GF
compared to GF animals (Figure 2(f)). These results
implicate that a physiological gut microbiome is
required for generating an adequate lymphocyte-
driven immune reaction in response to brain injury
and execute tissue protection. Because of this pro-
nounced effect of bacterial colonization on post-
stroke T cell responses, we examined the role of
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lymphocytes in mediating the cerebroprotective effects
of the microbiome in lymphocyte-deficient Rag1/
mice. Lesions were smaller in Rag1/ mice compared
to wild-type C57BL/6 J mice. However, we found no
difference in lesion volumes between GF Rag1/
mice and conventional Rag1/ mice, supporting the
finding that lymphocytes play an important role
in the microbiome-mediated effects on stroke
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Figure 1. Bacterial colonization is cerebroprotective after stroke. (a) Schematic illustration of experimental paradigm.
(b) Quantification of infarct volume in germfree (GF), colonized (Ex-GF) and SPF mice (n¼ 12 per group). Data are shown as
mean SD normalized to the mean of the SPF group as 100%. (c) Representative images of Iba-1 stained microglia/macrophages with
schematic illustration of imaging locations in the peri-infarct area 900mm distant from the border of the infarct core in the deep
cortical layer 4/5 and homotypical contralateral area. (d) Analysis of microglia cell counts (n¼ 5 per group) in the ipsilateral cortex.
(e) Analysis of microglial morphology showing increased sphericity (left) and reduced ramification (right) in ipsilateral hemispheres as
markers of microglial activation. (f) Gene expression analysis by RT-PCR for the indicated genes of mainly microglial/macrophage origin
in ipsilateral and contralateral hemispheres after stroke (n¼ 10–12 per group, mean SD). *p< 0.05, **p< 0.01, ***p< 0.001).
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(Figure 2(g)). Additionally, we did not detect a signifi-
cant impact of gut bacterial colonization on blood–
brain barrier integrity or cortical capillary density
(Supplementary Figure 2).
Discussion
This study provides a proof-of-concept that the gut
microbiome per se is cerebroprotective in experimental
stroke. These are novel and relevant insights for the
gut-brain axis field in stroke as well as other models
of acute brain injury because previous studies have so
far exclusively investigated the impact of alterations in
bacterial composition on disease outcome but did not
test the relevance of the microbiome as a bona fide
modulator of secondary neuroinflammation.
These experiments were so far lacking due to the
technical difficulties of GF mouse handling and surgical
stroke induction. We have overcome these technical
limitations by on one side ensuring germfree status
of animals despite surgical manipulation and on the
other side establishing natural recolonization as
comparable to conventional SPF mice on stroke out-
come, which allows the study of littermates (GF and
Ex-GF) for improved comparability. Ex-GF mice were
chosen as a superior control group for colonized
Figure 2. T cell priming by the gut microbiome is cerebroprotective. (a) Flow cytometric analysis of absolute cell counts per spleen
in GF and Ex-GF animals for total leukocytes (CD45þ), B cells (CD19þ) and T cells (CD3þ). While total leukocytes counts were
unaffected, bacterial colonization significantly increase T and B cells ounts in Ex-GF mice. (b) Representative gating strategy for the
flow cytometric analysis of Thelper cell counts and subsets of Foxp3
þ (Treg) and RoRgt
þ (Th17) cells in (c) the Peyer’s patches and in
(d) the spleen. (e) (c) RT-PCR for expression Thelper cell markers Foxp3, Il-10 and Il-17 in ipsilateral and contralateral brain hemispheres
five days after stroke (n¼ 10–12 per group). (f) Flow cytometric analysis of ipsilateral brain hemispheres five days after stroke in GF
and Ex-GF revealing significantly increased T cell counts in the ischemic hemispheres of recolonized Ex-GF animals. (g) Brain infarct
volumes in SPF WT, SPF Rag1/ and GF Rag1/ mice (n¼ 7–9 per group, mean SD normalized to SPF group as 100%). *p< 0.05,
**p< 0.01, ***p< 0.001.
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animals compared to SPF mice which have substantial
disadvantages including potential differences due to
genetic drift, epigenetic modifications and housing
conditions.
We have previously reported that large stroke lesions
induce changes in the gut microbiome, leading to a pro-
inflammatory over-activation of peripheral immune
responses and worse stroke outcome.2 In contrast, we
show here that also the complete lack of a gut flora
leads to enlarged brain lesions compared to colonized
littermates or conventionally housed SPF mice. This
notion contradicts the widely accepted concept that
the secondary inflammatory response to tissue injury
is per se ‘‘detrimental’’ and—in the case of acute
brain injury— ‘‘neurotoxic.’’ 1 However, recent reports
revised this paradigm of secondary neuroinflammation
as ‘‘too much of a bad thing’’ by considering secondary
neuroinflammation to be a physiologically relevant
protective mechanism in which both excessive
immune activation and immunosuppression can be
harmful.6
By investigating germfree, lymphocyte-deficient
Rag1/ mice, we provide evidence supporting a key
role for lymphocytes along the gut-brain axis. Our
results demonstrate that lymphocytes are required to
generate a neuroinflammatory milieu that is associated
with a reduction of secondary lesion expansion. We
observed that a lack of bacterial colonization was asso-
ciated significantly with an increased expression of pro-
inflammatory cytokines in the ischemic hemisphere. On
the other side, germfree animals displayed reduced
overall microglia/macrophage cell counts and a reduc-
tion in pro-inflammatory cytokine expression. These
findings could indicate a dysfunctional, non-physiolo-
gical microglial response to the ischemic injury which is
associated with secondary neurological deterioration.
Moreover, lymphocyte-dependent neuroprotection
under the control of the gut microbiome is likely to
be mediated also via non-immunological mechanisms
that contribute to lesion growth and recovery such as
growth factor secretion by lymphocytes, modulation of
neurogenesis or impaired vascular function7,8 although
our results exclude direct major effects on vascular
function. Additionally, while the role of B cells is less
investigated in stroke-immunology as well as the gut-
brain research field compared to T cells, the expansion
of splenic B cell counts and the lack of mature B cells in
Rag1/ mice warrant additional experiments investi-
gating the contribution of B cells to the observed
phenomenon.
Taken together, future experiments which were
beyond the scope of this proof-of-concept study are
urgently needed for the in-depth analysis of the poten-
tial pathways of lymphocyte–brain interaction that lead
to neuroprotection under control of the microbiome.
Our findings open up several new questions such as
the mode of microbiome interaction with intestinal
lymphocytes, the involved bacterial mediators and/or
antigens. Finally, the druggability of microbiome-lym-
phocyte interaction to prime a beneficial, pro-regenera-
tive immune response is of great future interest. More
detailed understanding of the gut-immune-brain axis in
stroke could open up a new field of microbiome-tar-
geted therapies for stroke patients.
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Supplementary Figure 1. Maintanance of germfree status and efficient germfree mouse colonization. (A) Image of the surgical setup 
used under sterile conditions for stroke induction and mouse handling. The body/caecum weight index (B), total DNA load in feces (C) 
and eubacterial abundance (D) were determined as markers of intestinal colonization at the end of the experiment. Results demonstrate 
successful germfree status in the GF group as well as effective colonization of Ex-GF mouse by co-housing. Quantitative analysis of 
alpha diversity (E) and (F) differential phyla abundance between SPF and Ex-GF littermates as measures of successful gut bacterial 
colonization (n=7 per group, mean ±SD).  *=p<0.05, **=p<0.01, ***=p<0.001. n.d.: not detected
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Supplementary Figure 2. No differences in blood-brain-barrier integrity or vascular morphology between GF and SPF mice. (A) Mice 
were given an intraperitoneal injection of Evans blue dye, 2 h later perfused and fluorometrically analyzed for the concentration of Evans 
blue in the brain parenchyma. The data represent the amount of extravasated Evans blue per g of the brain tissue in SPF and GF mice 
(n= 4 per group). (B) For the analysis of vascular morphology, brain coronal sections of SPF and GF mice were stained for the endothelial 
marker CD31. Representative images illustrate the region of interest (ROI) in the cerebral cortex for SPF and GF mice as specified in the 
scheme. Magnification 10x, scale bar: 100 µm. (C). No differences in the total vessel area in the cortical ROIs were detectable (n= 3 per 
group). (*p<0.05, Student’s t-test). All bar graphs: mean±SD, n.s. non-significant (p>0.05). 
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SUPPLEMENTARY METHODS 
 “The gut microbiome primes a cerebroprotective immune response after stroke” 
 
Animal experiments. All animal experiments were performed under the institutional 
guidelines for the use of animals for research and were approved by the governmental ethics 
committee of Upper Bavaria (Regierungspraesidium Oberbayern, license number 2532-65-
2014). Wild type C57BL/6J mice were obtained from Charles River Laboratories. Germfree 
(GF) C57BL/6J and GF Rag1−/− female mice were obtained from the Clean Mouse Facility, 
University of Bern, Switzerland. Animals were randomized to the treatment groups and all 
analyses were performed by investigators blinded to group allocation. Unblinding was done 
after the completion of statistical analysis. All mice were 10-12 weeks of age at time of stroke 
induction. All animal experiments were performed and reported according to the ARRIVE 
guidelines 1. 
GF mice handling and intestinal bacterial colonization. GF mice were housed in sterile 
HAN-gnotocages and received sterile food pellets and water as conventional SPF and colonized 
(Ex-GF) mice. All surgical procedures, mouse handling and cage changes were performed in a 
laminar flow microbiological safety cabinet. GF mice were colonized through co-housing with 
conventional SPF mice for 3 weeks. Co-housing was maintained also after stroke induction in 
all experimental groups. 
Permanent distal MCA occlusion model (cMCAo). Focal cerebral ischemia was induced as 
described previously by permanent occlusion of the MCA distal of the lenticulostriate arteries2. 
In brief, the mice were anesthetized with an i.p. injection of fentanyl (0.05 mg/kg), midazolam 
(5 mg/kg) and medetomidine (0.5 mg/kg). The skin incision was performed to expose the skull, 
a burr hole was drilled in the temporal bone, and the MCA was permanently occluded using 
high frequency electrocoagulation forceps. Immediately after surgery, anesthesia was 
antagonized by intraperitoneal injection of a combination of naloxon (1.2 mg/kg), flumazenil 
(0.5 mg/kg), and atipamezol (2.5 mg/ kg). After recovery, mice were returned to their cages 
with ad libitum access to water and food. Sham surgery was performed by the same surgical 
procedures without coagulation of the exposed MCA. During the surgical procedure, body 
temperature of mice was kept at 37°C. The overall mortality rate for the experimental model 
was less than 5%. Exclusion criteria were subarachnoid hemorrhage or death during surgery. 
Infarct volumetry. Perfused brains were removed at 5 days after stroke induction and frozen 
on dry ice. Coronal cryosections (20 µm thick) were cut at 400 µm intervals. The sections were 
stained with cresyl violet consistent with standard protocols and scanned at 600 dpi. Infarct area 
was measured in each section using ImageJ software. The total infarct volume was calculated 
by integrating the measured areas and intervals between the sections. Percent infarct volumes 
normalized to SPF or SPF WT group was presented.  
Cell preparation from lymphoid organs. Mice were deeply anesthetized with ketamine (120 
mg/kg) and xylazine (16 mg/kg). The mice were then transcardially perfused with normal 
saline. The spleen, and Peyer’s patches (PPs) were removed into cold phosphate buffer saline 
solution. The organs were homogenized and filtered through 40 µm cell strainers; in the spleen 
samples, the erythrocytes were lysed using isotonic ammonium chloride buffer. The total cell 
counts per organ were measured using an automated cell counter (Bio-Rad). The cells were 
then stained with different antibodies and washed before flow cytometric analysis. 
Cell preparation from brain hemispheres. Brain homogenates were prepared for FACS as 
previously described3. Briefly, after perfusion with saline, the ipsilateral brain hemispheres 
were removed and collected in 200µl Dulbecco´s Modified Eagle Medium (DMEM) +10% 
fetal calf serum (FCS). The samples were digested in 2ml of digestion mix [DMEM + 10%FCS 
+ 0.4% DNASEI (#11284932001, Roche) + 3% CollagenaseD (#11088866001, Roche)], 10 
min at 37ºC, and then mechanically dissociated. Cerebral mononuclear cells were subsequently 
isolated using a 70% and 40% discontinuous Ficoll gradient. 
Flow cytometry analysis. The following mouse antigen-specific antibodies were purchased 
from eBioscience: CD3 FITC (17A2), CD4 PerCP Cy5 (clone RM4 –5), CD45 eF450 (30-F11), 
FoxP3 PE (NRRF-30), RORγt APC (AFKJS-9). To quantify the various cell populations, cells 
were stained with specific antibodies in accordance with the manufacturer’s protocols. For 
intracellular transcription factor staining, cell suspensions from the spleen, mLN and PPs were 
stained using the Foxp3/Transcription Factor Staining Kit (eBioscience). Stained cells were 
measured in a FACSVerse flow cytometer (BD Biosciences) and analyzed using FlowJo 
version 10 (TreeStar). 
Iba1-staining of brain sections. The animals were anesthetized with a lethal dose of Ketamine 
(120 mg/kg) and Xylazine (4 mg/kg). The abdomen and thorax were opened and an incision 
was made into the right atrium. By applying a puncta to the left ventricle 20 ml of cold isotonic 
0.9 % Saline were used for cardiac perfusion. For fixation, mice were additionally perfused 
with 15 ml ice-cold 4 % Paraformaldehyde (PFA) in PBS. After PFA-perfusion, the brains were 
rapidly removed and post-fixed in 4 % PFA for 24 hours and dehydrated in 30 % sucrose for 
48 hours. Using a vibratome (Leica) 100 µm coronal sections were prepared and collected in 
0.1 M phosphate-buffered saline (PBS). For free-floating staining, the sections were blocked 
with goat serum blocking buffer in 48-well plates and stained with 1:200 anti-Iba1 (rabbit, 
Wako, #019-19741) and anti-rabbit coupled to Alexa-fluor 594 (goat anti-rabbit, Thermo Fisher 
Scientific, # A-11012). Nuclei were stained with 4′,6-diamidin-2-phenylindol (DAPI, 
Invitrogen, #D1306) 1:5000 in 0.01 M PBS. Sections were mounted on microscope slides 
(Menzel-Gläser Superfrost ® Plus, Thermo Fisher Scientific, #3502076) and covered with a 
coverslip (Menzel-Gläser 24-60 mm, #1, BB024060A1, Wagner and Munz) using aqueous 
mounting medium (FluoromountTM, Sigma-Aldrich, #F4680-25ML). Images were acquired 
using a Zeiss confocal microscope with a 40x magnification (objective: EC Plan-Neofluar 
40x/1.30 Oil DIC M27) with a size of 1024 x 1024 pixels and a depth of 8 bits. Images were 
collected in Z-stacks with a slice-distance of 0.4 µm for analysis of microglial morphology. 
Cell count and microglial morphology was assessed at a ROI 900µm distant from the border of 
the ischemic core and the homotypic area of the contralateral hemisphere. 
Analysis of microglial morphology. Confocal Z-stack images were processed and microglial 
morphology features were extracted using custom written scripts in MATLAB (R216b, The 
MathWorks, Natick, Massachusetts, USA), with dependencies on the Image Processing 
Toolbox as well as Statistics and Machine Learning Toolbox. Statistical analysis and data 
visualizations were performed in RStudio 4 using R version 3.2.2 5 and the packages ROCR 6, 
plyr 7, beeswarm 8 and corrplot 9. A Kruskal-Wallis test with post-hoc Bonferroni-correction 
was applied for multilevel comparisons between groups. The detailed protocol and properties 
of the MATLAB script have been previously described10. 
Metagenomic sequencing. Total DNA was isolated from mice fecal contents by using stool 
DNA isolation kit (Qiagen). Same amount of DNA was amplified by using following primers 
and settings:16S rRNA amplicons were generated using primers corresponding to the 
hypervariable regions V1-V3 (primer 27F: AGA GTTTGATCCTGGCTCAG; primer 534R: 
ATTACCGCGGCTGCT GG), and the PCR products were purified. Libraries were prepared 
using the standard tagmentation procedure (Nextera XT; Illumina). All samples were sequenced 
on an Illumina MiSeq platform using a 300 bp paired-end approach. Amplicon sequencing 
datasets were analyzed using the Metagenomics (MG)-RAST pipeline (version 3.3.6) (Meyer 
et al., 2008). Low-quality reads (comprising 0.01% of all reads) were trimmed using the 
SolexaQA program; only high-quality reads were included in the subsequent analysis. 16S 
rRNA genes were identified by performing a BLAT (Kent, 2002) search, and amplicons were 
clustered at 97% identity with an e-value cut off of 1e-5. A BLAT similarity search for the 
longest cluster representative was performed against the Ribosomal Database Project (RDP) 
database. Diversity, and phylogenetic analysis were performed using the MG-RAST platform. 
Read counts were normalized logarithmically for subsequent analysis. The DNA sequences 
have been deposited in MG-RAST (http://metagenomics.anl.gov/) under accession number 
9778.  
Bacterial DNA isolation and PCR. DNA was isolated from mouse feces using the QIAamp 
Fast DNA Stool Mini Kit (Qiagen). The total amount of DNA in each sample was measured 
using a Qubit (Life Technologies). Equal amounts of DNA from all samples were used for the 
PCR reactions and were amplified using SYBR Green ROX qPCR Mastermix (Qiagen) in a 
LightCycler 480 II (Roche). For the quantitative analysis of 16S rRNA sequences, PCR was 
performed using the following primers. EUB (eubacteria): Uni forward 340: ACT CCT ACG 
GGA GGC AGC AGT; Uni reverse 54: ATT ACC GCG GCT GCT GGC. Each run was 
performed in duplicate for each DNA sample. A linear dilution-amplification curve was 
obtained from diluted pooled samples, and the relative expression of each gene was calculated 
using the standard curve method. 
Quantitative RT-PCR. Brain tissue from the ipsilateral and contralateral hemispheres was 
lysed in the Qiazol Lysis Reagent (Qiagen) and total RNA was extracted using the MaXtract 
High Density kit (Qiagen). RNA was purified using the RNeasy Mini Kit in accordance with 
the manufacturer’s instructions (Qiagen). Equal amounts of RNA from each sample were used 
to synthesize cDNA with the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Pre-designed RT2 qPCR Primer Assays (Ambion) were used for the following 
genes: Foxp3 (PPM05497F), Il-10 (PPM03017C), Il-17A (PPM03023A), Il-1β (PPM03109F) 
and Tnf-α (PPM03113G). The quantitative expression was measured using SYBR Green ROX 
qPCR Mastermix (Qiagen) in a LightCycler 480 II (Roche). A linear dilution-amplification 
curve was obtained from diluted pooled samples. Using this curve, the expression of each gene 
was measured relative to the expression of the housekeeping gene encoding peptidylprolyl 
isomerase A. All assays were performed in duplicates. 
Statistical analysis. Sample size was estimated according to effect size of microbiota 
manipulation on stroke based on our previous reports11, 12 and on the variability of the used 
stroke model as previously published2. Data were analyzed using GraphPad Prism version 6.0. 
All summary data are expressed as the mean SD. All data sets were tested for normality using 
the Shapiro–Wilk normality test. Groups containing normally distributed data were analyzed 
with either t test (two groups) or ANOVA (>two groups). The groups contain non-normally 
distributed data were tested using Mann Whitney U test (two groups) or using Kruskal-Wallis 
test (for more than two groups). Similar variance was assured for all groups, which were 
compared statistically. A p value < 0.05 was considered to be statistically significant. 
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MICROBIOTA DIFFERENCES BETWEEN COMMERCIAL BREEDERS IMPACTS THE 
POST-STROKE IMMUNE RESPONSE 
SUMMARY 
Reproducibility of pre-clinical experiments and inter-laboratory differences are all components which 
contribute to the so-called reproducibility crisis. However, understanding the hurdle between 
laboratory and clinical care may aid to better understand failed trials. For the second aim, we 
designed a study to model the impact of the gut microbiota as a possible source for inconsistencies. 
We obtained C57BL/6 mice from 3 different commercial breeders across Europe CR, Taconic 
Biosciences (Tac) and Harlan (Har) (now known as Envigo)). 16S RNA sequencing analysis revealed 
substantial changes in the diversity and in the composition of the microbiota. Furthermore, we saw 
that Th17-inducing bacterial species named SFB, were lower or absent in the faeces of CR mice 
compared to Tac and Har mice. By flow cytometry we found that SFB presence correlated to higher 
levels of IL-17 cells, and lower levels of Tregs, as found in Tac and Har mice. On the contrary, CR mice 
had high percentages of Tregs and lower IL-17 cells. In another experiment we addressed whether 
SFB presence was causative of changes in gut immune cell polarisation. By cohousing SFB negative 
mice with SFB positive mice, we created SFB recolonised mice. This indeed was enough to increase 
IL-17+ cells and reduce Treg cell populations. We therefore decided to use this paradigm to test 
CD28SA an antibody previously shown to expand Tregs; however within basic stroke research in 
rodent models had contradictive results (Na, Mracsko et al., 2015, Schuhmann, Kraft et al., 2015). 
Upon treatment with CD28SA we saw that mice deficient of SFB did not experience a peripheral 
expansion of the Treg population compared to controls. This was on the contrary to SFB positive 
mice which did experience Treg expansion. Due to the changes within the immune system under 
CD28SA, SFB negative mice that underwent dMCAo surgery had significantly larger infarct volumes 
compared to mice who did not receive the treatment. Taken together this further highlighted the 
intimate interaction of the gut microbiota and immune system, but also showed that immunogenic 
therapies which experience a contraction in results may turn to the microbiota as a possible 
confounding factor. 
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Experimental reproducibility between laboratories is a major translational obstacle worldwide, particu-
larly in studies investigating immunomodulatory therapies in relation to brain disease. In recent years
increasing attention has been drawn towards the gut microbiota as a key factor in immune cell polariza-
tion. Moreover, manipulation of the gut microbiota has been found effective in a diverse range of brain
disorders. Within this study we aimed to test the impact of microbiota differences between mice from
different sources on the post-stroke neuroinflammatory response. With this rationale, we have investi-
gated the correlation between microbiota differences and the immune response in mice from three com-
mercial breeders with the same genetic background (C57BL/6). While overall bacterial load was
comparable, we detected substantial differences in species diversity and microbiota composition on
lower taxonomic levels. Specifically, we investigated segmented filamentous bacteria (SFB)—which have
been shown to promote T cell polarization—and found that they were absent in mice from one breeder
but abundant in others. Our experiments revealed a breeder specific correlation between SFB presence
and the ratio of Treg to Th17 cells. Moreover, recolonization of SFB-negative mice with SFB resulted in
a T cell shift which mimicked the ratios found in SFB-positive mice. We then investigated the response
to a known experimental immunotherapeutic approach, CD28 superagonist (CD28SA), which has been
previously shown to expand the Treg population. CD28SA treatment had differing effects between mice
from different breeders and was found to be ineffective at inducing Treg expansion in SFB-free mice.
These changes directly corresponded to stroke outcome as mice lacking SFB had significantly larger brain
infarcts. This study demonstrates the major impact of microbiota differences on T cell polarization in
mice during ischemic stroke conditions, and following immunomodulatory therapies.
 2017 Elsevier Inc. All rights reserved.1. Introduction been established as a key therapeutic target used to inhibit sec-Stroke is a devastating disease and the second most common
cause of death (Donnan et al., 2008). Over the last decade, it is neu-
roinflammation occurring at hours to days post lesion, which hasondary infarct progression and improve stroke outcome (Dirnagl
et al., 1999; Iadecola and Anrather, 2011). A critical event during
post-stroke neuroinflammation is the invasion of circulating leuko-
cytes into the ischemic brain (Gelderblom et al., 2009). In particu-
lar, it is during 3–5 days after stroke where the infiltration of T cells
into the brain parenchyma is known to be key in exacerbating sec-
ondary neuronal apoptosis and worsening stroke outcome
(Kleinschnitz et al., 2010). Interestingly, while pro-inflammatory
T cell subpopulations (i.e. Th1 and Th17) are neurotoxic and con-
tribute to the inflammatory collateral damage after stroke
(Gelderblom et al., 2009; Shichita et al., 2009), the immunosup-
pressive subpopulation of regulatory T cells (Treg) have been
shown to be neuroprotective after experimental brain ischemia
24 R. Sadler et al. / Brain, Behavior, and Immunity 66 (2017) 23–30(Liesz and Kleinschnitz, 2016; Liesz et al., 2009). The mechanisms
of T cell polarization before entry into the brain has been a key
question in the field of stroke-immunology; for example either
the polarization towards a neuroprotective Treg or harmful IL-
17/Th17 cell phenotype. The gut-associated-lymphoid tissue
(GALT) is where the majority of immune cells reside in the body
(Brandtzaeg et al., 1989). Furthermore, the gut itself harbors a
readily adapting composition of bacteria known as the gut micro-
biota which acts as the main source of antigens and immune-active
mediators within the gut (Lathrop et al., 2011). It has been repro-
ducibly shown that segmented filamentous bacteria (SFB) are able
to specifically increase IL-17-producing Th17 cells (Ivanov et al.,
2009; Round and Mazmanian, 2009). It has become evident that
the gut microbiota plays a key role in driving autoimmune mech-
anisms and the inflammatory response in a number of diverse
brain disorders. For example, in one study using experimental
autoimmune encephalomyelitis (EAE), the absence of the micro-
biota in germ-free mice was enough to alleviate the onset of symp-
toms (Berer et al., 2011) while the induction of Tregs by B. fragilis
antigen was able to alleviate EAE symptoms (Ochoa-Reparaz et al.,
2010). Finally, we have recently demonstrated that alteration of
the gut microbiota can have a major impact on secondary neuroin-
flammation and outcome after experimental brain ischemia
(Benakis et al., 2016; Singh et al., 2016).
Reproducibility of preclinical experiments has become a press-
ing challenge in translational research (Dirnagl et al., 2013;
Laukens et al., 2016; McNutt, 2014). Small inter-laboratory differ-
ences can largely impact and alter the results of experiments hin-
dering reproducibility. In retrospect, the microbiota could
potentially influence and partially explain the discrepancies seen
between similar studies with opposing results. Looking more into
the influence of microbiota-driven immune cell changes may aid
in understanding the hurdle between laboratory and clinical care
(Duda et al., 2014; Ioannidis et al., 2014).
In this study we have identified highly functional and relevant
differences in the microbiota composition of mice of the same
genetic background (C57BL/6) but from different commercial
breeders. We detected corresponding alterations in the intestinal
immune compartment—particularly changes in T cell homeosta-
sis—and abundance of specific bacterial species between the
groups. We then tested the impact of these microbiota differences
between commercial breeders on the immunological outcome of
an exemplary immunotherapeutic approach using CD28 superago-
nistic antibodies (CD28SA) in a murine stroke model.2. Results
2.1. C57BL/6 mice show clear breeder-dependent gut microbiota
differences
Despite being housed in the same environment and fed the
same diet 3 weeks prior to analysis, we observed significant differ-
ences in the microbiota composition of mice from the three inde-
pendent breeder sources; Charles River Laboratories (CR), Taconic
Biosciences (Tac) and Harlan Laboratories (Har). We did not detect
significant differences between the tested groups regarding total
bacterial density, indicating similar overall bacterial colonization
of the intestine (Fig. 1A). In contrast, we observed significant differ-
ences in bacterial diversity between mice of different breeder
source (Fig. 1B). Substantial differences between the microbiota
communities of the three breeders became also evident in the prin-
cipal component analysis (Fig. 1C). Furthermore, we noticed dis-
tinct differences in the relative abundance of specific bacterial
families between mice from different breeders, while the overall
taxonomic composition was consistent in mice from the samebreeder (Fig. 1D). Interestingly, we identified significant differ-
ences in the abundance of segmented filamentous bacteria (SFB),
a bacterial species that has previously been shown to be associated
with THelper cell polarization (Goto et al., 2014; Ivanov et al., 2009;
Round and Mazmanian, 2009). As detected by semi-quantitative
PCR, SFB were absent in all mice obtained from CR, but present
in fecal samples frommice obtained from Tac and were most abun-
dant in mice from Har (Fig. 1E). Finally, we performed a LEfSe anal-
ysis and identified several operational taxonomic units (OTUs)
which were significantly more represented in one breeder com-
pared to others, for example Prevotella in CR, Parabacteroides in
Tac or Rikenellaceae in Har (Suppl. Fig. 1). This suggests that differ-
ent commercial breeders supply mice with a significantly different
microbiota composition.
2.2. Specific microbiota differences are associated with T cell
polarization
After detecting specific differences in the gut microbiota of mice
from different breeder sources, we investigated the associated
polarization of immune cells within the Peyer’s patches (PP) of the
intestinal lymphoid tissue. Total and differential leukocyte counts
in the PP and spleen did not differ between breeder groups (Suppl.
Fig. 2). In contrast, we observed substantial differences in the abun-
dance of THelper cell subpopulations between breeders, thus indicat-
ing that the breeder-specific microbiota compositionmay influence
and impact immune polarization. We particularly analyzed the
polarization of Treg (Foxp3+) and Th17 (IL-17+) cells (Fig. 1F). We
observed high percentages of pro-inflammatory Th17 cells in mice
received from Tac—in contrast to mice received from CR (SFB-
deficient), which demonstrated high Treg cell counts but low pro-
inflammatory Th17 cell counts (Fig. 1G). This was demonstrated
clearly in the ratio of Foxp3 to IL-17 cells showing a much lower
ratio when SFB’s were present in the breeder mice. Interestingly,
this effect was specifically confined to the intestinal immune com-
partment (PP) as Treg and Th17 populations did not differ in spleens
between groups, however, general Treg properties such as cell fre-
quency, Foxp3 and CD28 expression did not differ per se between
spleen and PP (Suppl. Fig. 3B). These results indicated a potential
association between SFB abundance in the intestinal microbiota
and induction of pro-inflammatory T cell subpopulations.
2.3. Co-housing restores SFB content and shifts the T cell ratio in the
periphery
In order to investigate whether differences in T cell polarization
were indeed a cause of SFB presence within the intestinal micro-
biota, we co-housed SFB negative (Jax) and SFB positive mice for
2 weeks (Fig 2A). Due to the coprophagic behavior, SFB-negative
mice were able to naturally recolonize themselves with SFB from
the cohoused SFB-positive donor mice (Fig 2B). We then performed
flow cytometric analysis to examine T cell subpopulations follow-
ing SFB-colonization. SFB recolonized mice demonstrated a clear
shift in their T cell polarization pattern resembling largely the
effects observed in SFB-positive mice, particularly a consistent
reduction in the Foxp3/IL-17 ratio (Fig. 2C). anti-inflammatory Treg
cells were decreased and pro-inflammatory IL-17+ and IFNc+ cells
were increased in SFB-recolonized animals, although no effect on
RORct expression was observed. In order to validate these crucial
findings, we repeated this experiment using animals from CR as
SFB negative mice, confirming a similar treatment pattern with
reduction of the Foxp3/IL-17 ratio after recolonization in PP and
spleen as in the primary experiment (Suppl. Fig. 4). These results
demonstrate a causal relationship between intestinal SFB-
colonization and specific THelper cell polarization in the intestinal
immune compartment.
Fig. 1. Microbiota differences in C57BL/6 mice from different commercial breeders. (A) Total read counts per sample from the 16 S ribosomal gene sequencing. Kruskal-Wallis
test with Dunn’s multiple comparisons test (n = 5) (1 independent experiment). (B) Shannon a-diversity index for within-sample diversity of grouped data (n = 5 per group,
mean + SE). (C) Two-dimensional Bray-Curtis b-diversity PCoA plot of the microbial fecal communities (1 independent experiment). (D) Taxonomic summary representing the
distributions of bacteria found at family level. All families contributing <2% were grouped into the ‘‘Others” category (1 independent experiment). (E) Semi-quantitative qPCR
of SFB to EUB 16S rRNA (CR n = 8, Tac n = 7, Har n = 10; 2 independent experiments). (F) Representative dot plots and gating strategy for flow cytometric analysis of Foxp3 and
IL-17 populations from CD4 + THelper cells. (G) Analysis of the indicated THelper cell subpopulation based on the transcription factor and intracellular cytokine expression per
breeder group. From left CD4+, Foxp3+, IL-17+ and Foxp3/IL-17 ratio (n = 5 per group, 1 independent experiment). Kruskal-Wallis test with Dunn’s multiple comparisons test.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. CR = Charles River Laboratories, Tac = Taconic Biosciences, Har = Harlan Laboratories.
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immunotherapeutic efficacy
Next, we investigated whether the microbiota-dependent T cell
polarization between commercial breeders would affect stroke
outcome of an immunotherapeutic treatment. Previously we have
found that extensive brain injuries can alter the microbiota compo-sition by affecting intestinal motility function (Singh et al., 2016).
As a result of this, we chose the distal Middle Cerebral Artery
occlusion (dMCAo) model for these experiments—inducing only
moderate-sized cortical lesions—in order to exclude stroke-
induced microbiota alterations. Based on previous studies with
unexplained contradicting results, we selected the CD28 superago-
nistic antibody (CD28SA) as the exemplary immunotherapeutic
Fig. 2. SFB colonization is causally linked to THelper cell polarization. For natural recolonization of animals with a SFB-positive gut microbiome, SFB-deficient animals were co-
housed with SFB-laden animals (see Methods section for technical details). (A) Schematic illustration of the co-housing experiment and the three investigated mouse groups:
SFB-negative, SFB-positive and SFB-recolonized. (B) Semi-quantitative qPCR of SFB 16S rRNA relative expression, indicating efficient SFB recolonization by co-housing (n = 12
for SFB-negative and SFB-recolonized, n = 10 for SFB-positive). (C) Flow cytometric analysis of THelper cell polarization in Peyer’s patches according to data shown in Fig. 1. SFB
recolonization significantly alters THelper cell homeostasis and Foxp3:IL-17 ratio. (n = 13 for SFB-negative, n = 8 for SFB-recolonized, n = 10 for SFB-positive). Kruskal-Wallis
test with Dunn’s multiple comparisons test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Jax = The Jackson Laboratory, Tac = Taconic Biosciences, Har = Harlan
Laboratories.
26 R. Sadler et al. / Brain, Behavior, and Immunity 66 (2017) 23–30treatment (Na et al., 2015; Schuhmann et al., 2015). Control groups
received no treatment after confirming no difference in T cell
polarization between untreated and IgG isotype control treated
animals (Suppl. Fig. 5A,B) Interestingly, we found that
immunomodulation using CD28SA administered once at 3 h after
stroke induction was able to consistently expand all Treg and
Th17 cells in the spleen (Supp. Fig. 5C), but resulted in a differential
breeder-dependent T cell polarization in the PP (Fig. 3A). Specifi-
cally, CD28SA effectively induced Treg cells in (SFB positive) mice
from Tac and Har but failed to induce this neuroprotective T cell
population in CR mice, resulting in a significantly shifted balance
between pro-inflammatory Th17 and immunosuppressive Treg
cells. A similar, yet only partially significant, Treg expansion pat-
tern was also observed in brains by performing Foxp3 RT-PCR of
brain hemispheres after stroke. CD28SA induced a significant
increase in Tac mice as well as a non-significant expansion in
Har mice which was not observed in the CR group (Fig. 3B). The
microbiota-associated shift in T cell homeostasis after CD28SA
treatment was then correlated with the efficacy of this treatment
on stroke outcome.We detected exacerbation of the infarct volume
in CR mice—with a shift towards pro-inflammatory Th17 cell
expansion—compared to unaltered infarct volumes in Tac and
Har mice (Fig. 3C,D). These results propose that the microbiota
composition, particularly the presence of SFB, strongly influencesthe ability of CD28SA treatment to expand specific THelper cell sub-
populations and therefore affect disease outcome.3. Discussion
Our study has addressed the ongoing question of to what extent
do microbiota differences between conventional laboratory mice
obtained from different breeding sources impact the physiological
immune homeostasis and the neuroinflammatory response after
brain injury. We observed that specific changes in the microbiota
composition were associated with immunological alterations. In
particular, the presence of SFB was causally linked to T cell polar-
ization and these changes prevailed after experimental stroke and
influenced the efficacy of an immunomodulatory treatment. Our
results indicate that even minimal differences in the microbiota
composition may have a significant impact on the neuroinflamma-
tory response and the outcome of immunomodulatory therapies.
These findings are of high relevance for the design of future studies
and interpretation of previous reports in immunity and
neuroinflammation.
In accordance with previous reports, our study confirmed dif-
ferences in the microbiota composition at lower taxonomic levels
between mice from different commercial breeders (Ericsson
Fig. 3. Effect of CD28SA treatment differs between mice from different breeders. Mice from different breeders were administered either with CD28SA antibody or given no
treatment after stroke induction. (A) Percentage of THelper cell subpopulations (Foxp3, IL-17 and ratio) in Peyer’s patches (PP) according to the analysis strategy shown in Fig. 2
(for control: n = 5 per group (1 independent experiment), for CD28SA: CR = 6, Tac = 8, Har = 8 (2 independent experiments). 2way-ANOVA with Sidak’s multiple comparisons
test. (B) Semi-quantitative PCR analysis of Foxp3 expression in the ipsilateral and contralateral brain hemisphere after stroke induction per indicated treatment group (for
control: CR = 7, Tac = 6, Har = 8; for CD28SA: CR = 6, Tac = 6, Har = 5; 2 independent experiments). (C) Infarct volumetry of coronal sections 5d post dMCAo (for control: CR = 6,
Tac = 8, Har = 8; for CD28SA: CR = 6, Tac = 10, Har = 9; 2 independent experiments). Mann-Whitney U test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. (D)
Representative cresyl-violet staining for Control and CD28SA treated CR mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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CR were devoid of SFB in their gut microbiota, this concurs with
former studies, which report the same observation for animals
from Jax. C57BL/6 mice bred at CR were historically obtained from
Jax, supporting the concept that certain bacterial strains may be
inherited (Faith et al., 2015). In the past, SFB have been identified
as one of the most differentially abundant species in the micro-
biota of Jax and Tac mice (Ivanov et al., 2009). Furthermore, SFB
are known to play a prominent role in the induction of Th17 polar-
ization of T cells (Atarashi et al., 2015; Goto et al., 2014; Ivanov
et al., 2009). This suggests that the differences in the abundance
of single bacterial species within the gut microbiota can strongly
influence immune homeostasis and the immune response during
disease.
In fact, we have observed a striking difference in the
microbiota-dependent polarization of T cells between the intesti-
nal immune compartment (PP) and the spleen where the impact
of microbiota differences between groups was less prominent. This
finding further supports the concept of a site-specific priming of T
cell homeostasis in the intestine by the microbiota but also gives
rise to further questions on how this localized effect could poten-
tially impact distant neuroinflammation. In this line, we have pre-
viously demonstrated using in vivo T cell-labelling approaches that
approximately 25% of cerebral T cells after stroke are directlyrecruited from Peyer’s patches (Benakis et al., 2016; Singh et al.,
2016). Taken together, it seems well conceivable that a substantial
number of T cells in the brain have migrated from the intestinal
immune compartment where they have received a microbiota-
dependent ‘‘functional imprint” and thereby are able to modulate
the post-ischemic neuroinflammatory response.
Although the mice were originating from the same genetic
background, a potential limitation of comparing mice from differ-
ent commercial breeders is genetic drift due to inbreeding at each
breeding site over multiple generations. Taking our results into
consideration this may have an impact on the immune system.
Previous studies have addressed this exact question and reported
that of a potential 1449 single-nucleotide-polymorphisms (SNPs),
the Tac (C57BL/6NTac) and Har (C57BL/6NHsd) strains were iden-
tical, but differ from the original CR (C57BL/6J) at only 12 SNPs
(Mekada et al., 2009; Zurita et al., 2011). These SNPs were found
to be located in the NAD(P) transhydrogenase, a mitochondrial
gene which is not associated with immune homeostasis or T cell
polarization. Therefore, to finally investigate the T cell polarization
changes induced by microbiota differences observed between
breeders, we performed a microbiota recolonization experiment
by co-housing of SFB-negative and SFB-positive mice resulting in
efficient SFB recolonization of SFB-negative mice. Results from this
experiment unequivocally demonstrated the causal link between
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ated and currently unknown bacterial species) and the ability to
induce or change T cell polarization.
While the majority of Thelper cells in mice are naїve cells,
approximately 85% based on previous reports, the smaller popula-
tion of polarized cells determine disease course of T cell-driven
pathologies (Hashiguchi et al., 2011). The microbiota-associated
differences in T cell polarization did not have a significant impact
on infarct volume under naïve conditions. Nevertheless, the influ-
ence of microbiota-dependent immune priming became evident
when testing the efficacy of CD28SA treatment as a proof-of-
concept immunomodulatory approach. We identified selective
expansion of a T cell subpopulation upon treatment with the co-
stimulatory CD28SA which was determined by the microbiota-
dependent pre-polarization of the T cell population between mice
of different breeder source. Mice lacking SFB in the gut microbiota
were unable to efficiently expand the (neuroprotective) Treg pop-
ulation upon CD28 stimulation resulting in an increase of the pro-/
anti-inflammatory T cell subpopulation balance. Finally, the differ-
ing immunomodulatory response to CD28SA resulted in signifi-
cantly differing stroke outcomes between breeders, a finding
which should be validated in a larger, fully-powered confirmatory
study (Llovera et al., 2015). This specific example of CD28SA treat-
ment in experimental murine stroke can serve as a proof-of-
concept study, demonstrating the impact of microbiota alterations
on the immunotherapeutic outcome. These findings are of signifi-
cant relevance for the design of future preclinical studies particu-
larly aiming at T cell homeostasis, activation or expansion in a
variety of inflammatory disease models.
CD28SA treatment was chosen for this study with the rationale
of providing potential explanations for contradictory findings using
this drug in experimental stroke studies (Gauberti and Vivien,
2015; Na et al., 2015; Schuhmann et al., 2015; Veltkamp et al.,
2015). Interestingly, the two original studies reporting exacerba-
tion of infarct volume in one and reduction in the other manuscript
used the very same stroke model, antibody and similar readout
measures—however, mice were obtained from two different com-
mercial breeders (Har and CR) (Na et al., 2015; Schuhmann et al.,
2015). Based on the results from our study, it seems conceivable
that differences in the microbiome of the animals may have been
a relevant confounder explaining the contradictory outcome
between these studies. Notably, in this study we did not observe
a reduced infarct volume with CD28SA treatment in any breeder
mouse. However, due to the lack of information on the microbiota
composition in animals used in the previous studies investigating
CD28SA in experimental stroke—particularly as mice housed in
conventional animal facilities do not necessarily represent the
microbiota composition of the original breeder—it cannot be con-
cluded whether microbiota-dependent immune priming is the
exact reason of failed reproducibility.
In light of the so-called ‘‘reproducibility crisis” which draws
increasing attention in diverse research fields (McNutt, 2014) the
findings of the present study introduce the gut microbiota as a rel-
evant factor in the comparability of experimental studies. Strain,
sex and age of laboratory animals have become factors commonly
reflected in study design and reporting of experimental studies
based on well-accepted guidelines (Kilkenny et al., 2010). Due to
the intimate interaction of the microbiota and immune system,
not only do we agree with previous publications which stress the
importance of the microbiota composition in terms of reproducibil-
ity (Bleich and Hansen, 2012; Laukens et al., 2016), in addition we
clearly show that the neuroinflammatory response is also affected
by differences in microbiota composition between three commer-
cial breeders. For this, future studies must further characterize
the key immunogenic bacterial species of the microbiome in order
to enable a targeted analysis and reporting of these confounders.4. Materials and methods
4.1. Animals
All experimental protocols were approved by the responsible
governmental committees (Regierung von Oberbayern, Munich,
Germany). C57BL/6 inbred female mice were purchased as the
C57BL/6J substrain from CR (Sandhofer Weg 7, 97633 Sulzfeld,
Germany), C57BL/6NTac from Tac, (Bomholtvej 10, DK-8680 Ry,
Denmark) and C57BL/6NHsd from Har (Kreuzelweg 53, 5961 NM
Horst, Netherlands). In order to minimize genetic drift, inbred mice
of the indicated strains were backcrossed at Jax, CR and Tac every
fifth generation to original parent lines (Taft et al., 2006). On the
day of arrival mice were aged 4–6 weeks. For a further 3 weeks
mice were left to acclimatize to the housing environment (auto-
claved sawdust, cellulose, gnawing wood piece, water and food
(ssniff R/M-H) ad libitum). Mice were housed in autoclaved gnoto-
biotic cages under controlled temperatures (22 ± 2 C), with 12 h
light-dark cycle periods.
4.2. Co-housing experiments
Specific-pathogen-free (SPF) C57BL/6 mice (males; 6 weeks of
age) were purchased from Jax and allowed to acclimatize in the
animal facility for 1 week before being randomly assigned to
experimental groups. C57BL/6 mice from Jax were transferred into
an autoclaved mini-isolator cage and co-housed for 2 weeks with a
C57BL/6 mouse from Tac tested to be positive for SFB. Mice
received autoclaved drinking water and sterilized standard chow
ad libitum. For the validation co-housing experiments, mice were
received and left to acclimatize for 3 weeks. Three mice from CR
were co-housed with two Tac mice for 2 weeks for natural recolo-
nization. After, dMCAo was induced and mice were sacrificed
5 days post lesion.
4.3. Experimental stroke model
All surgical procedures were performed as previously reported
(Llovera et al., 2014). In brief, mice were anaesthetized with isoflu-
rane, delivered in a mixture of 30% O2 and 70% N2O. Throughout
the surgical procedure body temperature was maintained at
37 C with a mouse warming pad in addition Dexpanthenol eye
ointment was applied to both eyes. Skin was incised between the
eye and the ear revealing the temporal muscle. The temporal mus-
cle was removed from the skull using electrocoagulation forceps.
Upon location of the middle cerebral artery (MCA) under the skull,
a small hole was drilled to expose the MCA. The MCA was then per-
manently occluded using bipolar electrocoagulation forceps. After
visual confirmation of the occluded artery the mouse was sutured.
Mice were recovered in a nursing box at 32 C for 15 min and then
returned to home cages. Control mice received no CD28SA treat-
ment. The brain was carefully removed from the skull 5 days post
lesion, and placed immediately on dry ice. Microscopy slides were
mounted with 20 mM thick coronal cryosections cut at 400 mM
intervals. Sections were then stained with cresyl violet solution
(C5042-10G, Sigma Life Science). For the infarct volume, all slides
were scanned using 600dpi. Measurements were performed using
the ImageJ software (NIH). Using the scale of 23.62 pixels/mm, the
area of white or non-stained infarct tissue was measured and inte-
grated into the total brain area.
4.4. CD28SA treatment
CD28SA (clone: D665) was administered intraperitoneally 3 h
after electro-coagulation of the MCA. A single dose of 150 mg per
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iments (Gogishvili et al., 2009). For control experiments reported
in Suppl. Fig. 5, isotype control IgG1 (clone: MOPC-21) was admin-
istered intraperitoneally in a single dose of 150ug per mouse under
naïve conditions.
4.5. Flow cytometric analysis
Five days post lesion, mice were anaesthetized with intraperi-
toneal injection of ketamine and xylazine. Following saline perfu-
sion, approximately 6 PP per mouse and the entire spleen were
dissected and placed in ice-cold RPMI medium (Invitrogen), and
immediately used for flow cytometric analysis. All cells were iso-
lated under sterile conditions. Spleens were mashed through
40 mm cell strainers and treated with red blood cell lysis buffer.
PP tissue was mashed through a 30 mm pre-separation filter (Mil-
tenyi Biotec). For Isolation of brain leukocytes, brains were taken
from the skull, olfactory bulb and the cerebellum was removed
and the hemispheres separated. Each hemisphere was then trans-
ferred into a 7 ml dounce homogenizer containing 3 ml of RPMI
1640 with phenol red and disrupted with a pestle. The sample
was then mixed with Percoll to obtain a 30% solution. This was
then slowly overlaid 70% Percoll using a 10 ml syringe with a
20G needle. The Percoll gradients were centrifuged with no brake
at 500g for 30 min (18 C). The layer of cells were then carefully
removed and then used for flow cytometry. For intracellular
cytokines, triplicates of 1  106 cells for spleen and duplicates for
PP were plated with pre-coating of anti-mouse CD3e antibodies
(clone BM10-37). Cells were then co-stimulated with CD28 anti-
bodies (clone 37.51) and cultured for 40 h at 37 C and 5% CO2 in
complete RPMI medium (10% heat-inactivated fetal calf serum,
1% penicillin/streptomycin, and 10 mM 2-mercaptoethanol). Fol-
lowing incubation, GolgiPlug (BD Biosciences) was added for a fur-
ther 4 h. Cell surface markers were stained using the following
antibodies: Anti-CD4 PerCP-Cy5.5 (clone RM4-5), Anti-CD45 eFlu-
or450 (clone 30-F11), Anti-CD3 FITC (clone 17A2), Anti-CD8 PE
(53–6.7), Anti-CD11b PE/Cy7 (clone M1/70) Anti-CD11c APC/Cy7
(clone, Anti-Ly6C APC (clone HK1.4), Anti-Ly6G PE/Cy7 (clone
RB6-8C5), and Anti-CD28 PE/Cy7 (clone 37.51). Cells were then
fixed and permeabilized using the Foxp3/Transcription Factor
Staining Buffer Set (ebioscience). The following antibodies were
used for intracellular stainings (all eBioscience): Anti-IL-17A APC
(clone eBio17B7) and Anti-Foxp3 PE (clone NRRF-30). Respective
isotype antibodies were used as controls. Stained cells were ana-
lyzed on a BD FACSVerse flow cytometer (BD Biosciences) and
analysis performed by FlowJo software (version 10.0).
4.6. Sequencing data analysis and taxonomic profiling
Feces samples were always collected at 9.00 am, before and
5 days post-dMCAo and placed immediately on dry ice. DNA isola-
tion was performed using the QIAamp Fast DNA Stool Mini Kit
(Qiagen). The total amount of DNA in each sample was measured
using Qubit (Life Technologies). 16S rRNA amplicons were gener-
ated using primers corresponding to the hypervariable regions
V1-V3. All samples were sequenced on an Illumina MiSeq platform.
18 million paired-end reads were generated at 300-bp length. Prior
to taxonomic analysis, paired-end reads were pre-processed with
Trimmomatic (Bolger et al., 2014) to retain only high-quality
sequences, and joined using scripts from the BBMap/BBTools pack-
age (Bushnell B., sourceforge.net/projects/bbmap/). Joined reads
were quality filtered during demultiplexing with QIIME
(Caporaso et al., 2010), and chimeric sequences were removed with
USEARCH v. 6.1. OTU picking, taxonomic classification and diver-
sity analysis were then performed with QIIME v. 1.9. Open-
reference OTU clustering and taxonomy assignment of sequenceswere performed with UCLUST (Edgar, 2010) against the Silva data-
base release 119 (Quast et al., 2013) at the 97% similarity level.
OTUs with a number of sequences <0.01% of the total number of
sequences were discarded as a second level of quality-filtering.
Alpha diversity and beta diversity metrics were finally calculated,
after rarefying over the minimum number of sequences per sam-
ple. The linear discriminant analysis (LDA) effect size (LEfSe) algo-
rithm was used to detect microbial features having a statistically
different relative abundance between the microbiota of the three
different breeders. Experiments were performed with an alpha
error set to 0.05 and the LDA threshold set to 4.0.
4.7. Quantitative RT-PCR
For feces analysis: Segmented filamentous bacteria (SFB) (for-
ward: GACGCTGAGGCATGAGAGCAT and reverse: GACGGCACG-
GATTGTTATTCA) and Eubacteria (EUB) (forward: ACT
CCTACGGGAGGCAGCAGT and reverse: ATTACCGCGGCTGGC) were
used. The expression of the genes was quantified using a LightCy-
cler 480 II (Roche). For the cohousing experiments: Total bacterial
density of 16S rDNA sequences were amplified from fecal DNA
using 0.2 lM of the universal bacterial r16S gene primers 16S-
V2-101F (50-AGYGGCGIACGGGTGAGTAA-30) and 16S-V2-361R (50
-CYIACTGCTGCCTCCCGTAG-30) in conjunction with Maxima SYBR
Green/ROX qPCR Master mix 2 (Thermo Scientific). Amplifica-
tions were performed on a Chromo 4 Detector (Bio-Rad, Hercules,
CA) using a two-step cycling protocol as previously described
(Benakis et al., 2016). The standard curve was prepared using a
plasmid containing an E. coli 16S V2 rDNA fragment. Using the
same genomic DNA from each sample, real-time PCRs were com-
pleted using SFB primers as described above (Barman et al.,
2008). For brain qPCR the following primers were used from Qia-
gen; Foxp3 (PPM05497F-200) and PPIA (PPM03717B). Gene
expression was normalized to housekeeping gene PPIA using the
standard curve technique.
4.8. Statistical analysis
All statistical analyses were performed using GraphPad Prism
software (GraphPad, version 6.0). Sample size was chosen based
on comparable experiments from previous experiments (Singh
et al., 2016). A p value of <0.05 was regarded as statistically
significant.
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Supplementary Figure 1. Operational taxonomic units are differentially abundant between different 
commercial breeders.
(A) Linear discriminant analysis (LDA) was used to compare operational taxonomic units (OTUs) between CR, Tac 
and Har. An alpha error set to 0.05 and the LDA threshold set to 4.0 (1 independent experiment).CR=Charles River 
Laboratories, Tac=Taconic Biosciences, Har=Harlan Laboratories. Annotations generated using the SILVA 16S 
rRNA database.
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Supplementary Figure 2. Mice from different breeders do not differ in basic peripheral immunity. 
(A) Total cell counts were determined for Peyer’s patches (PP) and spleen in the indicated breeder groups. (B) 
Leukocyte subpopulations in spleens of the three breeder groups were analyzed for the percentage of TCytotoxic cells 
(CD8), THelper cells (CD4), monocytes (CD11b), Ly-6C high and low expressing monocyte subpopulations and 
granulocytes (Ly-6G). Kruskal-Wallis test with Dunn’s multiple comparisons test, (n=5 per group) (1 independent 
experiment). **= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. CR=Charles River Laboratories, Tac=Taconic 
Biosciences, Har=Harlan Laboratories.
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Supplementary Figure 3. Characterization of T cell polarization in the periphery.
(A) Spleens were collected from naïve mice obtained from the indicated breeder sources and analyzed for the 
frequency of Treg (Foxp3+) and Th17 (IL-17+) cells within the Thelper cell population, inadditon to the ratio of 
Foxp3/IL-17 cells. (n=5 per group) (1 independent experiment). Kruskal-Wallis test with Dunn’s multiple compari-
sons test. (B) Spleens and PP were collected from mice obtained from CR and analyzed for the frequency of Thelper 
(CD4+) and Treg (Foxp3+) cells within the T cell population. Mean fluorescence intensity was analyzed for the 
Foxp3+ cells for Foxp3 and CD28 (n=5 per group) (1 independent experiment). Mann-Whitney U test, *= p<0.05, 
**= p<0.01, ***= p<0.001, ****= p<0.0001. CR=Charles River Laboratories, Tac=Taconic Biosciences, Har=Harlan 
Laboratories, PP=Peyer’s patches.
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Supplementary Figure 4. SFB colonization is causally linked to the Foxp3/IL-17 ratio. 
 
For natural recolonization, we housed SFB neg. (CR) mice with SFB pos. (Tac) mice (see Methods section for 
technical details). (A) Schematic illustration of the co-housing experiment and the three investigated mouse groups: 
SFB neg., SFB pos. and SFB recol. (B) Semi-quantitative qPCR of SFB 16S rRNA relative expression in colon and 
cecum. Indicating efficient SFB recolonization by co-housing in the Cecum (For SFB neg. n=5, SFB pos. n=2, SFB 
recol. n=3 (1 independent experiment)). Two-way ANOVA with Tukey’s multiple comparisons test. (C) Flow cytomet-
ric analysis of THelper cell polarization in Peyer’s patches and (D) spleen according to data shown in Figure 2. SFB 
recolonization significantly alters THelper cell homeostasis and Foxp3:IL-17 ratio. Kruskal-Wallis test with Dunn’s 
multiple comparisons test. Brain hemispheres of these mice were processed and flow cytometry for the following 
immune cell populations was performed. (E) CD11b+CD45+ (F) Ly6C+Ly6G- (G) CD11b-CD45+ (H) CD4+CD3+ (I) 
Foxp3+. I= Ipsilateral cortex and C= Contralateral cortex. Two-way ANOVA with Tukey’s multiple comparisons test 
(1 independent experiment). *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. CR=Charles River Laboratories, 
Tac=Taconic Biosciences, Har=Harlan Laboratories.
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Supplementary Figure 5. Characterization of T cell polarization after isotype control or CD28SA treatment.
Naïve mice were treated with IgG1 isotype control and compared to untreated mice. 5d post injection spleens and 
PP were taken to assess peripheral T cell polarization. (A) Foxp3+, IL-17+ and Foxp3:IL-17 ratio found in the PP. 
(B) Foxp3+, IL-17+ and Foxp3:IL-17 ratio found in the spleen. For the naïve group n=4 for the IgG1 group n=5 (1 
independent experiment). Mann-Whitney U test. (C) Induction of Treg and Th17 was analyzed in spleens 5d after 
stroke and CD28SA treatment, then compared to controls. CD28SA administration equally expanded Treg and 
Th17 cells in all breeder groups, in contrast to the more selective T cell polarization observed in Peyer’s patches 
(see Figure 4). (For control: n=5 per group (1 independant experiment), for CD28SA: CR=6, Tac=8, Har=8 (2 
independent experiments)) , 2way-ANOVA with Sidak’s multiple comparisons test. *= p<0.05, **= p<0.01, ***= 
p<0.001, ****= p<0.0001. CR=Charles River Laboratories, Tac=Taconic Biosciences, Har=Harlan Laboratories.
C
Fo
xp
3+
 (%
C
D
4+
) 
IL
-1
7+
 (%
C
D
4+
) 
0
20
40
60
80
CR Tac Har CR Tac Har
2
4
6
8
10
0
[
Control
CD28SA
****
****
****
****
CR Tac Har
0
50
150
100
Fo
xp
3/
IL
-1
7+
 ra
tio
 
*
[*
75 | P a g e  
 
SHORT-CHAIN FATTY ACIDS IMPROVE POST-STROKE RECOVERY VIA 
IMMUNOLOGICAL MECHANISMS. 
SUMMARY 
From the three previous studies it was clear that the interaction between the immune system and 
microbiota was affecting stroke, and immunotherapies. While in the first study we characterised 
changes in the gut microbiota, evidence suggested that microbiota alterations were present for much 
longer time periods after stroke (Swidsinski, Loening-Baucke et al., 2012). For the third aim we 
wanted to investigate the role of the gut microbial metabolites on long-term stroke recovery.  
The SCFA (acetate, propionate and butyrate) are key bioactive metabolites produced from 
indigestible dietary fibre. We investigated the role of SCFA in post-stroke regeneration using 
supplementation of SCFA in drinking water. First, automated behavioural analysis demonstrated that 
SCFA supplementation specifically improved motor deficits at later time points after stroke. This 
indicated that SCFA could be affecting the plasticity and cortical reorganisation. Using in vivo calcium 
imaging we saw changes in dynamics of contralateral cortex connectivity following SCFA 
supplementation. In accordance with the altered connectivity, we saw that excitatory spine and 
synapse densities were changed under SCFA supplementation. RNA sequencing of the whole cortex 
indicated the potential involvement of microglia cells. Microglia are indeed the players involved in 
synaptic pruning. Using an automated morphology analysis of cortical microglia, we found more 
ramified structures, hinting at reduced microglia activation compared to controls. By flow cytometry, 
we characterised the immune cell populations within the brain as a potential source of 
neuroinflammation. SCFA supplementation reduced the cerebral lymphocytes after stroke. This was 
also evident in the spleens, suggesting SCFA were acting initially in the peripheral compartment. 
Using Rag–/– mice, we found that in the absence of T and B lymphocytes, microglia did not change 
morphology under SCFA supplementation. Taken together, these results suggest that microbiota-
derived SCFA are important for improved post-stroke recovery. More specifically, cells which are 
altered by SCFA in the periphery, migrate to the brain after stroke and alter the inflammatory milieu 
within the brain. The changed inflammatory state within the brain potentially affects microglia and in 
turn, the synaptic reorganisation after stroke.  
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Abstract   721 
Recovery after stroke is a multicellular process encompassing neurons, resident immune 722 
cells and brain-invading cells. Stroke alters the gut microbiome which in turn has 723 
considerable impact on stroke outcome. However, the mechanisms underlying gut-brain 724 
interaction and implications for long-term recovery are largely elusive. Here, we tested the 725 
hypothesis that short-chain fatty acids (SCFA), key bioactive microbial metabolites, are the 726 
missing link along the gut-brain axis and might be able to modulate recovery after 727 
experimental stroke. SCFA supplementation in the drinking water significantly improved 728 
recovery of affected limb motor function. Using in vivo wide-field calcium imaging, we 729 
observed that SCFA induced altered contralesional cortex connectivity. This was associated 730 
with SCFA-dependent changes in spine and synapse densities. RNA-sequencing of the 731 
forebrain cortex indicated a potential involvement of microglial cells in contributing to the 732 
structural and functional remodelling. Further analyses confirmed a substantial impact of 733 
SCFA on microglial activation, which depended on the recruitment of T cells to the infarcted 734 
brain. Our findings identified that microbiota-derived SCFA modulate post-stroke recovery 735 
via effects on systemic and brain resident immune cells.  736 
Significance statement  737 
Previous studies have shown a bi-directional communication along the gut-brain axis after 738 
stroke. Stroke alters the gut microbiota composition, and in turn, microbiota dysbiosis has a 739 
substantial impact on stroke outcome by modulating the immune response. However, until 740 
know the mediators derived from the gut microbiome affecting the gut-immune-brain axis 741 
and the molecular mechanisms involved in this process have been unknown. Here, we 742 
demonstrate that SCFA—fermentation products of the gut microbiome—are potent and 743 
proregenerative modulators of post-stroke neuronal plasticity at various structural levels. We 744 
identified that this effect was mediated via circulating lymphocytes on microglial polarization. 745 
  4  
These results identify SCFA as the missing link along the gut-brain axis and as a potential 746 
therapeutic to improve recovery after stroke.  747 
   748 
  5  
Introduction   749 
Stroke induces a multiphasic pathophysiological cascade, which consists of an initial 750 
excitotoxicity followed by a longer neuroinflammatory phase within the brain (Dirnagl et al., 751 
1999; Iadecola and Anrather, 2011). Moreover, stroke can be regarded as a systemic 752 
disease affecting also remote organ function including the lung (Austin et al., 2019) , heart 753 
(Bieber et al., 2017), immune system and intestinal function (Singh et al., 2016b) . Recently 754 
it has been shown that a dysbiotic gut microbiota is correlated with a worsened outcome in 755 
patients (Xia et al., 2019), and that these changes are evident up until 3 weeks after 756 
hospitalization (Swidsinski et al., 2012). We have previously demonstrated an important role 757 
of the gut microbiome on stroke outcome in proof-of-principle experiments using germ-free 758 
(GF) and recolonized mice (Singh et al., 2018). Further experimental studies in rodent stroke 759 
models have identified a key role for the immune system—particularly brain-invading 760 
lymphocytes originating from the intestinal immune compartment— in mediating along the 761 
gut-brain-axis (Benakis et al., 2016; Singh et al., 2016b).   762 
The gut microbiome produces a large number of bioactive metabolites which may affect 763 
brain function via modulating the immune system or afferent neuronal pathways (Kau et al.,  764 
2011; Cryan and Dinan, 2012). In particular, the metabolite group of short-chain fatty acids 765 
(SCFA) acetate, butyrate and propionate have been shown to readily cross the blood brain 766 
barrier (Frost et al., 2014; Morrison and Preston, 2016) and affect brain function in 767 
development, health and disease. For example, SCFA treatment improved the disease 768 
course in experimental autoimmune encephalitis by promoting anti-inflammatory 769 
mechanisms and reducing axonal damage (Haghikia et al., 2015). In mouse models of 770 
chronic stress, mice that received SCFA treatment exhibited significant improvements in 771 
antidepressant and anxiolytic behaviours, which was accompanied by reduced plasma 772 
corticosterone levels and differential gene regulation (van de Wouw et al., 2018).  773 
  6  
More recently, the role of SCFA in modulating the immune system has been studied in great 774 
detail. Through, these investigations, they have been shown to play a role in the polarization 775 
of T cells in the intestinal immune compartment and inducing anti-inflammatory T cell subset 776 
(Smith et al., 2013; Tan et al., 2016). Other studies have shown a critical role for 777 
microbiotaderived SCFA in the maturation of microglial cells, the brain’s resident immune 778 
cells (Erny et al., 2015). However, SCFA can have far-reaching pleiotropic effects also 779 
beyond the immune system, including a direct effect on neuronal function through their 780 
potent function as histone deacetylase inhibitors (HDACi) (Bourassa et al., 2016). 781 
Accordingly, the importance of SCFA function has been implicated in neurodegenerative 782 
diseases and even in post-ischemic neurogenesis (Chuang et al., 2009; Kim et al., 2009).  783 
Despite the key contribution of the gut microbiome to stroke outcome and the identification of  784 
SCFA as one of the microbiome’s primary bioactive mediators, the role of SCFA and their 785 
potential therapeutic use for post-stroke recovery in the chronic phase after brain ischemia 786 
has not been investigated. In this study, we comprehensively investigated the effect of SCFA 787 
administration on post-stroke recovery using advanced behavior analyses, in vivo wide-field 788 
calcium imaging, transcriptomic studies and histological analyses to study and link 789 
SCFAmediated recovery mechanisms from the molecular level up to behavior.  790 
 Materials and methods  791 
Animals and treatment. All experimental protocols were approved by the responsible 792 
governmental committees (Regierung von Oberbayern, Munich, Germany and Institutional 793 
Animal Care and Use Committee, UT Southwestern, Dallas, Texas, USA). SPF C57BL/6J 794 
female and male mice were purchased from Charles River Laboratories (Germany) or 795 
Jackson Laboratories (USA). On the day of arrival mice were aged 6-8 weeks. Mice were 796 
given SCFA (25.9mM sodium propionate, 40mM sodium butyrate and 67.5mM sodium 797 
acetate) or salt-matched control (133.4mM sodium chloride) (9265.1, ROTH) in drinking 798 
  7  
water ad libitum for 4 weeks as previously reported (Smith et al., 2013; Erny et al., 2015). 799 
For antibiotic treatment, mice received Metronidazol 0.5mg/ml, (Sigma, #46461) Neomycin  800 
0.5mg/ml, (Sigma, # N1142), Ampicillin 0.5mg/ml (Sigma, #31591), and Vancomycin 801 
0.5mg/ml (Sigma, #V8138) and with 5% sucrose in drinking water. All drinking water 802 
solutions were prepared and changed twice a week and blinded for experimenters.  803 
Experimental stroke model.   804 
For the photothrombotic stroke model (PT), mice were anaesthetized with isoflurane, 805 
delivered in a mixture of 30% O2 and 70% N2O. Mice were placed into a stereotactic frame, 806 
and throughout the surgical procedure body temperature was maintained at 37◦C with a 807 
mouse warming pad. Dexpanthenol eye ointment was applied to both eyes. A skin incision 808 
was used to expose the skull. Bregma was located and using the laser the lesion location 809 
was marked in the left hemisphere (1.5mm lateral and 1.0mm rostral to bregma). Mice were 810 
then injected intraperitoneally with Rosa Bengal (Sigma, #198250). Shielding was placed on 811 
skull allowing a 2mm diameter circular exposure over the lesion area. After 10 minutes, the 812 
laser (Cobolt Jive, 561nm, 25mV output power with fiber collimation at f=7.66mm) was 813 
applied to the lesion area for 17 minutes.  814 
For the distal, permanent occlusion of the middle cerebral artery (dMCAo), the distal middle 815 
cerebral artery was permanently electro coagulated as previously described (Llovera et al., 816 
2014). In brief, under isoflurane anesthesia mice were placed in the lateral position. A skin 817 
incision was made to expose the skull. Using a drill, a burr hole into the skull revealed the 818 
bifurcated middle cerebral artery. Using electric forceps, the artery was occluded, and 819 
checked for no blood flow. Mice were then sutured across the skull incision.   820 
For the filament, transient occlusion of the middle cerebral artery (fMCAo), the internal 821 
carotid artery was transiently occluded for 60min as previously described (Singh et al., 822 
2016b). In brief, mice were anaesthetized with isoflurane and an incision was made to 823 
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expose the temporal bone. A laser doppler probe was affixed to the middle cerebral artery 824 
territory to determine blood flow. At the neck an incision to the skin exposed the common 825 
carotid and external carotid artery, which were ligated. The filament was inserted into the 826 
internal carotid artery for 60 minutes. Mice were sutured across the neckline.   827 
After all surgeries, mice were recovered in a nursing box at 32°C for 15 minutes and then 828 
returned to home cages.   829 
Widefield calcium imaging. In vivo widefield calcium imaging was performed as previously 830 
published (Cramer et al., 2018). Briefly, we used Thy1GCaMP6s heterozygous reporter 831 
mice. Mice were scalped and transparent dental cement was placed upon the intact skull, at 832 
least 3 days before start of the experiment. Resting state in vivo imaging was performed 833 
under mild anesthesia (0.5mg/kg body weight of Medetomidin with 0.75% isoflurane 834 
inhalation). Mice were placed in a stereotactic frame below a customized macroscopic 835 
imaging set-up and the mouse cortex was illuminated with 450nm blue LED light. We 836 
recorded for 4min in resting-state with a CCD camera at 25Hz frame rate. Functional 837 
connectivity was computed for seed-based analysis with a seed pixel time series centered in 838 
the right caudal forelimb cortex (rCFL), contralesional to the infarcted cortex. Pearson’s 839 
correlation between the time course of this seed and any other signal time course within the 840 
masked area was computed, then Fisher’s z transformed and topographically displayed. 841 
Analogous functional connectivity between seed pairs was calculated as correlation between 842 
signal time courses of two seeds within the sensorimotor cortex. Seeds were defined as 843 
previously described (Cramer et al., 2018). Mean correlation per group was calculated for 844 
each time point. We used two sample T test and Bonferroni correction for statistical testing.   845 
Automated skilled reaching. Behavioral training and assessments were measured using an 846 
automated reach task previously described (Becker et al., 2016). Mice are trained to pull an 847 
isometric lever using the contralesional forelimb, with each successful application of force 848 
criteria rewarded by a drop of peanut oil. For the first week, mice were trained in groups of 849 
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23 littermates for six hours. During this time, spontaneous peanut oil deliveries occurred at 850 
randomly spaced time intervals ranging from 30sec to 5min. Additionally, the isometric 851 
handle was positioned approximately 0.5cm from the inner edge of the chamber during 852 
these six-hour sessions. The force criterion necessary to trigger a 4μl peanut oil droplet, was 853 
set just above electrical noise so that any slight touch could trigger peanut oil dispersion. For 854 
the next three weeks, mice were trained individually for 2-hour sessions. The handle was 855 
positioned further back at 1cm from the inner edge of the chamber. The criterion for success 856 
during training sessions was changed based on a customized, adaptive MATLAB program. 857 
The adaptive program initially set the criterion for success at a specified value of at least one 858 
gram. After the first 15 pulls, the criterion was adjusted to the median force value. The 859 
adjustments continued for the duration of the session unless the median reached the 860 
maximum force requirement of 20g. Finally, we fixed the criterion at 20g to measure baseline 861 
motor function for three consecutive sessions. After stroke, assessments of reaching 862 
behaviors were measured weekly for six weeks.  863 
SCFA quantification. Mice were saline perfused, and organs extracted. For feces, colon 864 
content was collected and for plasma, cardiac puncture blood was centrifuged at 4°C at  865 
3000rpm and the plasma removed. All samples were frozen immediately on dry ice. SCFA 866 
(acetic, propionic and butyric acid) were determined according to published protocols, using 867 
gas chromatography – mass spectrometry (Hoving et al., 2018). Briefly, for plasma 10µl 868 
were used, feces were homogenized with LC-MS grade water in a bead beater. Samples 869 
were spiked with deuterated internal standards for each SCFA. Subsequently, SCFA were 870 
derivatized using pentafluorobenzyl bromide and analyzed using gas chromatography – 871 
electron capture negative ionization in single ion monitoring mode. Quantification was 872 
carried out against external calibration lines.  873 
Infarct volumetry. After saline perfusion, the brain was removed from the skull and placed 874 
immediately on dry ice. Microscopy slides were mounted with 20µm thick coronal 875 
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cryosections cut at 400µm intervals for dMCAo and fMCAo lesions, and at 120µm intervals 876 
for PT lesions. Sections were then stained with cresyl violet solution. For the infarct volume, 877 
all slides were scanned using 600dpi. The area of infarct tissue was measured using the 878 
ImageJ software (NIH) and integrated for calculation of infarct volume.   879 
Spine density analysis. Following saline perfusion, mice were perfused with aldehyde fixative 880 
solution (Bioenno, #003780). Brains were then carefully removed and placed in fixative 881 
solution at 4°C overnight. Brains were then sliced at 100µm thick vibratome sections and 882 
immersed in impregnation solution (Bioenno, sliceGolgi Kit, #003760) for 5 days. Further 883 
staining was performed as described by the manufacturer (Bioenno). Images of dendrites 884 
were obtained at the same anatomical level for all brains, 400µm from the lesion perimeter in 885 
cortical layer 2/3. In total, 5 dendrites from 5 neurons each in both hemispheres were 886 
imaged (100x brightfield). Dendrites from the images were then reconstructed using Imaris 887 
x64 (version 8.4.0, Bitplane).   888 
Immunohistochemistry. Mice were perfused with saline and then 4% paraformaldehyde 889 
(PFA). Brains were removed and post-fixed in 4% PFA at 4°C overnight. Brains were then 890 
dehydrated in 30% sucrose in 1x PBS. Microglia staining was performed on 100µm thick 891 
sections using rabbit anti-iba1 (1:200, Wako, #019-19741), and then goat anti-rabbit 594 892 
(1:200, Thermo Fisher Scientific, #A-11012). Automated analysis of microglial cell counts 893 
and morphology was performed using a MATLAB automated morphology protocol as 894 
previously described (Heindl et al., 2018). For synaptic staining, sections were incubated 895 
with guinea pig anti-VGlut1 (1:1000, Millipore, #AB5905) and chicken anti-Homer1 (1:2000,  896 
Synaptic Systems, #160006) for 3d at 4°C. Then counterstained with goat anti-guinea pig  897 
488 (1:500, Invitrogen, #A11073) and goat anti-chicken 647(1:500, Invitrogen, #A21449) for 898 
18h at RT. For synaptic puncta analysis a z-stack of 3 slices at 0.33µm were used as 899 
previously described (Au - Ippolito and Au - Eroglu, 2010) using FIJI with the 900 
SynapseCounter plugin (Schindelin et al., 2012).   901 
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Flow cytometric analysis. Following saline perfusion in deep anesthesia, the entire spleen 902 
and both brain hemispheres were dissected. Spleens were immediately placed on ice cold 903 
1x PBS, were passed through a 40µm cell strainer and treated with red blood cell lysis 904 
buffer. Cell surface markers were stained using the following antibodies: Anti-CD3 FITC  905 
(clone 17A2), Anti-CD45 eFluor450 (clone 30-F11). Stained cells were analyzed on a BD  906 
FACSVerse flow cytometer (BD Biosciences) and analysis performed by FlowJo software 907 
(version 10.0).   908 
For brain, hemispheres were isolated and cells isolated by mechanical dissociation. 909 
Mononuclear cells were enriched using discontinuous Percoll gradient centrifugation by 910 
standard protocols and then with 30µm cell strainer, as described previously (Benakis et al., 911 
2016). Cell staining for flow cytometry was performed by first pre-incubation of cells with Fc 912 
receptor blocker (1:100, Invitrogen, 14-91-61-73) for 10 min and then staining with the 913 
following monoclonal antibodies: Anti-CD3 FITC (clone 17A2), anti-CD45 eFluor450 (clone  914 
30-F11) and anti-CD11b Pe-Cy7 (clone M1/70). Stained cells were analyzed on a BD  915 
FACSVerse flow cytometer (BD Biosciences) and analysis performed by FlowJo software 916 
(version 10.0).  917 
RNA sequencing and data analysis. Fourteen days post stroke, brains were extracted from 918 
the skulls and placed into a stainless-steel brain matrix. Brains were sliced coronally at 2mm 919 
distance caudally and rostrally away from the lesion. The cortex was removed, frozen on dry 920 
ice and the mRNA isolated using the RNeasy Mini Kit (Qiagen, #74109). For library 921 
preparation 100ng of total RNA were fragmented and processed using the Ovation Human  922 
FFPE RNA-Seq Library Systems (Nugen) according to the instructions of the manufacturer.  923 
Barcoded libraries were quantified using the Library Quantification Kit - Illumina/Universal 924 
(KAPA Biosystems). Cluster generation was performed with a concentration of 10nM using a 925 
cBot (Illumina). Sequencing of 2x 100bp paired-end reads was performed with a HiScanSQ 926 
sequencing platform (Illumina) using version 3 chemistry at the sequencing core facility of 927 
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the IZKF Leipzig (Faculty of Medicine, University Leipzig). Raw reads were mapped to the 928 
reference genome mm10 using split-read mapping algorithm implemented in segemehl 929 
(Hoffmann et al., 2009). Mapped reads were counted using featureCounts (Liao et al., 2014) 930 
according to RefSeq annotation. Differential expression was computed using DESeq2 931 
algorithm (Love et al., 2014). Raw data have been deposited at Gene Expression Omnibus 932 
database (Accession number GSE131788).  933 
RT-PCR. mRNA from brain tissue around the lesion was isolated as described above and 934 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 935 
#4368814) with RNasin Plus RNase Inhibitor (Promega, #N2611).   936 
The following primers were used: BDNF (forward: CGGCGCCCATGAAAGAAGTA and 937 
reverse: AGACCTCTCGAACCTGCCCT), TrkB (forward: ACTTCGCCAGCAGTAGCAG and  938 
reverse:  ACCTCAGGGCTGGGGAG),  Synaptophysin  (forward:  939 
AGTACCCATTCAGGCTGCAC and reverse: CCGAGGAGGAGTAGTCACCA), EphrinA5  940 
(forward: CTGGTGCTCTGGATGTGTGT and reverse: CCCTCTGGAATCTGGGGTTG) and  941 
PPIA  (forward:  ACACGCCATAATGGCACTGG  and  reverse:  942 
ATTTGCCATGGACAAGATGCC). The QuantiNova SYBR Green PCR Kit (Qiagen,  943 
#208052) was used with a LightCycler 480 II (Roche). All gene expression was expressed 944 
relative to the PPIA house keeping gene and calculated using the relative standard curve 945 
method.  946 
Experimental Design and statistical analysis. All statistical analyses were performed using 947 
GraphPad Prism software (GraphPad, version 6.0). Sample size was chosen based on 948 
comparable experiments from previous experiments (Singh et al., 2016b). For experimental 949 
design details on sample size, please refer to manuscript results and figure legends. A p 950 
value of <0.05 was regarded as statistically significant.  951 
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Results  952 
SCFA supplementation improves recovery and cortical reorganization after stroke  953 
We previously showed that stroke induces dysbiosis of the gut microbiome with the hallmark 954 
of reduced bacterial diversity (Singh et al., 2016b). In order to test the impact of post-stroke 955 
gut dysbiosis on the metabolic function of the microbiome, we performed targeted analysis of 956 
plasma samples for SCFA concentrations after stroke and sham surgery in mice by mass 957 
spectrometry. This analysis revealed significantly reduced plasma SCFA concentrations 3 958 
days after stroke surgery compared to sham-operated mice (Fig. 1-1 A). Therefore, we 959 
hypothesized that supplementation of SCFA would increase circulating SCFA  960 
concentrations, and potentially induce therapeutic effects within the chronic post-stroke 961 
recovery period. In order to test this hypothesis, we supplemented mice for 4 weeks with 962 
drinking water containing either a mix of acetate, butyrate and propionate (see methods 963 
section for details) or control drinking water with matched sodium chloride concentration. 964 
SCFA supplementation did not affect body weight (Fig. 1-1 B) or overt behavior of the 965 
animals. We performed photothrombotic stroke surgery after four weeks of SCFA 966 
supplementation and assessed post-stroke motor deficits of the affected forelimb with an 967 
automated lever pull test (Fig. 1A, B). Mice receiving SCFA supplementation performed 968 
significantly better in the chronic post-stroke phase at days 42 and 56 (Fig. 1B). In order to 969 
analyze cortical network plasticity as the morphological surrogate of behavioral recovery, we 970 
used Thy1-GCaMP6s mice and performed resting state in vivo calcium to record cortical 971 
widefield fluorescence from a neuronal based calcium reporter. Using the homotypical 972 
contralesional region of the cortex, we performed seed-based correlation analysis, indicating 973 
the connectivity strength (z-score) of this area to every other pixel in the cortex (Fig. 1C). 974 
Previous research using fMRI in stroke patients has indicated that the homotypical 975 
contralesional region receives less neuronal inhibition from the stroked hemisphere, leading 976 
to disinhibition of the contralesional hemisphere (Rehme and Grefkes, 2013). To analyze the 977 
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size of highly connected homotypical contralesional regions (i.e. the contralesional motor 978 
cortex), we measured the area of pixels with a z-score above 2.25 (Fig. 1D). We observed a 979 
significantly reduced area of the contralesional motor cortex in SCFA- compared to 980 
controltreated mice at D21 and D42 (Fig. 1E). In contrast, SCFA treatment did not 981 
significantly affect the primary infarct area by in vivo imaging (Fig. 1-1 C) and histological 982 
analyses with infarct volumetry in 3 different focal stroke models after stroke (Fig. 2-1 E). 983 
These results indicated that while SCFA supplementation did not affect the initial lesion 984 
development, SCFA improved behavioral stroke outcome and modulated cortical network 985 
plasticity at later stages after stroke.  986 
 987 
 988 
Figure 1. SCFA supplementation improves recovery after stroke. (A) Schematic 989 
diagram illustrating the timeline of SCFA supplementation and analysis timepoints. (B) 990 
Representative images obtained during the lever pull test of trained mouse successfully 991 
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reaching for the lever (left, above) and obtaining the peanut oil reward (left, below). Right 992 
panel: normalized success rate for lever pulls by the affected (contralesional) forelimb. 993 
Relative values are shown per time point normalized to the mean of the control group. N= 6 994 
per group, horizontal line indicates mean. (C) Topographic depiction of seed-based 995 
functional connectivity of both hemispheres at indicated time points of SCFA and 996 
controltreated mice. Seed is placed in the homotypic contralesional region to the ipsilesional 997 
lesion area (i.e. the contralesional motor cortex). Colour code indicates Fischer’s z 998 
correlation between the seed and every other pixel in the cortex. (D) Enlarged images of the 999 
contralesional motor cortex (region homotypic to the infarct lesion). Area highlighted with 1000 
dotted line indicates the highly connected functional motor cortex area (pixels with Fischer’s 1001 
z values >2.25). (E) Quantification of highly-correlated (Fisher’s z >2.25) area of the 1002 
contralesional motor cortex in control (open bars) and SCFA treated mice (grey bars). N=15 1003 
per group. Statistical tests in B and E have been performed using multiple T tests per time 1004 
point with Holm-Sidak’s correction for multiple testing.   1005 
SCFA supplementation modulates post-stroke synaptic plasticity.  1006 
After an ischemic brain injury, the entire cortex undergoes rapid functional and morphological 1007 
reorganization including neuronal dendritic plasticity which allows adult neurons to form new 1008 
connections. This process is correlated with improved functional connectivity after a cortical 1009 
lesion (Jones and Schallert, 1994; Biernaskie et al., 2004). In order to analyze underlying 1010 
morphological plasticity of the observed functional recovery in behavior and cortical 1011 
connectivity, we performed Golgi-Cox staining of brain sections to investigate the effects of 1012 
SCFA supplementation on dendritic spine density of pyramidal cells (Fig. 2A, B). We initially 1013 
performed this analysis in the brains of naive animals that received either SCFA or control 1014 
treatment, which revealed a higher pyramidal cortical spine density in the SCFA-treated mice 1015 
(Fig. 2C). Next, we quantified brains at 14 days after stroke to capture a time-period before 1016 
the behavioral and cortical connectivity improvements were evident. Correspondingly, we 1017 
  16  
observed that after stroke SCFA supplementation was associated with a significantly higher 1018 
spine density in the homotypic contralesional region, however, these differences were not 1019 
observed in the ipsilesional hemisphere (Fig. 2D) and were independent of infarct volume 1020 
(Fig. 2-1). Moreover, the analysis of spine length distribution revealed that SCFA treatment 1021 
induced a shift towards shorter spine lengths, specifically in the ipsi- but not contralesional 1022 
hemisphere (Fig. 2E, F, Fig. 2-1 F, G). In order to further investigate synaptic plasticity under 1023 
control of SCFA supplementation, we assessed synaptic density using co-staining for VGlut1 1024 
(pre-synaptic) and Homer1 (postsynaptic) (Fig. 2G). We detected a significant reduction of 1025 
the number of synapses (i.e. colocalized VGlut1 and Homer1 puncta) in the peri-lesional 1026 
cortex of SCFA-supplemented mice (Fig. 2H). Interestingly, the difference in synapse counts 1027 
was exclusively driven by the number of pre-synaptic VGlut1 puncta while Homer1-positive 1028 
puncta remained unaffected.  1029 
Additionally, this pattern was also mirrored in the mean size of VGlut1 and Homer1 puncta 1030 
(Fig. 2-1 H). Finally, we analyzed the transcriptional regulation of key factors involved in 1031 
synaptic plasticity (Fig. 2I). We observed that SCFA significantly increased the expression of 1032 
the presynaptic vesicle molecule synaptophysin and the BDNF (brain-derived neurotrophic 1033 
factor) receptor TrkB. BDNF itself, or the receptor tyrosine kinase EphA2 was not affected by 1034 
SCFA supplementation. These results indicate effects of SCFA on morphological, synaptic 1035 
plasticity which could potentially precede the effects observed on functional recovery at later 1036 
time points after stroke.   1037 
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 1038 
Figure 2. Post-stroke neuronal plasticity is altered by SCFA treatment. (A) 1039 
Representative images of Golgi-Cox stained brain sections 14d after stroke. Dotted area in 1040 
overview image indicates peri-lesional cortical area used for spine analysis. Magnifications 1041 
show representative pyramidal neuron and high-magnification image as used for spine 1042 
analysis. Top right shows a cortical pyramidal neuron. Lower right example of spines 1043 
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identified on dendrite. Scale bar = 10µm. (B). 3D reconstruction for a dendrite section with 1044 
spines as used for further quantification of spine densities and lengths, scale bar = 2μm. (C).  1045 
Quantification of pyramidal spine density per 10μm of dendrite in the cortex of control and  1046 
SCFA treated naïve mice (no stroke induction). Each colour represents a different mouse 1047 
and each dot a different dendrite. 5 neurons per hemisphere analysed in total for 4/5 mice 1048 
per group (Mann-Whitney U test). (D). Quantification of spine density per 10μm of dendrite in 1049 
the perilesional and contralesional cortex at 14d after stroke (Kruskal-Wallis test with Dunn’s 1050 
correction for multiple comparisons. (E) Histogram of the relative frequency (fraction) of 1051 
spines found at different lengths 14d after photothrombotic lesion in the perilesional cortex.  1052 
Bin width is 0.2µm (F). Quantification of short (0.2µm) and long (1.4µm) spines in control  1053 
(open bars) and SCFA (grey bars) treated mice. N=4/5 per group, Mann-Whitney U test. (G). 1054 
Representative particle images of presynaptic terminals by VGlut1 (green), postsynaptic 1055 
densities by Homer1 (red) and nuclei with DAPI (blue) of the cortex from control and SCFA 1056 
treated mice (scale bar = 20µm), as used for quantification of co-localized pre- and 1057 
postsynaptic particles (puncta). Arrowheads indicate co-localized (yellow) puncta. (H). 1058 
Synapse counts were quantified as co-localised VGlut1 and Homer1 puncta. Quantification 1059 
for co-localization (left and for single markers (middle and right) revealed significantly 1060 
changed synapse counts as a result of the reduced number of VGlut1+ terminals in the 1061 
perilesional cortex (contra: contralesional hemisphere; ipsi: ipsilesional hemisphere). N=3/4 1062 
mice (3 sections per mouse), statistical analysis performed with Kruskal-Wallis test with 1063 
Dunn’s multiple comparison correction. (I). Relative expression (RE) of mRNA for key 1064 
molecules involved in synaptic plasticity (left) synaptophysin, (left middle) TrkB, (right 1065 
middle) EphA5, (right) BDNF from the peri-lesional cortex in control (open bars) and SCFA 1066 
(grey bars) treated mice. N= 7 per group, Mann-Whitney U test. 1067 
 1068 
 1069 
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Brain transcriptomic analysis indicates microglia as the main cellular target of SCFA.  1070 
In order to determine whether the observed effects of SCFA were either directly mediated on 1071 
neuronal function or affecting other cerebral cell populations, we took an unbiased approach 1072 
to investigate the effects of SCFA on gene expression in the peri-infarct cortex. For this, we 1073 
first depleted the gut microbiome of mice as the main SCFA source by administration of 1074 
antibiotics, followed by supplementation of SCFA (Fig. 3A). Plasma GC-MS quantification 1075 
confirmed an increase of SCFA after supplementation in drinking water (Fig. 3-1). Fourteen 1076 
days post-surgery the infarct and peri-infarct region were isolated for RNA sequencing, 1077 
identifying 18 upregulated and 20 downregulated genes in SCFA supplemented mice (Fig. 1078 
3B, C).   1079 
The list of the top upregulated genes (Fig. 3C) hinted at a role for microglia as we found 1080 
numerous genes that have previously been reported to be involved in microglial function 1081 
and/or activation such as Ctsd, various complement molecules, Tyrobp and Laptm5 (Zhong 1082 
et al., 2018; Li et al., 2019). In order to ascertain which cell type SCFA supplementation was 1083 
mainly regulating in the brain, we took the 38 differentially regulated genes and compared 1084 
them to an existing RNA-Seq database which lists the fragments per kilobase of exon model 1085 
per million reads (FPKM) found in astrocytes, neurons, oligodendrocytes, microglia and 1086 
endothelial cells (brainrnaseq.org) (Zhang et al., 2014). From the total number of FPKM 1087 
values of the 38 differentially regulated genes (Suppl. Table 1), we discovered that the vast 1088 
majority of gene reads from the significantly regulated genes were associated with microglial 1089 
cells (Fig. 3D). Additionally, we performed an ingenuity pathway analysis on the 38 1090 
differentially regulated genes, and found that the complement system was the top pathway 1091 
and highly upregulated in mice supplemented with SCFA (Fig. 3E). Within the brain the 1092 
complement pathway is critical for microglia activation and has been associated with 1093 
synaptic pruning by microglia (Schafer et al., 2012; Stephan et al., 2012; Wu et al., 2015).   1094 
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 1095 
Figure 3. SCFA supplementation affects microglial gene signature after stroke. (A). 1096 
Schematic diagram illustrating antibiotic treatment regimen and followed by supplementation 1097 
with SCFA or control saline in drinking water. Delineated area on histological image illustrate 1098 
perilesional cortex isolated for mRNA sequencing. (B). Volcano plot of regulated transcripts 1099 
(SCFA/control) in the perilesional cortex 14d after stroke, n=3 per group. All gene transcripts 1100 
are in black, and gene transcripts with fold change (log2)>1 and -log10 adjusted p−value <  1101 
0.1 are in orange. (C). Heatmap of fold change (log2) for significantly regulated genes with 1102 
an adjusted p value <0.1. Each column represents one individual mouse. (D). FPKN 1103 
abundance and association per cerebral cell type of all significantly regulated genes (panel 1104 
C) was performed as detailed in the methods section, revealing the strongest association of 1105 
the significantly regulated genes with microglial cells. (E). Ingenuity pathway analysis 1106 
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showing the top networks regulated by SCFA supplementation in comparison to control 1107 
treatment.   1108 
SCFA modulate microglial activation and immune cell composition.  1109 
Based on the transcriptomic data’s indication that microglia are the effector of SCFA 1110 
mediated post-stroke recovery, we performed more in-depth analyses of microglial activation 1111 
and the inflammatory response to stroke. As a surrogate of microglia activation we 1112 
performed Iba-1 immunohistochemistry of the cortex (Fig. 4A) and assessed microglia 1113 
morphology using automated analysis (Heindl et al., 2018). 14d after stroke, cortical 1114 
microglia from SCFA supplemented mice displayed a significantly more ramified and less 1115 
spherical (i.e. less activated) morphology in comparison to controls (Fig. 4B). Additionally, 1116 
the total number of microglia were significantly reduced in SCFA- compared to controltreated 1117 
mice (Fig. 4C). These results indicate a modulation of the microglial response to stroke by 1118 
SCFA. Aside from evoking a microglial response, stroke induces invasion of peripheral 1119 
immune cells into the brain parenchyma, which can deteriorate stroke outcome (Iadecola 1120 
and Anrather, 2011; Liesz et al., 2015; Neumann et al., 2015; Selvaraj and Stowe, 2017). In 1121 
particular, lymphocyte counts in brains after photothrombosis are still elevated 14 days after 1122 
surgery (Feng et al., 2017). Additionally, cytokines secreted by brain-invading lymphocytes 1123 
can modulate microglial activation (Liesz et al., 2009; Meng et al., 2019). Therefore, we 1124 
performed flow cytometry of brain homogenates (Fig. 4D) and observed a significant 1125 
reduction in cerebral lymphocyte invasion in SCFA-treated animals compared to controls 1126 
(Fig. 4E).   1127 
The invasion of peripheral lymphocytes to the ischemic brain depends on the number of 1128 
circulating lymphocytes, the expression of cerebral endothelial adhesion molecules and the 1129 
chemokine gradient derived from the injured brain tissue (Ransohoff and Engelhardt, 2012). 1130 
In accordance with our non-targeted transcriptomic analysis (see results in Fig. 3) which did 1131 
not reveal significant regulation of chemokines or adhesion molecules by SCFA, also a 1132 
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targeted PCR analysis of key adhesion molecules and tight junction proteins involved in 1133 
post-stroke lymphocyte recruitment at the blood-brain barrier did not show a significant 1134 
regulation by SCFA (Fig. 4-1). In contrast, we detected a significant reduction of systemic T 1135 
cells counts by SCFA supplementation in the spleen (Fig. 4F), a secondary lymphatic organ 1136 
which well characterizes the systemic immune response after stroke (Offner et al., 2006; 1137 
Liesz et al., 2013; Roth et al., 2018).  1138 
These findings suggest that SCFA may primarily affect lymphocytes already in the peripheral 1139 
immune compartments which then might secondarily mediate changes in the cerebral 1140 
immune milieu after brain invasion. Therefore, we next aimed to test this hypothesis by 1141 
investigating the effects of SCFA on microglia in the absence of lymphocytes. For this we 1142 
used lymphocyte-deficient Rag1–/– mice which were given SCFA supplementation or control 1143 
drinking water. In contrast to lymphocyte-competent WT mice, SCFA supplementation in 1144 
Rag1–/– did neither affect microglia morphology nor did it reduce microglial cell counts (Fig.  1145 
4G, H), thus indicating a key role of lymphocytes for mediating the SCFA effects on 1146 
microglia.   1147 
  23  
 1148 
Figure 4. Modulation of post-stroke neuroinflammation by SCFA depends on 1149 
peripheral lymphocytes. (A). Representative maximum intensity projections of microglial 1150 
staining using Iba-1 (red) and DAPI (blue) in the ipsilesional hemisphere 14d after stroke 1151 
control (left) and SCFA (right) treated mice. (B). Microglial morphology was analyzed in 3D 1152 
using an automated analysis algorithm in the ipsilesional cortex of mice 14d post-stroke, 1153 
which revealed significantly reduced sphericity (left) and increased number of branch nodes  1154 
(right) as markers of reduced microglial activation by SCFA compared to control treatment. 1155 
Each symbol represents one microglia, different colors group together microglia from the 1156 
same mouse. (C). Number of microglia found per one high power (40x) field of view (FOV) in 1157 
the perilesional cortex. (D). Representative gating strategy for flow cytometric analysis of T 1158 
cells (CD45+CD3+). SCFA supplementation significantly decreased the frequency of T cells 1159 
in (E) brains and (F) spleens 14d post-stroke. N=9 per group. Quantification of (G) sphericity 1160 
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(left) and ramification index (right) and (H) absolute cell counts of microglia 14d post-stroke 1161 
in the peri-lesional cortex of Rag1–/– mice. In contrast to WT mice (compare to panel B, C), 1162 
SCFA treatment did not affect microglia activation in lymphocyte-deficient Rag1–/– mice. All 1163 
statistical analyses in this figure were performed using the Mann-Whitney U test.  1164 
Discussion  1165 
This study demonstrates that SCFA, critical metabolites derived from the gut microbiome, 1166 
are capable of improving post-stroke recovery via the modulating effects of brain-invading 1167 
lymphocytes on microglial function. Results from our study support this conclusion through 1168 
several key findings. First, stroke lowers blood SCFA concentrations. Second, SCFA 1169 
supplementation combats the deleterious effects of this post-stroke response which we 1170 
demonstrated by associated SCFA supplementation with improved behavioral recovery, 1171 
changes in cortical network connectivity which are generally associated with improved stroke 1172 
outcomes and changes in histological markers of synaptic plasticity. Third, we indicated a 1173 
potential mechanism for the observed improvements in the recovery of SCFA-treated 1174 
animals by finding changes in microglial function which were dependent on circulating 1175 
lymphocytes. Consequently, these findings indicate that SCFA affect peripheral 1176 
lymphocytes—maturation or egress from primary lymphatic tissue—and lymphocytes then 1177 
indirectly mediate the SCFA effects on the brain micromilieu either by their overall reduction 1178 
in cerebral invasion or polarization of the secreted cytokine profile.  1179 
These novel findings introduce SCFA as the most likely missing link in the  1180 
pathophysiological function of the gut-brain axis in stroke and post-stroke recovery, for which 1181 
the microbiota-derived effector molecules were so far unknown (Benakis et al., 2016; 1182 
Houlden et al., 2016; Singh et al., 2016b). Our use of a novel imaging modality, in vivo 1183 
widefield calcium imaging, provided a highly sensitive tool for assessing cortical network 1184 
plasticity after stroke (Cramer et al., 2018). This tool allowed us to perform analyses of 1185 
network plasticity by comparable analytical approaches to functional MRI in patients, with the 1186 
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exception of using a genetically encoded reporter for direct neuronal activation instead of the 1187 
blood flow surrogate marker (BOLD) used in MRI (Cramer et al., 2018). The analysis of 1188 
connectivity within the cortical network provides information about the dynamic changes in 1189 
defined cortical areas under resting-state conditions, which gave us a unique ability to 1190 
measure even the more subtle effects of SCFA supplementation on post-stroke plasticity.   1191 
In human stroke patients, interhemispheric resting-state connectivity is significantly 1192 
weakened following stroke. Specifically, it is thought that inhibitory projections from the 1193 
lesioned hemisphere to the homotypic contralesional hemisphere is attenuated, leading to a 1194 
disinhibition of the homotypic area in the contralesional hemisphere (Rehme and Grefkes, 1195 
2013). We confirmed this effect with our optogenetic imaging approach, by observing an 1196 
increase in the contralesional motor cortex area as an indicator of reduced transhemispheric 1197 
inhibition. This “blooming” effect of the contralesional motor cortex was significantly 1198 
ameliorated by the SCFA treatment at chronic time points after stroke, which could indicate 1199 
an improvement of interhemispheric connectivity and thereby reestablished inhibition of the 1200 
contralesional hemisphere. However, the further in-depth exploration of such 1201 
interhemispheric inhibition is impeded by several technical limitations of our imaging tool 1202 
such as autofluorescent artefacts in the peri-lesional territory and the lack of directional 1203 
information of the interhemispheric connections. This would require in vivo  1204 
electrophysiological studies on connectivity between the recovering peri-lesional tissue and 1205 
the homotypic contralesional brain area which are currently not yet established in stroke 1206 
research. The functional relevance for the changes within connectivity were ultimately 1207 
confirmed by the corresponding beneficial effects of SCFA on recovery of motor functions. 1208 
Behavioral recovery was assessed in a highly sensitive, rater-blinded and high-throughput 1209 
automated test, specifically analyzing motor deficits of the affected forelimb. Hence, 1210 
providing a reliable readout post-stroke recovery, even in the chronic phase. Something 1211 
which most conventional behavior tests lose their test sensitivity towards (Zausinger et al., 1212 
2000; Li et al., 2004; Manwani et al., 2011; Rosell et al., 2013).  1213 
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As an independent line of evidence for the effects of SCFA on post-stroke recovery, we 1214 
detected significant changes in dendritic spine densities and synaptic counts based on 1215 
histological analysis. Previous studies have demonstrated changes in dendritic spine density 1216 
of the peri-lesional cortex as well as contralateral hemisphere and have been identified as a 1217 
hallmark of post-stroke tissue remodeling and marker of synaptic plasticity (Brown et al., 1218 
2008; Huang et al., 2018). After stroke, it has been shown that there is a gradual increase of 1219 
spine density in the contralateral cortex (Huang et al., 2018) while spine density in the 1220 
perinfarct region is reduced by about 38% within the acute phase (Brown et al., 2008). 1221 
Accordingly, we observed significantly increased spine densities in the contralateral motor 1222 
cortex of SCFA supplemented mice, suggesting that these microbial metabolites could aid 1223 
recovery by promoting dendritic spine plasticity.   1224 
A key limitation of the various analysis readouts used in this study (calcium imaging, spine 1225 
density, synapse count) is their exclusive reflection of processes in excitatory neurons. The 1226 
expression of GCamp in Thy1-positive neurons, analysis of dendritic spines on pyramidal 1227 
neurons and the synapse count of VGlut1-positive (glutamatergic) synapses all limit the 1228 
analysis to the excitatory system of the forebrain cortex and does not account for potential 1229 
alterations in subcortical structures or the complex integration of information by (inhibitory) 1230 
interneurons within the cortex (Markram et al., 2004). However, the focus on the excitatory 1231 
cortical system across the different methodological approaches allowed us to thoroughly 1232 
investigate the impact of SCFA from a global network perspective (widefield imaging) to 1233 
synaptic (sub-)structures within the same system. This approach revealed a striking 1234 
alignment of results across different functional levels from synapse to network plasticity and 1235 
behavior that strongly support the impact of SCFA on post-stroke recovery. Despite this, 1236 
future studies need to address the intricate regulation of cortical microcircuits underlying this 1237 
effect and particularly the role of the various interneuron types.  1238 
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The transcriptomic analysis performed in this study indicated several genes which have 1239 
previously been associated with microglial activity and phagocytic function to be regulated by 1240 
SCFA in the post-stroke recovery phase. Therefore, we hypothesized that the SCFA effect 1241 
on post-stroke recovery and neuronal plasticity might be indirectly mediated via microglial 1242 
activity. Indeed, microglia are key players involved in synaptic pruning and dendritic 1243 
remodelling (Salter and Stevens, 2017). Upon pro-inflammatory stimuli, microglial activation 1244 
is associated with a change in cell morphology. While homeostatic microglia are highly 1245 
ramified, activated cells acquire a more ameboid shape. We observed after stroke an 1246 
increase in cell ramification by the SCFA supplementation, indicating reduced or altered 1247 
microglial activation state. Interestingly, microglial activation after stroke has previously been 1248 
associated with reduced phagocytic capacities (Faustino et al., 2011). Hence, modification of 1249 
microglial activation by SCFA could have an impact on synapse elimination and thereby 1250 
microglia-dependent synaptic plasticity (Salter and Stevens, 2017). However, microglial 1251 
elimination (“pruning”) of dendritic synapses is vice versa associated with synaptic activity, 1252 
i.e. less active pre-synaptic inputs are more likely to be phagocytosed. Reduced synaptic 1253 
activity in the peri-lesional cortex due to the tissue injury or in the contralesional cortex due 1254 
to loss of transcallosal innervation from the injured cortex, could both induce excessive 1255 
(pathological) dendrite pruning (Brown et al., 2008; Riccomagno and Kolodkin, 2015; Salter 1256 
and Stevens, 2017). This would suggest that dendritic spine remodelling and microglial 1257 
activation is a reciprocal, bi-directional interaction of neurons and microglia in the recovering 1258 
cortex after stroke. While the results of RNASeq analysis indicate that SCFA modulate 1259 
primarily microglial activation in this process, the detailed interaction of neurons and 1260 
microglia as well as the directionality of their association will require further experimental 1261 
studies. Finally, microglia activation has been associated with neuronal plasticity and 1262 
function beyond morphological reorganization and spine remodelling. We have recently 1263 
demonstrated, that microglia monitor neuronal function at the cell soma and that this somatic 1264 
interaction is altered during pathology after stroke (Cserép et al., 2019) a process that could 1265 
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likely contribute to the functional changes observed in cortical calcium imaging and 1266 
behavioural outcomes. However, the contribution of SCFA to this somatic cell-cell interaction 1267 
is so far unknown.  1268 
A large part of previous experimental studies with SCFA have focused on their effect on 1269 
circulating immune cells. SCFA modulate the polarization of lymphocyte subsets such as the 1270 
ratio of anti-inflammatory regulatory T cells (Treg) to pro-inflammatory TH17 cells (Arpaia et 1271 
al., 2013; Haghikia et al., 2015; Park et al., 2015; Asarat et al., 2016), as well as their 1272 
migratory behaviour between organs (Nakamura et al., 2017). Importantly, lymphocyte 1273 
invasion to the ischemic brain is a hallmark of post-stroke neuroinflammation (Iadecola and 1274 
Anrather, 2011). It is therefore likely, that SCFA may not exclusively act directly on resident 1275 
microglia per se, but also via the peripheral effects of SCFA which change lymphocyte 1276 
function. The altered peripheral lymphocytes later invade the injured brain and indirectly 1277 
influence the cerebral inflammatory milieu. Indeed, T cells have been consistently identified 1278 
in several reports as the invading leukocyte subpopulation with the largest impact on stroke 1279 
outcome with partially divergent functions of T cell subsets (Kleinschnitz et al., 2010). On 1280 
one hand, immunosuppressive Treg cells provide a neuroprotective function by suppressing 1281 
an overshooting inflammatory reaction to the brain infarct (Liesz et al., 2015), on the other 1282 
hand the pro-inflammatory TH1 and TH17 cells induce secondary neurotoxicity and lead to 1283 
infarct expansion with worsened functional outcome (Shichita et al., 2009; Gelderblom et al., 1284 
2012).   1285 
  1286 
Surprisingly, despite this obviously pronounced effect of lymphocytes in post-stroke 1287 
pathology, their role in activating or inhibiting microglial activation has so far barely been 1288 
investigated. We have observed indirect evidence for T cell effects on microglial activity in 1289 
previous experiments, in which depletion of circulating Treg cells affected microglial 1290 
activation and cytokine release (Liesz et al., 2009). Additional indirect evidence comes from 1291 
studies demonstrating T cell interaction and particularly the influence of T cell-secreted 1292 
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cytokines on multiple other cell types in the healthy and injured brain such as T cell-derived 1293 
Interferon-gamma on animal behavior (Walsh et al., 2015; Filiano et al., 2016). Yet, to our 1294 
knowledge, the role of T cells as indirect cellular mediators of microbiota-derived SCFA on 1295 
the brain has so far not been studied. In this study, we unequivocally demonstrate for the 1296 
first time that T cells are crucial to mediate the immunomodulatory effects of SCFA on 1297 
brainresident microglia because in lymphocyte-deficient mice this effect became abolished. 1298 
This finding is also in accordance with our previous proof-of-concept experiments showing 1299 
that circulating T cells were key in facilitating the impact of the gut microbiome on stroke 1300 
outcome in GF vs. recolonized animals as well as in mice with a healthy versus a dysbiotic 1301 
microbiome (Singh et al., 2016a; Singh et al., 2018). These previous reports by us and 1302 
independent reports by others have also consistently identified a translocation of 1303 
lymphocytes from the intestinal immune compartment to the post-stroke brain, providing a 1304 
cellular link by this circulating and highly motile cells across the gut-brain axis (Benakis et al., 1305 
2016; Singh et al., 2016b).   1306 
  1307 
Taken together, this study identified SCFA as critical metabolites derived from the gut 1308 
microbiome affecting T cell function and thereby indirectly modulating the neuro-regenerative 1309 
milieu. This expands our current understanding of the mechanisms along the gut-brain axis 1310 
in acute brain injury and recovery where post-stroke dysbiosis affects the production of key 1311 
microbiota-derived metabolites, their impact on immunological homeostasis and finally the 1312 
capability for efficient functional recovery. The efficacy of SCFA for promoting recovery in an 1313 
experimental stroke model on a functional as well as morphological level, opens up novel 1314 
therapeutic possibilities for improving recovery of human stroke patients. Future studies 1315 
should validate the pro-regenerative effect of SCFA on post-stroke recovery before further 1316 
translational development. However, based on the findings from this study and indications 1317 
for efficacy and similar modes of actions in primary autoimmune brain disorders (Melbye et 1318 
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al., 2019), it is well-conceivable that SCFA supplementation could be used as a safe and 1319 
practical add-on therapy to stroke rehabilitation.  1320 
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Figure 1-1. SCFA concentrations are reduced after stroke. 
(A) Plasma concentration (µM) showing a decrease of total SCFA (sum of acetate, propionate and 
butyrate) in mice 3 days after fMCAo stroke surgery (grey bars) compared to sham (open bars). N=4 per 
group (Mann-Whitney U test). (B) No difference of body weight in grams at baseline (BL) until D42 post 
PT in mice supplemented with SCFA (grey line) or control (black line). N=14/15 per group (2way ANOVA 
with Holm-Sidak correction for multiple testing). (C) Lesion size as measured in pixels did not differ 
between SCFA (grey bar) and control mice (open bar) at any time points. N=11/10 and statistical test 
with multiple T tests per time point and Holm-Sidak method correction for multiple testing. 
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Figure 2-1. SCFA supplementation does not alter tissue injury in 3 focal stroke models. 
Infarct volume from Nissl staining in mice supplemented with control mix (open bar) or SCFA (grey 
bar). (A) 24h after PT, N=10 per group; (B) 14d after PT, 10/9 per group; (C) 5d after dMCAo, 
N=6/9 per group; (D) 14d after dMCAo, N=9/8 per group; and (E) 14d after fMCAo, N=5/7 per 
group. Statistical analyses were performed using the Mann-Whitney U test. (F) As in Figure 2E, 
histogram of the relative frequency (fraction) of spines found at different lengths 14d after PT in 
the contralateral cortex (bin width = 0.2µm). (G) Quantification of short (0.2µm) and long (1.4µm) 
spines in control (open bars) and SCFA (grey bars) treated mice. N=4/5 per group, Mann-Whitney 
U test. (H) The size in pixels of synapses stained with VGlut1 (left) and Homer1 (right). Quantifica-
tion revealed larger synapse areas in the peri-lesional cortex which was significantly ameliorated 
with SCFA supplementation. Contra: contralateral hemisphere; ipsi: ipsilateral hemisphere, n=3/4 
mice (3 sections per mouse), statistical analysis performed with Kruskal-Wallis test with Dunn’s 
multiple comparison correction.
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Figure 3-1. SCFA supplementation increases plasma concentrations. 
Mice were pre-treated with antibiotic mix for 4 weeks, and then additionally given control (ABX, 
open bars) or SCFA supplementation (ABX+SCFA, grey bars). Total plasma concentration (µM) 
of total SCFA (acetate, propionate and butyrate) showing significant increase after SCFA supple-
mentation compared to control treated mice, N=4/5 per group (Mann-Whitney U test).
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Figure 4-1. SCFA supplementation does not affect cerebral endothelial expression. 
Relative mRNA expression (RE) for the tight-junction and adhesion molecules Claudin-5 (left), 
ICAM-1 (middle) and VCAM-1 (right) from the peri-lesional cortex in control (open bars) and SCFA 
(grey bars) treated mice (Mann-Whitney U test).
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DISCUSSION 
The major findings of this thesis were: 1) there is a bidirectional interaction between the gut 
microbiota and stroke; changes in the gut microbiota composition can alter stroke outcome, and 
stroke itself induces a dysbiosis of the gut microbiome. 2) By modulation of the peripheral immune 
system, the gut microbiome is able to influence the neuroinflammatory response to stroke. 3) The 
gut microbiota metabolites are altered after stroke, and modulation of these can improve long-term 
recovery.    
 
We found that the fMCAo (larger lesions) induced substantial changes in the gut microbiota 
composition. This was not evident within mice that underwent dMCAo (smaller lesions) and 
suggested that a greater dysbiosis was associated with larger stroke lesions. In other studies, a 
mathematical algorithm was designed for stroke patients which positively correlated the gut 
microbiome dysbiosis to the outcome of stroke. I.e. the greater the dysbiotic index, the worse the 
stroke outcome. Instead of causally correlating the infarct size with dysbiosis as performed in our 
mouse study, they assessed neurological patient’s scores. The results suggested that patients with a 
greater gut microbiome dysbiosis index had poorer stroke outcome (Xia et al., 2019). Our mouse 
study revealed that post stroke dysbiosis was causally linked to a slowing of the gut motility. In 
patients, care-givers or stroke patients themselves reported a 30% increase in bowel dysfunction 
after stroke. The umbrella term bowel dysfunction was used to categorise: diminished frequency of 
bowel movements, lumpy or hard stools, intestinal constipation, straining, incomplete evacuation, 
and incontinence (Engler, Dourado et al., 2014, Olsen, Hetz et al., 2013). A possible mechanism for 
how the reduced motility and thereby gut microbiome dysbiosis is induced after stroke, is via the 
elevated levels of catecholamines in the blood. The hypothalamus-pituitary-adrenal axis is 
responsible for the elevated levels of cortisol after stroke which is causally correlated to worse stroke 
outcome (Anne, Juha et al., 2007). The catecholamines have been shown to interact with the ENS, 
reducing gut motility and altering gut microbiota composition (Bailey et al., 2011). In our study, we 
saw elevated catecholamine levels after stroke. This suggested that larger strokes, with greater 
amounts of catecholamine release, have reduced gastrointestinal transit and a greater gut 
microbiota dysbiosis. 
 
From our study we observed that stroke-induced dysbiosis altered the polarisation of T cells in the 
spleen and PP. Utilising GF mice, we employed FMT techniques to investigate the intestinal immune 
cell priming from dysbiotic stroke gut microbiota. In general, we saw that when FMT was given more 
Tregs and fewer IL-17+ cells were present, and stroke outcome was improved. This is concurrent with 
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studies showing the neuroprotective role of Tregs and proinflammatory role of IL-17 producing cells 
in stroke (Gelderblom, Weymar et al., 2012, Kleinschnitz et al., 2010, Liesz et al., 2009, Shichita et al., 
2009). However, the novel connection linking the gut microbiome to the immune system in stroke 
has only recently become elucidated. A key study in this field showed that after stroke, the altered 
microbiota composition led to an imbalance of Treg to IL-17+ cells in the intestinal immune 
compartment, resulting in differences of stroke outcome (Benakis et al., 2016b). Whilst it is clear that 
the gut microbiome interacts with the local immune system, the contribution of intestinal immune 
cells to the neuroinflammation was unclear. In our study, we saw that 25% of all T cells located in the 
brain after stroke originated from the intestinal immune compartment, as shown with injection of 
CFSE dye in the PP. Furthermore, Benakis et al. used Kikume Green-Red transgenic mice, allowing 
illuminated cells to be photoconverted specifically in the intestinal compartment. The 
photoconverted T cells were then tracked to the show immune cells clustering at the meninges after 
stroke. It has been shown that the cytokine release from T cells indirectly modulates 
neurodegeneration and microglia in the brain (Appel, 2009, Liesz, Zhou et al., 2011). In our study and 
in Benakis et al., we saw that the proinflammatory cytokine levels in the brain were reduced when 
more Tregs were observed in the intestinal immune compartment. Our studies have identified the 
immune system as a key mediator along the gut-brain axis. However, at this point it is important to 
acknowledge the other potential routes of brain-axis communication. The vagus nerve acts as a 
direct link for the gut to the brain with 80% afferent and 20% efferent fibres (Agostoni et al., 1957). 
The afferent fibres do not sense the gut microbiota directly and mainly detect metabolites or 
mediators produced by the bacteria which may influence enteroendocrine cells. For example, 
butyrate and LPS have been shown to directly interact with afferent terminals (Hosoi, Okuma et al., 
2005, Lal et al., 2001). The efferent fibres work to alter intestinal permeability and reduce 
inflammation (Zhou, Liang et al., 2013). Acetylcholine (ACh) released from the distal end of the vagus 
nerve inhibits TNFα release by macrophages through the α7nicotinic ACh receptors (Wang, Yu et al., 
2003).  In studies which investigated the neural route for gut-brain axis communication in stroke, the 
authors showed that vagotomy or vagal nerve stimulation exhibited neuroprotective effects with 
reductions of proinflammatory cytokine TNFα in brain and in liver – potentially due to 
downregulation of microglial α7nicotinic ACh receptors (Jiang, Li et al., 2014, Ottani, Giuliani et al., 
2009). Whilst this study did not focus on the gut microbiota, but mainly the connection between the 
brain and the gut itself, interestingly it appears that both the immune and neural route work to alter 
stroke outcome by primarily modulating the inflammatory milieu in the brain. 
 
Our earlier studies and others have already clearly identified that modulation of the gut microbiome 
alters neuroinflammation and stroke outcome mainly within the acute phase via the immune system. 
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The peak infiltration of immune cells in the brain after experimental stroke is 3-5 days (Gelderblom et 
al., 2009). Therefore, investigation of the gut microbiome-priming of the immune system after stroke 
has mainly been focused within these acute time-frames. In other studies there is evidence to 
suggest that T cells infiltrate into the brain up to at least 1 month after stroke (Xie, Li et al.). This 
indicated that gut microbiome-priming of the immune system could play a role in the recovery phase 
after stroke. In our mouse models, we showed that the gut microbiota composition was altered in 
the larger fMCAo model up until D3 after stroke. So far there has been no mouse studies which 
investigate the long-term effects of stroke on the gut microbiome. However, in patients, a 
longitudinal study showed that the stroke induced dysbiotic microbiome was evident until day 20 
after stroke and then began to normalise (Swidsinski, Loening-Baucke et al., 2012b). Within our 
studies, instead of investigating the longitudinal changes to the gut microbiota after stroke, we 
focused on the metabolites produced by the gut microbiome. We found that the key bioactive 
metabolites named SCFA were low in concentration after stroke compared to sham. Using pre-
supplementation of SCFA in drinking water we investigated the role of these bacterial derived 
metabolites on the recovery after stroke. Other studies using this treatment of SCFA have revealed 
neuro-protective properties (Bourassa, Alim et al., 2016). For example, in the multiple sclerosis 
mouse model, EAE, pre-treatment with SCFA was shown to reduce axonal damage and induce an 
anti-inflammatory immune system (Haghikia, Jorg et al., 2015).  For the first time, our results show 
that the gut microbiota metabolites alter the recovery phase after stroke indirectly by the immune 
system. Different techniques must be employed when analysing the stroke outcome within the 
recovery phase. Conventional methods used in the acute phase, such as infarct volumetry do not 
provide accurate representation of stroke severity, i.e. it is difficult to quantify lesion volume due to 
missing or scarring to tissue. For this reason, behavioural tests which measure functional outcome 
are often used as a readout. Our study utilised an automated, rater-blinded behavioural test 
specifically assessing motor improvement of the affected forelimb (Becker, Meyers et al., 2016). 
Assays must be extremely sensitive to detect differences in post stroke recovery phase, as small 
changes in metabolites produced by the gut bacteria are likely to result in subtle differences. It is 
important to have a behavioural test which discriminates between these less obvious changes after 
stroke which limits rater-dependant effects (Li, Blizzard et al., 2004, Manwani, Liu et al., 2011, Rosell, 
Agin et al., 2013, Zausinger, Hungerhuber et al., 2000).  
 
The recovery phase after stroke entails reorganisation of cortical networks which requires 
multicellular process encompassing neuronal plasticity, resident immune cells and brain-invading 
cells. In our study we saw SCFA altered the dynamics of cortical connectivity after stroke. Stroke 
patient fMRI has shown that interhemispheric resting-state connectivity is significantly weakened 
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following ischemic stroke. Specifically, it is thought that inhibitory activity from the stroked 
hemisphere to the homotypic contralateral hemisphere is attenuated, leading to a disinhibition or a 
more active homotypic contralateral hemisphere (Rehme & Grefkes, 2013(Grefkes, Nowak et al., 
2008, Grefkes, Nowak et al., 2010, Rehme, Eickhoff et al., 2011)). During the recovery phase after 
stroke, it has been shown that the strength of interhemispheric connectivity increases, and is 
associated with motor improvements (Golestani, Tymchuk et al., 2013, Park, Chang et al., 2011, 
Wang, Yu et al., 2010). Within our study, we used widefield in vivo calcium instead of fMRI to analyse 
network connectivity. One limitation of the technique is that unlike fMRI, the assessment of the 
whole brain is not possible. In vivo calcium imaging is spatially and temporally more sensitive, 
allowing characterisation of the different topographically located functional areas across the cortex 
(Cramer, Gesierich et al., 2018). In accordance with studies performed in patients, our in vivo calcium 
imaging revealed an increase of the contralesional motor area after stroke. This was significantly 
ameliorated by the SCFA treatment during the recovery phase. This implied that the stroked 
ipsilateral hemisphere in SCFA mice had re-established interhemispheric connectivity providing 
stronger inhibition of homotypic contralateral regions compared to controls. There is existing 
evidence, which supports the concept of inhibitory interneurons altering post stroke recovery 
(Clarkson, Huang et al., 2010, Zeiler, Gibson et al., 2013). However, in our study, one main limitation 
was the lack of information on directionality, and inhibitory connections found between the two 
hemispheres after stroke. Due to the techniques used within this study, (GCamp in Thy1-positive 
neurons, analysis of dendritic spines on pyramidal neurons and the synapse count of VGlut1-positive 
(glutamatergic) synapses) assessment of excitatory connections was only possible. On one hand, our 
findings in the contralateral hemisphere may only reflect changes in the functional connectivity as 
shown with calcium imaging. On the other hand, our results may relate to changes in physical trans-
callosal connectivity between hemispheres. In previous studies, interhemispheric connections after 
stroke have been assessed with neuronal tracers. Tracers such as wheat-germ agglutinin horse radish 
peroxidase visualised with immunohistochemistry, and manganese visualised with MRI, are injected 
into the perilesional area and show the pathway of neuronal processes. It was shown that at 4-10 
weeks after stroke tracers were significantly increased in the contralateral hemisphere due to an 
enhancement of interhemispheric connectivity at these time points (van der Zijden, Bouts et al., 
2008). This is in line with our study where we saw a decrease in area of the highly active contralateral 
seed at 3- and 6- weeks post stroke. One could hypothesise that the interhemispheric neuronal 
connections from the ipsilateral cortex were restored. It is thought that after stroke the inhibitory 
connections are diminished between hemispheres within the acute phase (Grefkes et al., 2008, 
Grefkes et al., 2010, Rehme et al., 2011, Rehme & Grefkes, 2013). Disinhibition is when the 
contralateral hemisphere does not receive inhibitory input. This concurs with our study where we 
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see a “blooming” of the contralateral motor seed. Hypothetically at chronic time points the 
restoration of interhemispheric connections could be mainly inhibitory resulting in a reduction of 
excitatory activity as seen in our results. This would therefore suggest that SCFA promote the 
interhemispheric connections between hemispheres after stroke, as we see significantly smaller 
contralateral motor seeds compared to controls. However further studies need to be performed to 
clarify the interhemispheric neuronal connections after stroke specifically after SCFA 
supplementation.  
From our study we saw higher spine density in mice supplemented with SCFA compared to controls. 
This was evident in sham operated mice and within the contralateral hemisphere after stroke 
surgery. A sign of cortical recovery after stroke has been associated with a gradual increase in 
contralateral cortical spine density (Huang, Chang et al., 2018). The higher spine density in the 
contralesional cortex after stroke was linked to neuroprotection in SCFA supplemented mice. In 
another brain disease, autism spectrum disorder (ASD), elevated levels of faecal SCFA have been 
reported (Wang, Christophersen et al., 2012). Additionally, it was also shown that the SCFA levels in 
ASD were associated with increased spine density of cortical pyramidal neurons (Hutsler & Zhang, 
2010). Although ASD and stroke have both a completely different pathophysiology, taken together in 
general it suggests that SCFA may be able to regulate spine density in the brain. Spine density may be 
altered via either molecular cues, guidance molecules, self-destruction, or synapse elimination 
(Riccomagno & Kolodkin, 2015). The mechanisms of how SCFA increased neuronal spine density 
remain still to be elucidated. Our study demonstrated that SCFA supplementation resulted in 
increased molecular cues such as Tropomyosin receptor kinase B (TrkB) and Synaptophysin. TrkB is a 
receptor for BDNF and upon activation leads to plasticity, dendrite outgrowth, proliferation, 
differentiation and survival (Yoshii & Constantine-Paton, 2010). Synaptophysin is a presynaptic 
vesicle marker which has shown to be decreased where reduced spine density is present (Karson, 
Mrak et al., 1999). This is concurrent with our results where we see higher spine density with and 
greater TrkB and Synaptophysin mRNA expression. Therefore, in our studies TrkB is likely to be a 
better method for indication of synaptic outgrowth after SCFA treatment, whereas Synaptophysin 
represents a second indicator for spine density and that synapses are likely to be functioning (Tarsa & 
Goda, 2002). SCFA could alter TrkB and Synaptophysin gene expression via epigenetic modifications, 
due to their ability to function as histone deacetylase inhibitors (HDACs).  Bacterial derived SCFA 
have a clear role in modulating epigenetic markers in CD4+ T cells at the Foxp3 gene locus (Arpaia et 
al., 2013, Furusawa et al., 2013), CD8+ T cells (Luu, Weigand et al., 2018) and in general lymphocytes 
(Luu, Pautz et al., 2019). Furthermore there is evidence that shows the HDAC function of SCFA are 
able to alter transcription within brain resident cells such as microglia and neurons (Patnala, 
Varumugam et al., 2017, Sharma, Taliyan et al., 2015). SCFA could influence the transcriptional 
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profile of neuronal molecular cues, and therefore be a possible route of synaptic modulation. 
Another explanation for differences in spine density is altered synaptic pruning by microglia and 
astrocytes (Chen, Jalabi et al., 2014, Chung, Clarke et al., 2013, Ji, Akgul et al., 2013). In our RNA 
sequencing we saw that SCFA supplementation resulted in an increase in cortical complement and 
phagocytic genes which were lysosomal associated. Complement based synaptic pruning of spines 
has been shown in microglia and found to be independent of astrocytes (Chung et al., 2013, Stevens, 
Allen et al., 2007). In turn we observed altered microglia morphology under SCFA supplementation. 
Specifically, we saw that microglia were more ramified with SCFA, hinting that microglia were resting 
compared to controls. Other studies have also shown that specifically microglia are affected by SCFA 
supplementation whilst other brain resident cells were unaffected (Erny, de Angelis et al., 2015). 
However, further investigations need to pinpoint mechanism of how SCFA affect spines; indirectly by 
microglia as hypothesised in our study, or directly alter the molecules cues in neurons. This could 
potentially be solved with SCFA supplementation in combination with TrkB inhibitors (Shimada, 
Mason et al., 1998) or via blockade of synapse elimination via microglia i.e. with C1q–/– mice (Ma, 
Ramachandran et al., 2013).  
In our study we observed that SCFA supplementation was associated with reduced number of T cells 
in the brain and ramified microglia. We then supplemented mice in the absence of T and B 
lymphocytes (Rag–/– mice), and saw that microglia cells were unaffected by the SCFA. The cross-talk 
between microglia and T cells has been shown to affect the activation state of microglia after stroke 
(Wang, Zhang et al., 2016). Our suggests that in general, the lower number of T cells present in the 
brain found under SCFA supplementation, led to lower levels of neuroinflammation and reduced 
microglia activation. Previously it has been shown that different subsets of T cells influence different 
effects on the microglia. Th1 and Th17 cells induce a proinflammatory microglia phenotype via TNF-
α, IFN-γ and IL-17 release (Chabot et al., 2001, Shichita et al., 2009). Th2 and Tregs induce an anti-
inflammatory microglia phenotype via IL-4, IL-10 and TGFβ (Gonzalez & Pacheco, 2014, Liesz et al., 
2009). Therefore, the infiltration of T cells into the brain can highly influence microglia activation. 
SCFA have previously been reported to change the polarization states of T cells in the intestinal 
immune compartment, inducing Tregs (Smith et al., 2013, Tan, McKenzie et al., 2016). However, in 
our study there was no clear change in the intestinal immune compartment of the Tregs (not 
reported). Recent studies investigating the impact of SCFA in an uveitis model also showed that 
prolonged treatment (4 weeks) of SCFA in drinking water was sufficient to reduce Treg counts in the 
intestinal immune compartment (Nakamura, Janowitz et al., 2017). This therefore suggested that 
changes in microglia activation after SCFA supplementation was not due to different T cells subsets 
infiltrating into the brain. Other studies using antibiotic treatment to alter the microbiome, and thus 
SCFA reduction, showed that more T cells entered the CNS in the EAE model of MS (Kadowaki, Saga 
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et al., 2019). One could hypothesise that the decrease in SCFA resulted in more T cell recruitment to 
the brain. This agrees with our study where we found high levels of SCFA reduced T cells entering the 
brain. After stroke microglia secrete chemokines which recruit T cells to the brain (Mirabelli-Badenier 
et al., 2011, Ramesh, MacLean et al., 2013) and local chemokines home T cells to the gut (Kunkel, 
Campbell et al., 2003). Chemokines located in the gut or the brain could also influence the number of 
T cells recruited to the brain, and thus the interaction with microglia after stroke. Further studies 
must be done to elucidate the role of SCFA on T cell migration into the brain, and thus the effects of 
microglia activation.  
In our studies we have used Rag–/– mice to validate the effect of SCFA in the absence of T cells and B 
cells on stroke outcome. While, we have mainly focused on the role of T cells in our studies, 
potentially B cells could also play a role in post stroke outcome. The research of B cells in stroke 
outcome is somewhat controversial (Javidi & Magnus, 2019). On the one hand there is evidence to 
suggest B cells do not play a role in stroke outcome. Transfer of B cells in Rag–/– mice (Kleinschnitz et 
al., 2010), and depletion of B cells (Schuhmann, Langhauser et al., 2017) did not alter stroke 
outcome. On the other hand, others suggest a role for B cells in stroke; IL-10 from B cells and B cell 
administration improves stroke outcome (Chen, Bodhankar et al., 2012, Ren, Akiyoshi et al., 2011). 
Importantly B cell counts have been shown to be elevated at much later at around 7-12 weeks post 
stroke, in particular IgA production is elevated in the brain (Doyle, Quach et al., 2015) and 
systemically in stroke patients at day 90 (Tsai, Berry et al., 2019). This shows that B cells could 
potentially play a role in the regeneration phase after stroke. Furthermore, SCFA have been shown to 
alter the function of B cells; promoting IL-10 release (Austin, Ku et al., 2019), and reducing the gut 
IgG, IgA and IgE responses (Sanchez, Gan et al., 2018). To what extent the B cells altered by SCFA in 
the periphery change the stroke outcome, is yet to be elucidated, as lower rates of migration to the 
brain was seen in B cells in comparison to T cells (Benakis, Brea et al., 2016a). In our studies we have 
clearly focused on the effects of T cells on post stroke regeneration following SCFA supplementation. 
However, from all of our studies utilising Rag–/– mice, there is scope to additionally investigate the 
role of the gut microbiome on B cells, particularly in the recovery phase after stroke.  
In order to investigate the impact of the gut microbiota on the host system after stroke, one can 
eradicate or deplete the gut microbiota from the host. In the studies discussed in this thesis, we have 
demonstrated two methods; the use of GF mice (as shown in the 1st and 2nd manuscript) and the use 
of antibiotic treatment (as shown 4th manuscript). Both of these methods however have limitations. 
GF mice are expensive, difficult to maintain GF, have developmental defects, and an altered immune 
system. However, they are sterile and allow for colonisation with defined microbes. Antibiotic 
treated mice are not completely bacteria free, may have off target neuroprotective affects, but can 
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be utilised in many transgenic models and have no developmental defects (Hooks, Konsman et al., 
2018, Kennedy et al., 2018, Lundberg, Toft et al., 2016, Round & Mazmanian, 2009). In order to 
account for unwanted changes observed between these two methods in our studies we carefully 
compared the appropriate treatment and mouse model. The comparison of GF mice with GF 
recolonised was to account for any developmental defects and immunological differences. Antibiotic 
treatment was then used to compare control supplementation or SCFA supplementation, as a tool to 
show reduction and restoration of SCFA concentrations. Whilst the use of GF mice in stroke research 
is a cleaner approach, methodologically, stroke experiments are difficult to perform under GF 
conditions. The use of antibiotics as a model to research stroke, is easier however has led to 
somewhat variable results across different institutes. First, mice are likely to be purchased from 
different breeders, which, as we learnt from our third study resulted in polarised T cells induced by 
different gut microbiota composition. Second there is no standardised antibiotic protocol for dosage 
or for antibiotic type. This has led to various doses and antibiotic cocktails, which are different in 
their effectiveness for eradicating different bacterial populations. Therefore, investigation of 
antibiotics on stroke, and not as a tool for microbiota depletion has led to different outcomes. In one 
study, the authors used a broad spectrum of antibiotics (ampicillin, vancomycin, ciprofloxacin, 
imipenem, and metronidazole) and reported that depletion of gut did not alter stroke outcome 
(Winek et al., 2016). On the contrary, Benakis et al. reported that stroke outcome was improved 
following antibiotic (vancomycin) treatment. Benakis et al. raised mice to have a specific bacterial gut 
microbiome which was resistant to amoxicillin and clavulanic acid antibiotics and compared this to 
mice which had a microbiome which was sensitive to antibiotics. The results revealed that antibiotic 
resistant mice had a worse stroke outcome with more IL-17 cells and less Treg cells compared to the 
antibiotic sensitive mice. The results while different, in general both studies claimed that the gut 
microbiota composition altered the immune system and in turn stroke outcome.  
 
Recently many researchers have highlighted the gut microbiota as potential source of variability in 
the reproducibility conversation (Begley & Ioannidis, 2015, Franklin & Ericsson, 2017, Knight, Vrbanac 
et al., 2018, Velazquez et al., 2019). Inconsistent findings which derive from differences in microbiota 
composition, demonstrate the impact on various diseases, infections (Velazquez et al., 2019), and 
even immunotherapies as shown in our study. In 2016 the participating members of the DFG Priority 
Program 1656 “Intestinal Microbiota” released a study showing the extent of variability between 
C57BL/6 mice across Germany (Rausch, Basic et al., 2016). Not only did they find a huge variability 
across institutions within the country, but additionally differences within the same facility. The 
authors suggested that animal husbandry was the main cause for this variability, with deviations in 
food content, bedding, circadian rhythms and housing conditions. As shown in our study between 
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commercial breeders, the differences were evident up until phylum level, and the largest changes 
were at species level. Our study revealed that mice purchased from CR were absent in SFB. This fits 
with previous studies which showed mice from the Jackson Laboratory (JL) were also absent from 
SFB (Ivanov et al., 2009). Interestingly, it also favours the concept that some bacterial species are 
inherited, as CR mice were originally from JL (Faith, Colombel et al., 2015). In our experiments, we 
also investigated whether the changes in gut microbiota composition from different commercial 
breeders could partly contribute to the reproducibility crisis within the stroke field. We saw that mice 
with small changes in gut microbiota composition had a different stroke outcome following CD28 
superagonist (SA) treatment. CD28 is a co-stimulatory receptor found on T cells which encourages 
proliferation and expansion. The immunotherapy named CD28SA was designed to theoretically boost 
the immune system, with specific preferential expansion of the immunosuppressive Treg population 
(Hünig, 2007, Lin & Hünig, 2003). Experimental research showed that expansion of the Treg 
population was neuroprotective in stroke (Liesz et al., 2009). However, two studies using CD28SA in 
stroke published controversial results on the one hand exacerbating stroke (Schuhmann et al., 2015) 
and the other improving outcome (Na et al., 2015). The mice in these two studies were purchased 
from two different commercial breeders CR and Har. Interestingly this is in accordance with our 
results which showed CD28SA resulted in exacerbated stroke outcome dependent on the gut 
microbiome composition. Other studies have also reported outcomes of immunotherapies or disease 
models affected by the gut microbiome from different commercial breeders, for example in bone 
density immunotherapies (McCabe et al., 2013) and infection susceptibility to salmonella (Velazquez 
et al., 2019). 
 
In this thesis we have clearly shown that stroke is affected by the gut microbiome composition and 
that modification of the gut microbiome can improve recovery. We used GF mice and Ex-GF to show 
that the presence of the gut microbiota was protective in stroke. Using other GF mice models, others 
have also elucidated the importance of gut microbiota in brain disease. In a study which investigated 
the multiple sclerosis mouse model EAE, they showed that spontaneous EAE did not occur in GF mice 
and that gut microbiota was essential for diseases onset (Berer et al., 2011). On one hand this implies 
that general concepts about brain disease and gut microbiota cannot be compared; GF models of EAE 
are protective, whilst in stroke we saw worsened outcome. On the other hand, the impact of brain 
disease on gut dysbiosis has seemingly similar consequences. For example, variations of certain phyla 
such as the Bacteroides was not only found to alter in our experimental stroke model but also was 
altered in multiple sclerosis (Tremlett, Fadrosh et al., 2016). Treatment by FMT to reverse the effects 
of dysbiosis is currently a very attractive therapy for many brain diseases. There are over 292 clinical 
trials registered for FMT, however currently Clostridium difficile infection is the only disease which 
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has FDA approval. Within these 292 clinical trials, 17 of those are investigating the use of FMT to 
specifically treat brain diseases such as epilepsy, bipolar disorder and Parkinson’s disease. In order 
for stroke to reach FMT clinical trials many more investigations in the patient populations must be 
completed, to compare experimental findings in rodents to stroke patients. Presently, clinical trials 
for stroke and gut microbiota are ongoing (GUTSTROKE, NCT02008604). The focus of this trial is to 
characterise the gut microbiota differences after stroke and correlate this to peripheral immune 
system.  
 
 
Figure 6. Schematic representation of key concepts identified. From the four papers contributing to this thesis work, there 
have been key concepts about the gut microbiome and stroke established. Stroke can alter microbiome composition, and 
likewise, modulation of the microbiome composition can alter stroke outcome. The dysbiotic gut microbiome induced after 
stroke changes the polarisation of immune cells in the periphery, which migrate to the brain and alter the inflammatory 
milieu. Mice from different commercial breeders with the same genetic strain hold small differences in their gut microbiome 
composition. This in turn effects how immunotherapy performs after stroke. Supplementations of microbial metabolites 
improve functional post stroke recovery. 
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CONCLUSIONS AND OUTLOOK 
The four publications presented within this thesis have focused on the role of the gut microbiota in 
stroke. We have demonstrated a bi-directional interaction between the gut microbiota and stroke. 
We have shown that the presence of the gut microbiota or FMT treatment post-surgery is 
neuroprotective in experimental stroke models. We have observed that mice from different 
commercial breeders had a different gut microbiota composition, which resulted in altered response 
to immunotherapy after stroke. Finally, we discovered that the gut microbial metabolites, SCFA were 
beneficial within the post-stroke recovery phase. The questions answered within the thesis have 
opened up further experimental questions, however it is clear that gut microbial and dietary 
intervention could improve stroke outcome. I believe this thesis provides outlook to begin 
therapeutic research within patients, investigating an easy and practical metabolite or bacterial-
based add-on alongside existing stroke recovery therapies.  
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